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Brain metabolism is usually thought of in terms of energy production. Decades of 
research has shown that the brain derives the majority of its energy from the oxidative 
phosphorylation of glucose transported from the blood into the brain. Because of this, cerebral 
blood flow (CBF), the cerebral metabolic rate of glucose consumption (CMRglc), and the 
cerebral metabolic rate of oxygen consumption (CMRO2) generally are tightly coupled. Indeed, 
the coupling between CBF, CMRglc, and CMRO2 is robust enough such that many investigators 
believe them to be equivalent measures of brain activity. 
 Nevertheless, research over the last few decades has shown that cerebral metabolic 
coupling is not stoichiometrically exact. Perhaps the best example of metabolic uncoupling 
occurs during focal increases in brain activity. Sensory stimulation, for instance, increases CBF 
and CMRglc to a much greater extent than CMRO2. This response results in: 1) an increase in 
nonoxidative glucose consumption, and 2) an increase in oxygenated blood in the brain’s 
vasculature, the phenomenon which underlies blood oxygen dependent (BOLD) functional 
magnetic resonance imaging (fMRI).  
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Importantly, metabolic uncoupling is not restricted to periods of increased neural activity. 
The primary goal of this thesis is to investigate other examples of uncoupling between CBF, 
CMRglc, and CMRO2.  I performed four separate studies that all examine metabolic uncoupling 
from a different perspective. In the first study, I performed a meta-analysis of published papers 
to show that at rest, nearly 10% of the brain’s glucose consumption uses nonoxidative pathways 
that do not end in lactate efflux. If CMRglc and CMRO2 were completely coupled, then one 
would not expect to find any nonoxidative glucose consumption (NOglc). The second study 
expands upon the first by showing that there are regional differences in the amount of glucose 
consumed using nonoxidative pathways. In some brain regions, such as the precuneus and 
medial prefrontal cortex, NOglc accounts for nearly 20% of resting CMRglc. Conversely, there 
does not appear to by any NOglc in the cerebellum.  
The aim of the remaining two studies was to determine if changes in blood glucose 
concentration produce similar changes in CBF, CMRglc, and CMRO2. Although multiple studies 
have reported that hypoglycemia focally increases CBF in humans, it is not clear how it impacts 
regional CMRglc. Therefore, I examined both regional CBF and regional CMRglc during 
moderate hypoglycemia. Although hypoglycemia decreased CMRglc in every region of the 
brain, it only increased CBF significantly in the globus pallidus. This suggests that CBF does not 
increase during hypoglycemia to prevent a fall in CMRglc. Next, I examined regional changes in 
brain metabolism during hyperglycemia. Previous studies have established that acute 
hyperglycemia alters the topography of cerebral glucose metabolism. However, the impact of 
hyperglycemia on regional CBF and CMRO2 has not yet been determined. Therefore, I examined 
CBF, CMRglc, and CMRO2 in several brain regions during hyperglycemia. Hyperglycemia did 
not change CBF or CMRO2 in any brain region. However, hyperglycemia did increase CMRglc 
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in white matter and in the brain stem by over 30%. CMRglc was not altered by hyperglycemia in 
any other region. Therefore, hyperglycemia appears to selectively increase NOglc in the brain 
stem and white matter. 
Taken together, the four studies that make up this thesis show that metabolic uncoupling, 
in particular NOglc, is an important part of brain metabolism. These results also highlight the 




Chapter 1: A historical review on regional cerebral blood flow 
and metabolism 
 
1.1 Chapter organization 
 
The focus of this thesis is uncoupling between three major aspects of metabolism in the 
adult human brain: cerebral blood flow (CBF), the cerebral metabolic rate of glucose (CMRglc), 
and the cerebral metabolic rate of oxygen consumption (CMRO2). The underlying theme of all 
the original work presented here is that uncoupling between these three measures of metabolism 
has important physiological consequences that need to be understood. As such, the primary goal 
of this introductory chapter is to review what is known about uncoupling between CBF, 
CMRglc, and CMRO2. With this goal in mind, I have divided this introductory chapter into six 
sections. The first section discusses early studies of brain metabolism, with a particular emphasis 
on how techniques for measuring regional brain metabolism support the hypothesis that cerebral 
metabolism is coupled to neural activity. In the following section, I review the fairly large 
literature which shows that the coupling between cerebral metabolism and neural activity is not 
quite as tight as early studies suggested. Then, in section three, I explore the various mechanisms 
that have been proposed to explain metabolic uncoupling during neural responses to imposed 
tasks. After section three, the remaining text focuses on resting brain metabolism. In section four, 
I review the evidence that a significant proportion of the brain’s resting CMRglc is not consumed 
via oxidative pathways. Next, I argue, in section five, that metabolic uncoupling occurs in many 




1.2 Early studies of brain metabolism 
 
The idea that brain activity is coupled to cerebral blood flow and metabolism is often 
attributed to the work of Roy and Sherrington in 18901. Since then, establishing how metabolism 
supports brain activity has been the focus of an extensive body of literature. One of the important 
early discoveries, made by several investigators in the early 20th century, was that oxidative 
consumption of blood-borne glucose is the brain’s primary fuel source under normal conditions. 
These studies used cerebral arterio-venous differences of CO2 and O2 to show that the respiratory 
quotient (the ratio of CO2 produced to O2 consumed) was nearly 1.0, which would only occur if 
nearly all of cerebral oxygen consumption was used for the oxidation of glucose2-4. The 
implication of these studies is that brain activity is maintained using ATP generated solely 
through the oxidative phosphorylation of glucose. Subsequent studies provided support for this 
hypothesis by showing that reductions in the availability of glucose have profound effects on 
brain function. Insulin-induced hypoglycemia, for example, decreases cerebral glucose and 
oxygen consumption and can result in coma5-7. The brain is also extremely sensitive to oxygen 
availability, with electrical activity in the brain effectively ceasing after several seconds without 
oxygen8. 
Early evidenced seemed to indicate that brain activity was supported by metabolism. 
However, if the Roy-Sherrington hypothesis was to be proven correct, a correlation would have 
to be shown between brain activity, cerebral blood flow, and metabolism. Perhaps the first 
researcher to address this question was Angelo Masso, who as early as 1879 reported that mental 
activity increases fluctuations in cerebral blood volume9,10. However, the first group to 
specifically measure blood flow and metabolism in humans during a cognitive task was Louis 
Sokoloff and colleagues in 195511. Using the Kety-Schmidt method12, an early technique that 
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used cerebral arteriovenous differences to obtain metabolic rates, Sokoloff et al. measured global 
CBF and CMRO2 in young men while they performed a mental arithmetic task. While 
substantial shifts in EEG patterns were reported, a finding consistent with an alteration in neural 
activity, neither CBF nor CMRO2 increased during the mental arithmetic task. To explain their 
seemingly contradictory results, Sokoloff et al. proposed that, although global CBF and CMRO2 
may not change during periods of task-driven increased brain activity, changes may occur in 
specific brain regions. However, establishing that regional CBF is elevated by neural activity 
would require the development of techniques that could quantify brain metabolism at the 
regional level in healthy individuals.  
Fortunately, methods for assessing regional brain metabolism were developed quickly. In 
1955, the same year as the Sokoloff et al. report, Seymour Kety and colleagues introduced a 
method that allowed for the regional quantification of CBF in animal models13. This technique 
used a relatively simple model of inert gas exchange to relate the cerebral uptake of a radioactive 
tracer, trifluorolodomethane (CF3I131), to local CBF. Louis Sokoloff and others quickly applied 
this technique to the question of brain activation in the cat14. They found that visual stimulation 
increased CBF in several brain regions, including the visual cortex, lateral geniculate nucleus, 
and superior colliculus. Unfortunately, the CF3I131 technique could not be applied to living 
humans, as the quantification of tracer uptake required tissue samples from each brain region. An 
early attempt at solving this problem was developed by Ingvar and Lassen15. Instead of tissue 
samples, their technique measured the concentration of [85Kr] using scintillation detectors placed 
directly on the scalp. Although this technique was severely limited in spatial resolution, as tracer 
concentration could only be measured near the detector, it did allow for the measurement of CBF 
in humans16,17. Using this technique, Ingvar and Risberg found that a backwards digit-span task 
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increased average gray matter CBF, with a particular focus in brain regions superior to the lateral 
sulcus18. This finding, along with the animal work discussed above, provided support for the 
Roy-Sherrington hypothesis that increases in neural activity are accompanied by increases in 
cerebral blood flow. Other techniques, however, were necessary to determine if cerebral glucose 
and oxygen consumption were also increased by task engagement. 
The [14C]-2-deoxyglucose ([14C]-DG) tracer method was the first robust strategy for 
measuring the CMRglc within specific brain regions. Published by Sokoloff et al. in 1977, the 
technique relied on the fact that like glucose, deoxyglucose is transported into brain cells and 
phosphorylated by hexokinase19. However, unlike glucose, deoxyglucose is effectively trapped 
within cells after it is converted to 2-deoxyglucose-6-phosphate by hexokinase. It cannot move 
further down the glycolytic pathway because the lack of a hydroxyl group on the second carbon 
atom of deoxyglucose-6-phosphate prevents it from being converted to fructose-6-phosophate by 
phosphoglucose isomerase20. Furthermore, the relatively low activity of glucose-6-phosphtate in 
the brain21 limits the amount of deoxyglucose-6-phosphate being converted back to 
deoxyglucose. As a result of the trapping of 2-deoxyglucose-6-phosphate within brain cells, the 
amount of [14C]-DG taken up by a tissue is directly proportional to CMRglc. Moreover, no 
corrections need to be made for loss of tracer due to the efflux of metabolites. 
Several studies relating CMRglc to functional activity were quickly published using the 
[14C]-DG tracer. Sharp et al. reported that CMRglc was increased in the olfactory bulb of rats 
after exposure to amyl acetate22. In a pair of influential studies, Kennedy et al. found that: 1) 
Electrical stimulation of the sciatic nerve in the rat increased CMRglc in the ipsilateral lateral 
dorsal horn of the spinal cord, 2) Inducing a seizure in the motor cortex of the monkey with 
potassium benzyl penicillin increased CMRglc in the motor cortex, putamen, globus pallidus, 
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caudate, and thalamus, 3) Unilateral visual deprivation in the rat reduces CMRglc in the superior 
colliculus, lateral geniculate, and visual cortex, and 4) Unilateral visual deprivation in the 
monkey decreases CMRglc in alternating 0.3 – 0.4 mm stripes in visual cortex, revealing the 
presence of ocular dominance columns23,24. Finally, the increase in CMRglc within the rat 
superior cervical ganglion following electrical stimulation of its afferent fibers is proportional to 
the frequency of stimulation25. From these and other reports in the literature (for a review see26), 
it became clear that, at least in animal models, cerebral glucose consumption is coupled to brain 
activity.  
Like the CF3I131 technique for measuring CBF, the original [14C]-DG method was 
unsuited for human studies because tissue samples were required to quantify tracer uptake. 
However, the development of positron-emission topography (PET) in the 1970s by Michel Ter-
Pogossian and colleagues27 provided a way to track radioisotopes in the brains of within living, 
healthy humans. PET imaging took advantage of the fact that radioisotopes, such as 15O, 11C, 18F, 
that emit positrons as they undergo radioactive decay. After traveling a few millimeters, an 
emitted positron undergoes an annihilation event with an electron, producing two photons. 
Because the two photons have equal energy (511 keV) and travel in approximately opposite 
directions, the location in space of the original positron can be determined if the two photons are 
detected simultaneously by a pair of scintillation counters (i.e., a coincidence event). If one 
employs a series of scintillation detectors, a 3D image representing the tissue concentration of 
the radioactive tracer can be reconstructed using mathematical algorithms. For more information 
on the development of PET, see the review by Raichle and the references therein28. 
The first study using PET imaging to measure glucose metabolism in the brain was 
published in 1978 by Raichle et al. 29, who used [11C]-glucose to measure CMRglc in rhesus 
6 
 
monkeys. However, the measurement of CMRglc with [11C]-glucose can be complex as [11C]-
glucose is metabolized by cells throughout the body, resulting in radiometabolites that must be 
accounted for. The following year Reivich et al. used [18F]-2-deoxy-2-fluoro-D-glucose ([18F]-
FDG) to measure regional CMRglc in humans30. Like [14C]-DG, [18F]-FDG is also effectively 
trapped within cells after it is phosphorylated by hexokinase31, greatly simplifying the 
quantification of CMRglc. Within a few years of the report by Reivich et al., several studies used 
[18F]-FDG to assess the relationship between functional activity and regional CMRglc in humans 
(for a review of early findings see Phelps et al.32). In 1981, Phelps, Kuhl, and Mazziotta showed 
that visual simulation increased CMRglc in the primary and associative visual cortex33. The 
magnitude of the increase in CMRglc was found to be proportional to the complexity of the 
visual stimulus; stimulation with a constant white light increased CMRglc by approximately 
10%, whereas a complex visual scene resulted in increases of 40 to 60%. Unstructured 
illumination is similarly a weak driver of neural responses in primate visual cortex34. 
A little over a month later, Greenberg et al. used [18F]-FDG to study the effect of visual, 
tactile, and auditory stimulation on local CMRglc35. They found that CMRglc was significantly 
increased from resting controls in the visual cortex during the visual task and in the primary 
auditory cortex during auditory task. Tactile simulation also increased CMRglc in the postcentral 
gyrus, although the increase was not statistically significant. Taken together, the results of these 
early [18F]-FDG PET studies made it clear that like CBF, CMRglc increases in specific brain 
regions during periods of heightened brain activity.  




By the early 1980s, strong evidence had been presented that both CBF and CMRglc 
increase in specific brain regions as a result of functional activity. The remaining piece of the 
puzzle was to determine how activity affects the cerebral metabolic rate of oxygen consumption 
(CMRO2). Early methods for measuring regional CMRO2 in humans were presented as early as 
197036. Similar to the [85Kr] technique for quantifying regional CBF, Ter-Pogossian et al. 
measured regional CMRO2 using five external scintillation detectors following the injection of 
[15O]-O2. Using this technique, Ter-Pogossian et al. were able to quantify CMRO2 in very large 
brain regions (i.e., frontal, parietal, and occipital lobe). The resolution was greatly improved, 
however, with the adaptation of the [15O]-O2 PET imaging by Frackowiak et al. in 198037. A few 
years later, Fox and Raichle used [15O]-O2 PET to determine if CMRO2 was focally increased by 
vibratory stimulation of a single hand38. Although they found that vibratory stimuli slightly 
increased CMRO2 in the sensorimotor cortex (~ 5%), the increase was not statistically 
significant. Conversely, they found that CBF, measured with [15O]-H2O PET, increased by 29% 
percent in the sensorimotor cortex. As a result, the oxygen extraction fraction (OEF), or the 
fraction of arterial oxygen that is extracted by the brain, actually decreased during the 
stimulation trials. Although unexpected, these results provided some of the first evidence that 
cerebral blood flow and metabolism are not entirely coupled to neural activity in the healthy 
human brain. 
Two years later in 1988 Fox and Raichle published a follow-up study that was even more 
influential than their previous work39. In this study Fox and Raichle showed that although visual 
stimulation increases CBF and CMRglc by nearly 50%, it only increases CMRO2 by a small 
nonsignificant amount (~5%). This result has two primary implications. First it shows that 
metabolic uncoupling between CBF and CMRO2 during task-evoked activity is not limited to the 
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sensorimotor cortex. Second, and more importantly, because CMRglc increases to a greater 
extent than CMRO2, it shows that a significant portion of the glucose that is consumed during 
task performance is metabolized via non-oxidative pathways. In their 1998 paper, Fox and 
Raichle suggested that the excess CMRglc is converted to lactate via glycolysis39. Since then, 
many investigators have referred to non-oxidative increases in CMRglc during task performance 
as an increase in “aerobic glycolysis”. The term was originally used to refer to Otto Warburg’s 
discovery that cancers cells produce excess lactate via glycolysis despite sufficient oxygen to 
completely metabolize glucose via oxidative phosphorylation40. It is important to note, however, 
that in this context, the term aerobic glycolysis does not necessarily mean that the ultimate fate 
of all of non-oxidative glucose consumption (NOglc) is lactate. There are many metabolic 
pathways in the brain that do not require complete oxidation of glucose to CO2 and H2O, some of 
which bypass lactate production entirely (Error! Reference source not found.)  
Fox and Raichle’s 1988 paper was immediately controversial41. The prevailing view at 
the time accepted the Roy-Sherrington hypothesis, which postulated that increases in neural 
activity necessitated greater energy production than what would be possible if a portion of 
glucose were to be metabolized anaerobically. This hypothesis was supported by the large body 
of literature reviewed in the first several paragraphs of this chapter. The work of Fox and Raichle 
showed that CBF, CMRglc, and CMRO2 were not completely coupled during functional 
activation and that the increase in energy production during visual stimulation performance was 
a small fraction of the brain’s resting energy needs. Specifically, they estimated that, due to the 
high rate of NOglc, the maximum increase in the rate of ATP production during visual 
stimulation was 8% of baseline39. Raichle and Fox’s work was supported by earlier evidence for 
uncoupling during neural. In 1975, Cooper and colleagues reported that visual stimulation, motor 
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activity, and reading produce focal elevations in oxygen concentration42, suggesting that 
increases in CBF during activation are not matched by increases in CMRO2. 
Despite the initial skepticism, subsequent research has largely confirmed the findings of 
Fox and Raichle that task-evoked activity results in greater increases in CBF and CMRglc than 
CMRO2. Both Ginsberg et al. and Kuwabara et al. reported that CBF and CMRglc are generally 
well-coupled during somatosensory activation43,44. Blomqvist et al. combined [18-F]-FDG PET 
with [1-11C]-glucose PET to show that NOglc is increased in the motor cortex during voluntary 
motor activity45. Several studies using magnetic resonance spectroscopy (MRS) reported focal 
increases in brain lactate concentration in humans during visual46-56, motor57-59, and other 
cognitive60 tasks. Although some investigators have reported no significant changes in regional 
CMRO2 during task performance44,61-63, the majority of studies have found modest (~10-20%) 
increases in CMRO2 during task performance51,64-71. Consistent with moderate task-induced 
increases in CMRO2, Buxton performed a meta-analysis of studies which measured ΔCBF (%) 
and ΔCMRO2 (%) during activation, and found that in most studies ΔCBF was 2-4 times greater 
than ΔCMRO272.  
Perhaps the best evidence corroborating the Fox and Raichle result came with the 
discovery of the bold oxygen level dependent (BOLD) effect and functional magnetic resonance 
imaging (fMRI)73,74. BOLD contrast relies on the fact that deoxyhemoglobin, which is 
paramagnetic, attenuates the MRI signal because it creates small local distortions in the main 
MRI magnetic field75. During periods of increased neural activity, CBF increases more than 
CMRO2 causing a relative increase in the concentration of oxyhemoglobin over 
deoxyhemoglobin and producing a measurable increase in the MRI signal. Therefore, the 
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thousands of papers that employ BOLD imaging each year to measure brain function76 depend 
on uncoupling between CBF and CMRO2. 
1.4 Proposed mechanisms underlying uncoupling 
 
Metabolic uncoupling during functional activity, particularly that resulting in an increase 
in NOglc, is perplexing from an energetic perspective. Complete oxidative phosphorylation of 
glucose yields approximately 30 molecules of ATP, whereas glycolysis creates only 2. Why 
would the brain utilize an energetically less efficient pathway during periods of increased 
activity? First, it is important to recall that only a small increase in oxidative phosphorylation is 
necessary because the increase in ATP during task performance is small fraction of the baseline 
production rate39. This was confirmed by Lin et al., who used magnetic resonance spectroscopy 
(MRS) to show that visual stimulation increased ATP production by only about 15%51 (see Zhu 
et al. for a higher estimate77). Furthermore, Lin et al. found that the moderate increase in ATP 
production could be accounted for by a modest increase in CMRO2 from baseline values (~15%). 
This is consistent with early animal model studies that reported that task-induced increases in 
energy production could be almost entirely accounted for by oxidative consumption of 
glucose78,79. Similarly, a meta-analysis of human studies estimated that nearly 90% of the task-
induced increase in ATP production is met by oxidative phosphorylation80. Thus it appears that 
although it takes up more glucose that is necessary for oxidative phosphorylation, the brain still 
relies on oxidative phosphorylation to meet its energy needs during periods of increases activity.  
Why then does the brain consume an excessive amount of glucose? One explanation, 
suggested by Raichle and Mintun, is that glycolysis is used to quickly generate the ATP that is 
not created by oxidative phosphorylation81. This hypothesis is supported by the fact that 
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glycolysis can operate at a much faster rate than oxidative phosphorylation, at least in active 
skeletal muscle82,83. Another hypothesis that predicts that neural activity should increase 
glycolytic ATP production is the astrocyte-neuron lactate shuttle hypothesis (ANLS)84. Pellerin 
and Magistretti developed the ANLS to explain their finding that glutamate stimulated glycolysis 
and subsequently lactate release from cultured astrocytes85. The first step in the ANLS model is 
the astrocytic uptake of glutamate from the synaptic clef during neural activity. The uptake of 
glutamate by astrocytes is facilitated thorough the GLT-1 and GLAST transporters, which couple 
glutamate influx with the uptake of 3 molecules of Na+86. Therefore, astrocytes must remove 
both excess intracellular glutamate and Na+ in order to retain the ability to remove glutamate 
from the synapse. To remove excess glutamate, astrocytes convert it glutamine using glutamine 
synthetase, a reaction that costs 1 ATP. Glutamine is then transferred back to neurons where it 
can be synthesized back into glutamate. At the same time, excess Na+ is removed from 
astrocytes using the Na+/K+ ATPase. The Na+/K+ ATPase requires one molecule of ATP to 
remove 3 Na+ ions. According to the ANLS, the two molecules of ATP that are needed to 
remove glutamate and Na+ are met by the two ATP generated by glycolysis. Finally, the lactate 
that is produced as the end point of glycolysis is shuttled to neurons where it undergoes oxidative 
phosphorylation.  
A large body of experimental evidence supports the ANLS mechanism (for a 
comprehensive review, see Magistretti and Allaman87). Several studies have shown that the 
structure and enzymatic organization of astrocytes and neurons is set up to promote a transfer of 
lactate between the two cell types. The endfeet of astrocytes surround capillaries88 and express 
glucose transporters89, making them well positioned to take up glucose from the blood. 
Astrocytes also are in direct contact with synaptic terminals90, which have been shown to be the 
12 
 
site of the majority of glucose uptake during electrical stimulation91,92. Lactate dehydrogenase 
(LDH), the enzyme that converts lactate to pyruvate, exists in five distinct isozymes93. 
Astrocytes contain a high concentration of LDH594,95, the form of LDH typically found in 
glycolytic tissues such as muscle96. Conversely, neurons primarily express LDH194, which is 
usually found in oxidative tissues such as the heart96. Similarly, neurons, but not astrocytes, 
contain high quantities of pyruvate dehydrogenase95, the enzyme necessary to convert pyruvate 
to acetyl-CoA, the first molecule in the TCA cycle. Finally, astrocytes have a significantly higher 
NAD+/NADH ratio as compared to neurons, which is consistent with greater lactate production 
in astrocytes97. 
There is also a good deal of functional evidence supporting the ANLS. Studies employing 
whisker stimulation in rodents have shown that increases in barrel cortex CMRglc: 1) occur 
primarily in astrocytes98, and 2) are strongly attenuated in mice with GLT-1 and GLAST 
knockout mutations99. Studies in culture have also shown that neurons prefer to oxidize external 
cellular lactate over glucose100,101. Consistent with this fact, elevated blood lactate decreases 
CMRglc in humans102,103. Finally, studies using MRS in rats have reported a nearly 1:1 
relationship between cerebral glucose oxidation and glutamate cycling104,105. This is exactly what 
one would expect if astrocytes use glycolysis to generate 2 ATP to power glutamate turnover and 
then shuttle lactate over to neurons for complete oxidation80. 
Despite this evidence, the ANLS remains controversial, having been criticized on both 
experimental106,107 and theoretical grounds108 (for an extremely detailed critical discussion see 
the review by Dienel109). For example, Lundgaard et al. used two-photon microscopy with a 
fluorescence 2-deoxyglucose analogue to show that glucose consumption is higher in neurons 
than astrocytes at rest and during neural stimulation106. More generally, one of the most 
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pervasive critiques of the ANLS is that most of the evidence in its favor comes mostly from in 
vitro studies; in particular no study has shown that glucose-derived lactate is transported from 
astrocytes to neurons in vivo. However, recent results have begun to address this criticism. 
Zimmer et al. reported that simulation of glutamate uptake increases CMRglc in rats110. 
Furthermore, Mächler et al. showed that in transgenic mice: 1) Astrocytes have higher lactate 
concentration than neurons at baseline, 2) Intravenous lactate injections increase lactate more in 
neurons than astrocytes, and 3) Intravenous pyruvate injections result in greater lactate efflux 
from astrocytes than neurons111. Taken together, these findings suggest that glycolysis in 
astrocytes creates a lactate gradient between astrocytes and neurons, which supports lactate flow 
down this gradient. It is likely, though, that the ANLS will remain a source of controversy until 
shuttling of glucose-derived lactate from astrocytes is observed directly in vivo.  
It is important to note, however, that in its original formation the ANLS does not explain 
the rise in NOglc during increased neural activity. Instead, the ANLS predicts a rise in non-
oxidative glucose use in astrocytes, followed by an increase in oxidative phosphorylation in 
neurons85. In this model, there is in no total increase in non-oxidative glucose use, which 
contradicts the NOglc reported by Fox and Raichle39. To explain this discrepancy, several 
alternative explanations have been proposed. Pellerin et al. hypothesized that increased neural 
activity produces different metabolic alterations at different time scales84. According to their 
model, immediately following depolarization, neurons undergo oxidative metabolism to provide 
the Na+/K+ ATPase with the ATP necessary to remove excess Na+. This is consistent with the 
work of Kasischke et al., who reported that in the first 10 seconds after electrical stimulation, 
NADH levels are decreased in neurons112. Next the inhibition of neuronal glucose uptake by 
glutamate release113, causes an increase in lactate consumption in neurons. Experiments in both 
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rats114 and humans115 which show decreased cerebral lactate concentration immediately 
following activation support this hypothesis. The continued release of glutamate from neurons 
activates the Na+/K+ in astrocytes84, which results in enhanced astrocytic glucose uptake and 
lactate production as described earlier85. The excess lactate is then is transported to neurons, 
where it can be used to oxidatively generate the ATP necessary for continue neural activity. 
Multiple studies in humans46-57,59,60,116 and animals114,117-123 have shown that neural activity 
stimulates lactate production. Furthermore, Kasischke et al. showed that NADH activity starts to 
increase in astrocytes approximately 10 seconds after activation112.  
During periods of sustained activity, however, the model proposed by Pellerin et al. 
predicts that astrocytes use glycogen to supplement the glucose supplied from the blood. 
According to this model, it is glycogen replenishment that is responsible for the increase in 
NOglc during neural activity. A similar hypothesis was also proposed by Shulman and 
colleagues124, who pointed out that glycogen synthesis reduces the ATP generated from 
glycolysis from 2 ATP per mole of glucose to 1 ATP per mole. Therefore, to generate the same 
amount of ATP from glycolysis, twice the amount of glucose would need to be consumed, 
resulting in twice the amount of lactate production. Although shunting glucose down the 
glycogen pathway is energetically less efficient and results in substantial NOglc, Shulman et al. 
hypothesize that it is used during neural activity because glycogen can be quickly broken down 
during periods of greater energy requirements.  
Brain tissue contains approximately 5-10 µMol∙g-1 119,120,122,125 of glycogen, although the 
exact value is fairly sensitive to measurement technique119,125. At euglycemia, the concentration 
of glycogen in the brain is considerably higher than that of glucose, which typically exists in 
concentrations around 1.0 µMol∙g-1126-129. Interestingly, glycogen in the brain is largely confined 
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to astrocytes130. Consistent with the models proposed by Pellerin et al. and Shulman et al., neural 
activity has been shown to deplete glycogen stores in animal models118-120,122,131. Furthermore, 
prolonged periods of wakefulness have been shown to reduce cerebral glycogen content in 
rodents132 (but see133), and to increase glycogen turnover in astrocytic processes near synapses134, 
further implicating glycogen use during neural activity. However, glycogen turnover has been 
shown to be quite slow in the resting brain in both humans135 and rats136. Moreover, a study in 
humans reported that glycogen concentration in the occipital lobe was not changed by visual 
stimulation135. Although it is has been argued that the experimental methods and kinetic 
modeling used by this study were not sufficient to detect glycogen breakdown137, there are, to 
our knowledge, no other studies examining glycogen change during task-evoked activity in 
humans. Studies in rats have also reported that there is little evidence of non-oxidative glucose 
use 15 minutes after activation118, even though glycogen levels are still below baseline118,119. 
Therefore, more studies are needed to clarify how much glycogen turnover contributes to non-
oxidative glucose metabolism driven by neural activity. In particular, methods are need to 
properly assess glycogen flux in vivo, as changes in glycogen concentration might not accurately 
reflect changes in the flux of glucose through the glycogen pool122. 
An alternative hypothesis is that astrocytes produce more lactate during increased neural 
activity than can be oxidized by neurons. This would result in a temporary increase in NOglc. 
Then, after activity has returned to basal levels, the excess lactate could either be removed from 
the brain or oxidized. Studies employing MRS in humans have reported that lactate levels peak 
after a few minutes of stimulation and then decline thereafter, either towards a new slightly 
elevated baseline46,47,60, or to pre-stimulation levels48,52. Studies in both humans116 and rats138 
have shown that increased brain activity stimulates lactate efflux from the brain. Other evidence 
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suggests that lactate oxidation is increased after functional activity. Specifically, PET studies in 
humans have reported that CMRO2 increases during prolonged stimulation71,139, whereas 
CMRglc decreases140. Similarly, Madsen et al. reported in rats that as brain lactate concentration 
returns to baseline following sensory stimulation, the brain uses more oxygen than can be 
accounted for by glucose consumption118.  
Not all the evidence is consistent with the idea that NOglc is elevated during task because 
of a temporary increase in lactate consumption. Several human MRS studies have reported that 
lactate concentration remains elevated during prolonged stimulation49,50,53,54,58. Furthermore, 
additional human studies have shown that NOglc persists well after task-performance116,141. 
Finally, rodent studies have argued that lactate production has a limited role in explaining 
NOglc. The same Madsen et al. report mentioned previously estimated that less than 54% of the 
NOglc that occurred during stimulation could be accounted for by lactate production118. Based 
on metabolite measurements from extracellular fluid following the infusion of [3,4-14C]-glucose, 
Ball et al. estimated that lactate oxidation can only account for a very small fraction of activity 
dependent increases in NOglc138. Therefore, although the existing evidence suggests that 
excessive lactate production plays a role NOglc during neural activity, it is unlikely to be the 
only factor.  
An alternative, albeit non-exclusive, hypothesis is that NOglc during task-evoked activity 
is directed towards glutamate synthesis. Specially, Hertz and Fillenz proposed that increased 
neural activity stimulates the production of glutamate, which is then consumed via oxidative 
phosphorylation once activity levels have returned to baseline142. In support of this hypothesis, a 
[6-14C]-glucose labeling studying in rats reported a significant increase in the labeling of 
glutamate during sensory stimulation120. In addition, most50,53,54,56,58,143,144, but not all48,55, studies 
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have reported that sensory stimulation increases glutamate concentration in humans by a small 
amount (typically less than 5% averaged over a large ROI in the appropriate sensory area). 
Interestingly, some investigators have also found that brain aspartate concentration decreases as 
glutamate concentration increases50,54,56. This suggests that some of the increase in glutamate 
production may be due to the malate-aspartate shuttle49,145. The malate-aspartate shuttle is a 
critical metabolic pathway, as it generates NAD+ needed for glycolysis and transfers reducing 
equivalents, in the form of NADH, from the cytosol to mitochondria, where they are required for 
oxidative phosphorylation109,146. However, not all studies have reported decreases in aspartate 
concentration with sensory simulation53,55,143. Therefore, more research is needed to determine 
what role the malate-aspartate shuttle plays in glutamate production during neural activity. More 
generally, the extent to which glutamate synthesis is responsible for NOglc during task 
performance remains unclear. Although the evidence discussed above indicates that glutamate 
concentration is elevated during sensory stimulation, the increases are typically only a small 
percent of baseline values. Quantitative studies are clearly needed to establish how much NOglc 
is dedicated to glutamate production during neural activity.  
One final hypothesis deserves to be discussed. Multiple authors have proposed that 
NOglc provides the brain with the biosynthetic precursors needed for neural development and 
plasticity147,148. Early support for this hypothesis was obtained by Madsen et al. in 1995, who 
found that the whole-brain average NOglc remained elevated for more than 40 minutes after 
participants performed the Wisconsin Card Sorting Test116. Interestingly, Madsen et al. later 
reported in rats, that cerebral NOglc was effectively eliminated only minutes after tactile 
simulation118. These discrepant results suggest that increases in NOglc following task 
performance may be species dependent. More recently, Shannon and colleagues expanded upon 
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the work of Madsen et al. using PET imaging141. They reported that approximately 2 to 3 hours 
after performing a motor learning task, NOglc was increased in Brodmann area 44, an area 
which is active during motor responses149. Taken together, these two studies suggest that NOglc 
plays a role in learning-induced synaptic plasticity. 
Studies employing radiolabeled glucose infusions in rats have also provided evidence that 
glucose is used for biosynthesis during neural activity. Cruz et al. reported that, after acoustic 
stimulation, 10-25% of the recovered radiolabel was found in products of the pentose phosphate 
shunt121,150, a pathway used for nucleic acid synthesis151. Similarly, Dienel et al. found that tactile 
stimulation increased the amount of radiolabel recovered in a large number of glucose 
metabolites, including the amino acids glutamate, GABA, and alanine120. Finally, advocates of 
the biosynthesis hypothesis often point out that, during human development, a period 
characterized by brain growth and synaptic development152, approximately 30% of the brain’s 
glucose is consumed via non-oxidative pathways153 (but see154). Similarly, developmental studies 
in primates have shown that glucose consumption peaks at around the same time as rates of 
myelination and synaptogenesis148. 
There is, therefore, credible evidence that part of the brain’s NOglc passes through 
biosynthetic pathways. However, despite the fact that biosynthesis plays an important role in 
synaptic plasticity155, there is currently no evidence that glycolytic by-products are directly 
incorporated into new structural elements (e.g.., synapses) during learning. Critics of the 
biosynthesis hypothesis also argue that use of glucose for biosynthesis would result in 
uncontrolled brain growth154. Although this criticism ignores turnover of synaptic elements156,157 
and proteins158,159, as well as alternative mechanisms for the efflux of glucose metabolites138,160, 
it does highlight the fact that we do not yet know how carbon consumed via biosynthetic 
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pathways leaves the brain. Methods that can track the movement of glucose in and out of the 
brain’s biosynthetic machinery are needed to clarify the relationship between plasticity and 
NOglc. 
Currently, no single hypothesis entirely explains why NOglc is elevated during periods of 
increased neural activity. It is more likely that a combination of mechanisms, including those 
discussed in the previous paragraphs, is needed to account for all glucose consumption in excess 
of oxygen utilization. An accurate model of task-evoked NOglc will likely be complex, as it will 
need to account for, among other things, multiple metabolic pathways and interactions among 
cell types. Moreover, the effect of NOglc may not be confined to the area of activation, as 
glucose metabolites can spread to neighboring tissues via gap junctions in astrocytes121. Finally, 
a useful working model will need to consider non-oxidative uses of glucose that go beyond 
merely energy metabolism. Recent work has begun to establish the role of lactate as signaling 
molecule161, with a critical role in formation of long-term memories87. For example, Suzuki et al. 
showed that blocking the transfer of lactate from astrocytes to neurons impairs long-term 
memory formation in rats162. Importantly, it does not appear that blocking lactate transport 
impairs energy metabolism, as direct injection of glucose does not rescue memory formation. 
Instead, lactate appears to induce the expression of genes such as Arc162,163 that are related to 
synaptic plasticity155. These studies suggest that NOglc may promote biosynthesis in more ways 
than just providing metabolic precursors for biosynthesis. Furthermore, studies linking lactate 
signaling and learning reinforce the need for a model of metabolism during neural activity that 
incorporates more than just the energetic perspective. 




Since the work of Fox and Raichle in 1988, the majority of research on metabolic 
uncoupling in the brain has focused on understanding uncoupling during periods of increased 
neural activity. However, it is important to realize that it was recognized as early as 1942 that 
during periods of rest the brain consumes more glucose than would be expected given its rate of 
oxygen consumption4. Early studies reported that the whole-brain average oxygen-to-glucose 
index (OGI), which is the molar ratio of oxygen to glucose consumption, was around 5.5 (for 
review see164). If glucose is entirely consumed via oxidative pathways, the OGI should be 6, as 6 
moles of oxygen are required to oxidize 1 mole of glucose. An OGI of 5.5 indicates that nearly 
10% of the brain’s glucose consumption at rest does not undergo oxidative phosphorylation. 
Following its discovery, the importance of non-oxidative glucose metabolism was largely 
underappreciated. Most investigators argued that lactate (or pyruvate) efflux accounted for nearly 
all of the NOglc in the brain4,165,166. This argument was also presented by Siesjö in his influential 
textbook Brain Energy Metabolism167. According to Siesjö, “… an OGI of less than 100% [6.0] 
could be explained in terms of production of lactate … there is no need to explain an OGI value 
of less than 100% [6.0] in terms of synthesis of amino acids or other compounds.” To this day, 
many investigators still hold to this view. For example, in recent review, Dienel wrote that 
“Submaximal OGI in resting brain is ascribed mainly to lactate production and efflux from 
brain…”109. 
Despite the widely held view that non-oxidative glucose metabolism at rest merely 
reflects lactate efflux, and is therefore of little physiological importance, there is evidence 
suggesting otherwise. Based differential arterio-venous measurements of glucose, lactate, and 
oxygen in humans, Scheinberg et al. reported in 1965 that cerebral NOglc could not be explained 
by lactate efflux to venous blood168. They also presciently concluded that “… the portion of 
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utilized glucose not accounted for by oxidation may be involved in the synthesis of other 
substances, in particular amino acids of cerebral proteins.” More recently, Vaishnavi et al., using 
PET measurements of CMRglc and CMRO2, showed that there are regional differences in 
NOglc147. The lowest rates of NOglc were found in the cerebellum and medial temporal lobe, 
whereas the highest were found in the prefrontal and parietal cortices. Interestingly, the regions 
with elevated NOglc overlapped strongly with two resting state networks (RSNs), that is, regions 
of the brain whose spontaneous activity is highly correlated at rest169. The first RSN was the 
cognitive control network, a network that encompasses parts of the lateral prefrontal and parietal 
cortices and is thought to be involved in attention and working memory170. The second RSN was 
the default mode network (DMN), a collection of regions including the prefrontal cortex, 
precuneus, and lateral parietal cortex171. The defining feature of the DMN is that, although it is 
metabolically active at rest, it becomes less so during goal-directed task performance171-173. The 
DMN has traditionally been associated with self-referential processes such as mind-
wandering174,175; however there is evidence that the DMN has more expansive role (for a review 
see176). The fact that resting NOglc is spatially correlated with regions associated with RSNs 
suggests that these regions may have unique metabolic needs compared to other brain regions. 
More recently, Goyal et al. reported that the expression of genes related to synaptic 
plasticity and development is enriched in brain regions with high levels of NOglc153 (but see177). 
This suggests that a portion of the brain’s non-oxidative glucose metabolism in spent on 
plasticity and other biosynthetic processes (for a similar argument during task-evoked activity 
see Proposed mechanisms underlying uncoupling above). In support of this idea, Glasser et al. 
showed that there is a negative spatial correlation between regional NOglc and a putative 
measure of cortical myelination178. Furthermore, Segarra-Mondejar et al. reported that glucose 
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consumption, specifically glycolysis, is necessary for neurite growth in vitro and in vivo in 
mice179. Although intriguing, these and the studies discussed in the preceding two paragraphs do 
not definitively establish the function of NOglc in the resting brain. As in metabolic uncoupling 
during task-evoked activity, it is likely that multiple mechanisms are at play. To further establish 
the role of NOglc at rest, there is a need for techniques that can quantify the flux of glucose into 
multiple metabolic pathways, including those responsible for biosynthesis. To address these 
issues,13C MRS180,181 and hyperpolarized 13C MRI182 in vivo and metabolic flux analysis in 
vitro183 provide intriguing opportunities. 
1.6 Brain metabolism in altered metabolic states and disease 
 
So far, this chapter has focused almost exclusively on brain metabolism in healthy 
individuals. However, understanding the effect of acute metabolic states and neurological 
diseases on brain metabolism has been an active area of study since methods for measuring brain 
metabolism in humans were first developed. The same year that he published his influential 
article establishing the nitrous oxide technique for measuring CBF in humans12, Kety published 
five papers studying the relationship between whole-brain CBF and CMRO2 and 
schizophrenia184, intracranial pressure185, diabetic coma6, hypertension186, and hypercapnia187. 
One of the interesting findings that emerged from these studies is that CBF and CMRO2 often are 
uncoupled during metabolic challenges. For example, Kety reported that hypercapnia 
dramatically increases CBF, without a proportional increase in CMRO2187. Conversely, Kety 
found that, although patients experiencing diabetic coma had a greatly reduced CMRO2, their 
CBF values were largely in the normal range6.  
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Since these initial studies by Kety and colleagues, multiple investigators have reported 
uncoupling between CBF, CMRO2, and CMRglc during acute metabolic challenges. 
Hypoglycemia was intensively studied in the 1940 and 1950s since insulin shock was, at the 
time, considered a viable treatment for schizophrenia188. Consistent with Kety’s study in patients 
suffering from diabetic coma, profound hypoglycemia decreased whole-brain CMRglc greatly, 
whereas CBF and CMRO2 changed modestly7,184,189,190. Another notable example is hypoxia. 
Studies in both humans166,187,191 and rats192 have shown that hypoxia dramatically increases 
global CBF without altering CMRO2. Furthermore, CMRglc increases modestly during 
hypoxia166. The increase in CMRglc without a proportional increase in CMRO2, results in 
increased NOglc during hypoxia166,193, which appears to be due to lactate production166,194. This 
is consistent with the finding that acute hypocapnia results an in a temporary increase in 
NOglc195. 
The variety of the examples discussed in the previous two paragraphs should make it 
clear that alterations in systematic metabolism often disrupts metabolic coupling in the brain. In 
some cases it is fairly simple to come up with a reasonable hypothesis to explain the divergent 
changes metabolism. During hypoxia, for example, it is possible that CBF and lactate production 
increase to prevent energy failure167. In other cases, coming up with a satisfactory explanation is 
more difficult. Despite a great deal work, there is still no complete account of what fuel sources 
the brain uses to maintain CMRO2 during hypoglycemia (for a review see196).  
In addition to its role in acute disorders, metabolic uncoupling has also been implicated in 
chronic neurological disease. For example, temporal lobe epilepsy has been shown to decrease 
CMRglc in the temporal lobe to a greater extent than it does CBF197-199. Interestingly, metabolic 
uncoupling also occurs during traumatic brain injury, which increases whole-brain NOglc200. 
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Given these results, one would expect that metabolic uncoupling would be an active area of 
study for those interested in understanding neurological diseases, but this is not always true. A 
promising example of where research on metabolic uncoupling could contribute to the study of 
neurological disease is in Alzheimer’s disease (AD) research. AD research is a field which has 
grown quickly in the last few decades201, due, in part, to the increased economic and social 
burden that AD is expected to have on aging populations202.  
Pathologically, AD is defined by the development of amyloid-beta plaques, followed by 
tangles of hyperphosphorylated tau203. However, another hallmark of AD is focal decreases in 
glucose consumption. AD patients typically show deficits in glucose consumption in the frontal, 
parietal, and temporal lobes, as well as in the precuneus and posterior cingulate204. It is generally 
accepted in the field that decreased glucose use in AD is a sign of synaptic dysfunction203,204; a 
conclusion that is based on studies that have shown that most of the glucose consumed during 
neural activity is taken up by synapses91,92. There is, however, a lack of empirical evidence that 
decreased glucose consumption in AD patients is entirely due to energy failure at synapses. 
Although glucose metabolism measured using FDG PET is one of the most common biomarkers 
reported in AD studies205, cerebral oxygen metabolism is rarely assessed. Early studies showed 
that in patients with severe dementia, global CMRO2 declines by about 20%206, with the largest 
declines occurring in the parietal lobe207. However, as these studies did not simultaneous 
measure glucose consumption, it is not clear if CMRglc declines in proportional to oxygen 
consumption. Indeed, regional decreases in CMRglc in excess of 30-40% have been reported in 
individuals with AD208,209. Therefore, the claim that AD patients have lower cerebral glucose 
consumption entirely because of synaptic dysfunction relies on the assumption that there is a 
tight coupling between synaptic activity and glucose consumption in individuals with AD.  
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However, as we have seen, metabolic coupling becomes much less pronounced in many 
neurological diseases. Indeed, there is evidence for uncoupling in AD patients (for a review 
see210). CMRglc has been shown to decrease to a greater extent than CMRO2 in individuals with 
both early-onset211 and late onset AD212-214. This indicates that NOglc decreases during AD, in 
addition to the decline of NOglc that has been noted during healthy aging215. Intriguingly, Hoyer 
et al. also showed that in later stages of AD, CMRO2 drops sharply, which eliminates much of 
the difference between changes in CMRglc and CMRO2212. This suggests that the relationship 
between AD and brain metabolism may evolve as the disease progresses. Consistent with this 
hypothesis, it was recently reported that there is a negative correlation between tau deposition 
and NOglc in cognitively normal individuals216. However, this correlation was only found in 
individuals that were at risk for developing AD due to high levels of amyloid plaques. It is 
therefore possible that amyloid plaques mediate the relationship between NOglc and AD. In 
agreement with this proposal, Vlassenko et al. reported that the regions of the brain with high 
levels of amyloid plaques in individuals with AD are the same regions that have high levels of 
NOglc in healthy young adults217. A few years later, Bero et al. replicated this finding by 
showing a positive regional correlation between lactate production and amyloid plaque loads in a 
transgenic mouse model of AD123. Together, these results suggest that high rates of NOglc may 
put a brain region at risk for developing amyloid plaques later in life. Determining if deficits in 
NOglc lead to the development of AD pathology, or if they are merely an epiphenomenon, will 
require more direct research.  
1.7 Overview of dissertation 
 
The previous sections in this introductory chapter have argued that metabolic uncoupling, 
in particular that resulting in NOglc, has important consequences that extend beyond energy 
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metabolism. This is in contrast to the conventional view, which posits that metabolic uncoupling 
is a minor phenomenon of relatively little physiological importance. Therefore, the goal of the 
remaining chapters in this thesis is to further explore discrepancies between CBF, CMRglc, and 
CMRO2. 
In Chapter 2, I will examine whole-brain NOglc at rest in healthy individuals. As 
previously mentioned, an early review by Kety concluded that the whole-brain OGI was 
approximately 5.5164, which shows that around 9% of CMRglc is metabolized without oxygen 
consumption. Conversely, a recent small meta-analysis (n=8) reported that the whole-brain OGI 
may be as low as 5.1218. To resolve the quantitative discrepancy, I performed a large meta-
analysis of studies reporting whole-brain OGI (n=40). Also because it is widely believed that 
excess glucose in the brain is accounted for by lactate production167, we analyzed studies (n=39) 
that reported the whole-brain oxygen-to-carbohydrate index (OCI), a measure that includes 
lactate as well as glucose consumption. If the OGI is less than 6.0 due to lactate production, then 
the average whole-brain OCI from our meta-analysis should not be statistically different from 
6.0. Alternatively, an OCI significantly less than 6.0 suggests that some of the brain’s NOglc 
proceeds down metabolic pathways that do not end in lactate production (e.g., biosynthetic 
pathways). A slightly modified version of Chapter 2 has been published elsewhere219. 
The topic of Chapter 3 is regional differences in NOglc in the brain at rest. A previous 
study from our laboratory reported that the fraction of glucose consumed via non-oxidative 
pathways varies across the human brain147. The precuneus, frontal lobe, and parietal lobe have 
high rates of NOglc, whereas the cerebellum and medial temporal lobe have lower rates. This 
report was recently challenged by Hyder et al., who argued that these regional differences are 
methodical artifacts220. In the original report, Vaishnavi et al. calculated cerebral glucose and 
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oxygen consumption using local-to-global tracer uptake ratios147, instead of quantifying absolute 
CMRglc and CMRO2 directly in each region. Although the lack of absolute units can result in 
misleading inferences221, uptake ratios are a commonly used technique because they remove 
global variance and do not require invasive arterial sampling. In their paper, Hyder et al. 
attempted to show that there are no regional differences in NOglc if a proper kinetic model is 
used to compute absolute CMRglc and CMRO2220. However, a careful reading of the Hyder et al. 
paper suggested that the authors actually reported regional differences in their data that were 
simply masked by a combination of misleading data visualization and improper statistical 
techniques. I therefore reanalyzed the Hyder et al. data using simple, direct methods to confirm 
this impression. The results of this analysis were also reported in a previous article222. 
 Although the focus of Chapters 2 and 3 are on brain metabolism in healthy individuals 
under normal physiological conditions, the goal of Chapter 4 is to examine regional cerebral 
blood flow and glucose metabolism in participants experiencing moderate hypoglycemia. Many 
studies have examined how regional CBF changes in response to hypoglycemia (for a review 
see223). These studies have found that, in humans, hypoglycemia focally increases CBF in the 
thalamus, globus pallidus, and medial prefrontal cortex224-226. In contrast, most of the studies 
measuring CMRglc during hypoglycemia have reported only global values. Although global 
CMRglc is substantially lower in subjects experiencing profound hypoglycemia184,189, it does not 
begin to decline until moderate hypoglycemia (~50 mg/dL) occurs227,228. The sole study 
examining regional CMRglc during moderate hypoglycemia humans reported changes in every 
region examined229,230. Thus, hypoglycemia seems to affect CBF, which changes focally, 
differently than CMRglc, which changes uniformly across the brain. To test this hypothesis, I 
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used [15O]-H2O and 1-[11C]-D-glucose PET to measure regional CBF and CMRglc in 18 patients 
during stepped hypoglycemia.  
 Lastly, Chapter 5 will investigate regional changes in blood flow, glucose consumption, 
and oxygen metabolism in hyperglycemic individuals. It is well-known that during euglycemia, 
more glucose is present in the blood than is taken up by cells in the brain 231. Therefore, one 
would predict that increases in blood glucose concentration would not change CMRglc. 
However, there is evidence that this may not be true. Although statistically significant in only 
one report232, multiple studies have reported that hyperglycemia increases global CMRglc 
slightly232-235. More interestingly, two separate studies have reported that white matter is 
particularly affected by hyperglycemia, with CMRglc increasing by over 40% in both 
studies232,234. Conversely, the same two studies found that the increases in CMRglc within gray 
matter where either much smaller (~20%)232, or not significant234.There currently is no 
explanation as to why hyperglycemia increases CMRglc specifically in white matter. As 
metabolic uncoupling occurs in so many neurological conditions (see Brain metabolism and 
disease above), it is possible that hyperglycemia selectively increases NOglc. I used [18F]-FDG 
and [15O]-O2 PET imaging to determine if changes in glucose consumption during 
hyperglycemia are matched by changes in oxygen consumption. Finally, I used [15O]-H2O PET 




Gray boxes denote each separate pathway that glucose can enter once inside the brain. The 
majority of glucose enters the glycolytic pathway and then is reduced to CO2 and water in the 
TCA cycle. However, the TCA cycle also produces many important amino acids such as 
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Figure 1.1: Major metabolic pathways for cerebral glucose metabolism 
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the polyol pathway, or used to generate intermediates for nucleic acid biosynthesis via the 
pentose phosphate shunt. Abbreviations are as follows: 1,3-Bisphosphoglycerate (1,3PG), 2-
Phosphoglycerate (2PG). 3-Phosphoglycerate (3PG), Phosphoglycerate kinase (3PGK), 6-
Phosphogluconate (6-PGD), 6-Phosphogluconolactone (6-PGDL), Acetylcholine (ACh), 
Aconitase (ACON), Adenosine diphosphate (ADP), α-Ketoglutarate dehydrogenase (α-KGDH), 
Alanine (Ala), Aldose reductase (AR), Aspartate (Asp), Adenosine-triphosphate (ATP), 
Coenzyme A (CoASH), Citrate synthase (CS), Dihydroxyacetone phosphate (DHAP), Erythrose 
4-phosphate (Ery4P), Flavin adenine dinucleotide (FAD), Dihydroflavine adenine dinucleotide 
(FADH2), Fructose-bisphosphate aldolase (FBA), Fructose 1,6-bisphosphate (Fru-1-6-P2), 
Fructose 6-phosphate (Fru-6-P), Glucose-6-phosphate dehydrogenase (G6PD), Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH), Glyceraldehyde 3-phosphate (GAP), Guanosine 
diphosphaste (GDP), Glucose-1-phosophate (Glc-1-P), Glucose-6-phosphate (Glc-6-P), 
Glutamine (Gln), Glutamate (Glu), Glycine (Gly), Gluconolactonase (GNL), Glycogen synthase 
(GS), Guanosine triphosphaste (GTP), Hexokinsae (HK), Isocitrate dehydrogenase (IDH), 
Lactate dehydrogenase (LDH), Malate dehydrogenase (MDH), Nicotinamide adenine 
dinucleotide (NAD+, NADH), Nicotinamide adenine dinucleotide phosphate (NADP+, NADPH), 
Nucleoside-diphosphate kinase (NDPK), Pyruvate dehydrogenase (PDH), Phosphoenolpyruvate 
(PEP), Phosphofructosekinase (PFK), Phosphoglucose isomerase (PGI), Phosphoglucomutase 
(PGM1), Phosphoglycerate mutase (PGM2), Pyruvate kinase (PK), Pyrophosphate (PP), 
Pyruvate (Pyr), Ribulose-5-phosophate (R5P1), Ribose-5-phosphate (R5P2), Ribulose-5-
phosphate 3-Epimerase (RPE), Ribulose-5-phosphate Isomerase (RPI), Sedoheptulose 7-
phosphate(S7P), Succinyl coenzyme A synthetase (SCS), Succinate dehydrogenase (SDH), 
Transaldolase (TAL), Transketolase (TKT), Triose-phosphate isomerase (TPI), Uridine 
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diphosphate (UDP), UTP-glucose-1-phosphate uridylytransferase (UDPGP), Uridine 
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Chapter 2: A systematic meta-analysis of oxygen-to-glucose and 




Glucose is the predominant fuel supporting brain function. If the brain’s entire glucose 
supply is consumed by oxidative phosphorylation, the molar ratio of oxygen to glucose 
consumption (OGI) is equal to 6. An OGI of less than 6 is evidence of non-oxidative glucose 
metabolism. Several studies have reported that the OGI in the resting human brain is less than 
6.0, but the exact value remains uncertain. Additionally, it is not clear if lactate efflux accounts 
for the difference between OGI and its theoretical value of 6.0. To address these issues, we 
conducted a meta-analysis of OGI and oxygen-to-carbohydrate (glucose + 0.5*lactate; OCI) 
ratios in healthy young and middle-aged adults. We identified 47 studies that measured at least 
one of these ratios using arterio-venous differences of glucose, lactate, and oxygen. Using a 
Bayesian random effects model, the population median OGI was 5.46 95% credible interval 
(5.25-5.66), indicating that approximately 9% of the brain’s glucose metabolism is non-
oxidative. The population median OCI was 5.60 (5.36-5.84), suggesting that lactate efflux does 
not account for all non-oxidative glucose consumption (NOglc). Significant heterogeneity across 
studies was observed, which implies that further work is needed to characterize how 




i This chapter is slightly modified version of a previously published article: Blazey TM, Snyder AZ, Goyal MS, 
Vlassenko AG, Raichle ME. A systematic meta-analysis of oxygen-to-glucose and oxygen-to-carbohydrate ratios in 
the resting human brain. PLoS ONE 2018; 13: e0204242. 
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Glucose and oxygen consumption are tightly coupled in the brain at rest, with the 
majority of glucose undergoing complete oxidative phosphorylation1. Furthermore, the ratio of 
carbon dioxide production to oxygen consumption is very close to one2, indicating that nearly all 
of oxygen consumption is used for carbohydrates. The standard measure of coupling between 
oxygen and glucose utilization is the oxygen-to-glucose index (OGI), which is the molar ratio of 
oxygen to glucose consumption. An OGI of 6 indicates that all glucose is consumed via 
oxidative pathways.  
The measurement of cerebral arterio-venous differences of oxygen and glucose is 
regarded as the gold-standard technique for obtaining OGI. With this method, arterial samples 
are collected from a peripheral artery (e.g. radial or brachial artery) and venous samples from the 
internal jugular vein at the jugular bulb. The primary assumption of this technique is that the 
venous blood in the jugular bulb comes solely from the brain. If blood from other sources is 
present, than the arterio-venous difference is no longer only the result of cerebral metabolism. 
This bias is likely to be small, however, as it has been estimated that 97.4% of the blood in the 
jugular bulb comes from cerebral sources3.  
Although the arterio-venous technique has been used to study whole-brain OGI for over 
sixty years4, there remains some uncertainty as to the exact value. Individual studies using 
arterio-venous differences in humans at rest have reported values ranging from 4.65 to 7.56. In 
1957, Kety reviewed sixteen studies of both healthy and diseased populations and reported a 
mean value of 5.544. A more recent meta-analysis of eight studies of metabolism during exercise 
found a whole-brain OGI of 5.17. These two reviews suggest that anywhere from 8 to 15% of the 
brain’s glucose uptake is consumed via non-oxidative metabolism. Thus, the value of cerebral 
OGI in resting, healthy humans is known only approximately. 
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 The fate of glucose consumed by non-oxidative pathways is also a matter of some debate. 
It has been suggested that lactate efflux to venous blood may completely account for non-
oxidative glucose metabolism8. Two more recent reviews have reported conflicting results7,9. 
Both studies performed a meta-analysis of the oxygen-to-carbohydrate index (OCI), also referred 
to as the cerebral metabolic ratio (CMR). The OCI is computed as the molar ratio of the arterio-
venous difference of oxygen to glucose plus ½ lactate. (The factor of ½ arises because each mole 
of glucose theoretically yields two moles of lactate). If lactate efflux to venous blood completely 
accounts for an OGI less than 6, then the OCI should equal 6 or greater. Alternatively, an OCI 
less than 6 indicates that lactate efflux to venous blood does not alone account for all of non-
oxidative glucose metabolism. Consistent with the original finding of Siesjö8, Quistroff et al. 
reported that the population mean OCI from eight studies is approximately 6. However, 
Rasmussen et al., in a partially overlapping sample of eight studies, reported that the resting OCI 
was 5.3. Thus, it remains unclear whether lactate fully accounts for non-oxidative glucose 
metabolism in the resting human brain. 
 To provide a more accurate estimate of both OGI and OCI in the healthy human brain at 
rest, we conducted a systematic meta-analysis10 of studies reporting arterio-venous differences 
for glucose, oxygen, and lactate. We identified 40 studies with OGI data and 37 partially 
overlapping studies with OCI data. We then performed a random effects Bayesian meta-







 Our meta-analysis was conducted using the Preferred Reports Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines10. Figure 2.1 shows a flow diagram of the 
study procedures. Table 2.1 contains the PRISMA checklist. We did not complete or register an 
a priori study protocol.  
Eligibility Criteria 
 We included studies that reported mean OGI and/or OCI along with either SD or standard 
error of the mean (SE), or the data necessary to estimate the mean and SE. Only studies that used 
arterio-venous differences to measure whole-brain OGI and/or OCI were included. OGI and OGI 
data were typically taken from text or tables, but were extracted from figures if necessary. Table 
2.2 lists the data source for each study. If a study did not report either ratio but contained the 
necessary arterio-venous data, we contacted the corresponding author via the listed email address 
and requested the required data. Although positron emission tomography (PET) can be used to 
measure whole-brain OGI12,13, we chose to exclude these studies because of uncertainty in the 
value of the lumped constant for [18F]-FDG14. We did not include studies from older adult 
cohorts or from diseased populations (e.g., cardiac, neurological, or mental disorders).  
Study Identification 
 We searched the PUBMED database with several combinations of the terms “Arterial”, 
“Arterio”, “Brain”, “Carbohydrate”, “Cerebral”, “Glucose”, “Index”, “OCI”, “OGI”, “Oxygen”, 
“Ratio”, and “Venous” (Table 2.3). In total, we performed 24 separate search queries. All 
searches were constrained to articles published between 1900 and August 10th, 2017. To limit the 
amount of animal model studies returned by our searches, we added the Medical Subject 
Heading (MeSH) keyword “Human” to every search. In addition, the first author (TB) conducted 
a search of his personal archives for any papers that included measures of cerebral oxygen, 
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glucose, and lactate metabolism. The papers in the final dataset that were only found in the first 
authors archives are listed in Table 2.2. 
Statistics 
 A random effects Bayesian meta-analysis11 was performed to calculate the population 
average OGI and OCI. A random effects model accounts for differing variance in each study’s 
estimates of OGI and OCI, while simultaneously allowing for heterogeneity between studies. 
Separate models were run for OGI and OCI. If a study reported multiple values for OGI or OCI, 
a fixed effects meta-analysis was performed to calculate an overall estimate for that study15. Our 
model assumed that each study’s estimate, !", is a random sample from a normal distribution: 
!"~$(& + &", )") (2.1) 
where& is the population mean, &"is random offset for study i, and )" is the study standard 
deviation. No covariates or other explanatory factors were included in the model. We assume 
that )" is equal to each study’s standard error of the mean. The random offsets for each study 
were also assumed to follow a normal distribution:  
&"~$(0, ,)  (2.2) 
where , is the random effects standard deviation, which reflects the heterogeneity across studies.  
 The model parameters, &, &", and , were estimated using Hamilton Markov Chain Monte 
Carlo (MCMC) implemented in Stan16. The population mean, &, was given a broad normal prior 
with a mean of 6 and standard deviation of 2. The random effects standard deviation, , , was 
given a uniform prior with a lower limit of 0. Eight randomly initialized chains of 20,000 
samples were run for each model. The first 10,000 samples of each chain were discarded as 
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warm-up. Sample autocorrelation was minimized by only considering every 5th sample. As a 
result, all inferences are based upon 16,000 posterior samples. Convergence was assessed using 
the Gelman and Rubin potential reduction statistic, -.17,18. -. is the ratio of within chain variance 
to the pooled between chain variance. At convergence, -. should be equal to one. For both 
models, -. was with within 10-3 of 1 for every parameter. All results are summarized with 
medians and 95% equal-tailed credible intervals.  
 The primary parameters of interest where the population means, &, for OGI and OCI. We 
also computed the percent of glucose metabolism that is entirely non-oxidative. This was done 
by assuming a 6:1 stoichiometric ratio: 100 ∙ (1 − 234 6.0⁄ ). Replacing OGI in this expression 
with OCI gives the percent of carbohydrate metabolism that is non-oxidative. 
Assessment of Bias and Heterogeneity 
 Risk of bias within studies was assessed by considering four factors: study population, 
interval between catheterization and measurement, the presence of experimental manipulations, 
and fasting state. Bias assessment was not a factor in the random effects meta-analysis, and no 
sub-group analyses are reported. The possibility for bias across studies was assessed using funnel 
plots19. A funnel plot is used to determine if there is any relationship between the reported 
OGI/OCI value and its standard error. If a meta-analysis is free from publication bias and 
heterogeneity, the plot should resemble a funnel with the studies with the smallest standard 
errors clustered around the population average. An asymmetric funnel plot can be an indication 
of reporting bias or study heterogeneity20. To test for funnel plot asymmetry, we used the method 
recommended by Egger et al.19,21, which involves a regression model with effect size as the 
dependent variable and standard error as the independent variable. Our regression model, 
implemented in the R metafor package15, also estimated a random effect for each study.  
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 The possibility of study heterogeneity was further quantified using posterior predictive 
intervals22 for a random new study. Posterior predictive intervals, which incorporate the 
uncertainty in parameter estimates, provide a credible interval in which we would expect a new 
study to fall. All posterior predictive intervals were computed using 16,000 random samples. 
Finally, we computed the I2 statistic23,24: 




where ,̂8 is the estimated between study variance from the random effects model, and );8 is the 













where L is the number of studies and M" is the precision of the mean for study i: M" = 1 )"
8⁄ . We 
calculated 48 for each MCMC sample of ,̂8 and then computed the median 48 along with its 95% 
equal-tailed credible intervals. Higher values of 48 indicated a greater relative proportion of 




 Our searches of PUBMED (see Methods) and our own archives identified 927 potential 
records (Figure 2.1). After reviewing the titles, and if necessary, abstracts of all 927 records, 810 
were discarded from further consideration. Records were discarded at this step if they were 
clearly irrelevant for our purposes (e.g. animal studies). The remaining 117 papers were then 
subjected to a critical full text review. This review resulted in the rejection of 65 papers (Table 
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2.4). The majority of papers were rejected because they did not acquire the data necessary to 
calculate OGI/OCI (n=38) or because they reported values only in experimental states (n=17). 
For OGI, we found 52 papers that met our requirements for inclusion, 34 of which reported OGI. 
In addition, we sent 19 requests for data to authors of studies that had the data necessary to report 
OGI but did not do so. We received data from 6 of these authors, resulting in a total of 40 
studies. For OCI, 43 papers met our inclusion requirements. Of these, 32 papers reported the 
required data, and data requests were sent for the remaining 11. After receiving data from 5 
authors, our final OCI dataset contained 37 studies. A summary of the characteristics for the 
included studies is in Table 2.2. A total of 30 studies measured both OGI and OCI. 
Population Average OGI and OCI 
 Forest plots for OGI and OCI are shown in Figure 2.2 and Figure 2.3, respectively. Note 
that the random effects models effectively decrease the weight of studies with high standard 
errors. The population average OGI was 5.46 with a 95% CI of 5.25 to 5.66. As the CI does not 
overlap 6.0, we can infer that there is significant NOglc at rest. The population average OCI was 
5.60 with a 95% CI of 5.36 to 5.84. The fact that the credible intervals do not contain 6 indicates 
that a significant portion of the brain’s glucose consumption is non-oxidative and cannot be 
accounted for by lactate efflux to the blood.  
Bias and Heterogeneity  
 Within-study bias was assessed in four separate categories: study population, waiting 
period between catheterization and measurement, experimental manipulations, and fasting state 
(Table 2.5). The most frequent bias in study population was the use of all male subjects. Nineteen 
studies included only male subjects. No study included only female subjects. The majority of 
studies consisted of younger subjects (Table 2.5). Across all studies that reported an average age, 
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the mean age was 27.2 with a standard deviation (SD) of 4.6. Only five studies specifically 
mentioned including subjects over the age of 4025-29. A few other studies included only hospital 
patients (e.g. Scheinberg et al., 1949, Takeshita et al., 1972) or competitive athletes (e.g., Voliantis 
et al., 2008 and Bain et al., 2016). More than half (24/47) of studies included no mention of a 
waiting period between catheterization and blood sampling. Blood sampling was performed in a 
variety of positions, the two most common being supine (13) and semi-supine (20). The majority 
of measurements were performed in the absence of any overt experimental manipulation, however 
a few studies did include the injection of labeled compounds (e.g., Boyle et al., 1994 and Glenn et 
al., 2015) or saline (Hasselbalch et al., 1996 and Volianitis et al., 2011). Finally, the requirement 
for fasting subjects was mixed, with 19 requiring at least some fasting period, 20 including no 
mention of performing measurements in a fasting state, and the remaining 8 studies assessed 
subjects in a post-absorptive state.  
To assess bias across studies, funnel plots were constructed for both OGI (Figure 2.4A) 
and OCI (Figure 2.4B). No asymmetry was apparent in either plot. This impression was 
quantified with a regression test for asymmetry19. No significant evidence for asymmetry was 
found for either OGI (p=0.2013) or OCI (p=0.1948). The lack of asymmetry suggests the 
absence of reporting bias in our sample. There was, however, substantial horizontal scatter 
around the population averages, indicating heterogeneity across studies. To further assess this 
heterogeneity, we computed posterior predictive intervals for a new random study for each ratio. 
Both ratios showed considerable variability, with the 95% posterior predictive interval for OGI 
spanning 4.35 to 6.60 and from 4.32 to 6.91 for OCI. Furthermore, the I2 values were consistent 
with substantial between study heterogeneity. An estimated 85.03% [95 CI 75.88-91.35] of the 
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total variance in the OGI meta-analysis was due to study heterogeneity. A similar value of 
84.96% [95 CI 75.09-91.60] was found in the OCI analysis.  
2.5 Discussion 
 
Our meta-analyses of OGI and OCI reveals that both measures are significantly less than 
6. The fact that OGI is less than 6 indicates that a proportion of glucose consumption is non-
oxidative, while OCI being less than 6 shows that not all of non-oxidative metabolism can be 
accounted for by lactate efflux to venous blood. Expressed in terms of percentages non-oxidative 
metabolism accounts for 9.0% 95 CI [5.67-12.5] of glucose consumption and 6.7% 95 CI [2.67-
10.67] of carbohydrate metabolism. Our estimates of the population average OGI (5.46 95% CI 
[5.25-5.66], and OCI (5.60 with a 95% CI [5.36-5.84]) are based on a much larger set of studies 
than previous reviews, and are therefore more likely to accurately reflect the true population 
means. It is of some interest to note the close agreement between our population average OGI 
and the value of 5.54 originally reported by Kety4. 
 Although we did not find any evidence for publication bias, we did find considerable 
heterogeneity across studies. We computed I2 for each ratio, which indicated that ~85% of the 
total variance is attributable to study heterogeneity. Substantial methodical differences (Table 
2.5) may account for the variability in measured OGI and OCI values. Many studies included 
only males and there is evidence of differences in metabolism between males and females30,31. 
Thus, it is likely that our population averages are more representative of male metabolic ratios. 
Similarly, our population averages are weighted towards the predominantly young adult samples 
included in our meta-analysis. Many studies also did not specify if they included a waiting period 
between catheterization and measurement. This may have influenced the reported values, as 
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metabolic ratios have been shown to decrease during arousal32. Finally, not all investigators 
insured that measurements were performed while subjects were in a basal metabolic state. A few 
studies infused labeled carbohydrates, and many studies did require that subjects be in a fasting 
state. Either factor could have affected the published results. For example, OGI is known to 
increase during hypoglycemia29. More direct studies are clearly needed to quantify the sources of 
heterogeneity in studies measuring OGI and OCI. 
There is no clear consensus concerning the role of non-oxidative glucose metabolism in 
the brain33. It has been variously proposed that NOglc (i) allows for the rapid creation of ATP for 
the Na+/K+ ATPase in astrocytes34, (ii) regulates cellular redox potentials35, (iii) is a by-product 
of glycogen breakdown during increased neuronal activation36, (iv) is necessary for the 
degradation of glutamate by astrocytes37, (v) reduces oxidative stress, particularly during periods 
of cellular growth38, or (vi) is used to fuel biosynthetic processes39,40. Part of the difficulty here is 
the uncertainty regarding the ultimate fate of glucose that enters non-oxidative pathways. It was 
traditionally thought that lactate production, and subsequent efflux to venous blood, could 
completely account for any non-oxidative glucose use8. The results of our meta-analysis are not 
consistent with this idea. The fact that the population average OCI was greater than the average 
OGI does show that some glucose is converted to lactate and leaves the brain via the venous 
system. The OCI was less than 6, however, which means this route does not account for all non-
oxidative glucose use.  
One potential explanation for the OCI being less than 6 is that resting arterio-venous 
differences simply underestimate the amount of lactate that leaves the brain. Brain lactate 
concentration has been shown to decrease during sleep41, suggesting that measurements taken 
during conscious rest do not fully account for all of lactate efflux. Alternatively, lactate may 
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leave the brain via routes that bypass the sampling sites used for arterio-venous differences. This 
idea is supported by a study by Ball et al., who found that injection of radiolabeled glucose and 
lactate into the inferior colliculus labeled the meninges42. Subsequent tracer experiments 
identified a potential perivascular clearance pathway from the inferior colliculus to the cervical 
lymph nodes42. More recently, components of the glymphatic system have been shown in mice to 
regulate lactate efflux, as well as the concentration of lactate in cervical lymph nodes41. Neither 
of these experiments, however, quantified the proportion of lactate efflux that occurs via these 
pathways. Furthermore, if perivascular/glymphatic clearance does play a role in lactate removal, 
it is not clear what impact it would have on arterio-venous difference measurements. In sheep, 
rats, and rabbits approximately half of CSF is cleared through lymphatic pathways43. The other 
half enters the venous sinuses through the arachnoid villi, and therefore would presumably be 
accounted for by venous samples taken at the level of the jugular bulb. Although exact 
proportions are not available, it has been proposed that the arachnoid pathway plays a much a 
larger role in humans43. If true, this would suggest that perivascular/glymphatic clearance cannot 
fully account for the OCI being less than 6. Direct experimental approaches are clearly needed to 
address this question. 
 An alternative possibility is that the carbon from non-oxidative glucose metabolism 
leaves the brain as metabolites other than CO2 or lactate. Although pyruvate is well-known to 
have a net efflux from the brain, it is unlikely to account for much of the unexplained fraction, as 
net pyruvate efflux is nearly an order of magnitude less than that of lactate44. Numerous other 
carbon-containing compounds, however, have also been shown to leave the brain. For example, 
there is a small net efflux of glutamine from the brain45,46. In addition, peptides and proteins are 
known to exit the brain via the CSF47. The most well-studied of these are amyloid-beta48,49 and 
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tau50, which are both markers of Alzheimer’s disease51. Other molecules, such as leptin52 and 
cholesterol53, have also been shown to leave the brain in small amounts. In contrast, Rasmussen 
et al. reported that using nuclear magnetic resonance spectroscopy , there were no detectable 
cerebral arterio-venous differences for any carbon sources other than glucose and lactate54. 
However, it is unclear exactly which carbon-based compounds were examined by Rasmussen et 
al. Therefore, future experiments with labeled compounds are needed to elucidate how, and in 
what proportions, glucose derived carbon leaves the brain.  
Although we are not aware of any studies directly linking NOglc with the synthesis, and 
subsequence efflux, of specific glucose metabolites, there is evidence linking non-oxidative 
metabolism with biosynthesis more generally. Madsen et al., found that OGI was depressed after 
the performance of the Wisconsin Card Sorting task, while lactate efflux returned to baseline 
values55. Similarly, our group recently reported that, hours after the performance of a covert 
motor learning task, non-oxidative glucose use was elevated in Brodmann Area 4456. Moreover, 
the change in non-oxidative glucose use was positively correlated with performance during the 
learning task. Both of these studies are consistent with the hypothesis that glucose is used in a 
non-oxidative manner to support learning-induced synaptic plasticity. Extending these findings 
to other learning paradigms (e.g. episodic memory) would provide additional evidence along 
these lines.  
A prior meta-analysis from our group found that non-oxidative glucose use is markedly 
elevated during early childhood40, a period of brain growth57. This finding was recently 
supported by Segarra-Mondejar et al., who found that glucose consumption is necessary for 
neurite outgrowth in vitro and in vivo 58. Interestingly, the findings of Segarra-Mondejar et al. 
also suggest that at least a part of the glucose necessary for neurite outgrowth is directly 
64 
 
incorporated into newly synthesized lipids58. Finally, regional differences in non-oxidative 
metabolism39,59 have been shown to correlate positively with expression of genes related to 
synaptic plasticity and development40. Taken together, these findings strongly suggest that 
NOglc contributes to biosynthetic processes in the brain. Quantifying the contribution of non-
oxidative glucose metabolism to biosynthesis will be an important topic for future studies. 
Combining a PET marker of protein synthesis60, such as L-[1-11C]-leucine PET61,62 with 
measures of non-oxidative glucose use during a learning task could provide further evidence that 
learning is accompanied by increases in biosynthesis and non-oxidative glucose metabolism. 13C 
magnetic resonance spectroscopy could also be used to measure the movement of glucose and 
other carbohydrates through different metabolic pathways63,64. 
 In summary, on the basis of a meta-analysis of 47 studies, we estimated that non-
oxidative processes account for 9% of glucose metabolism in the brain, a significant portion of 
which cannot be accounted for by lactate efflux to the blood. We also found substantial 
heterogeneity across studies, likely attributable to differences in methodology. Future studies are 
needed to determine both the function of non-oxidative metabolism and the ultimate fate of 




Included studies were selected using the indicated selection criteria. 
  
Figure 2.1: Modified PRISMA flow diagram 
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Blue squares represent the reported mean OGI for each study. Black lines represent 95% 
confidence intervals. Numeric values for these quantities are also listed. The blue diamond is the 
population average from the Bayesian random effects meta-analysis. Error bars/values for the 
population mean are 95% CIs (n=40).  
Figure 2.2: Forest plot for OGI meta-analysis 
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Same convention as in Fig 2 (n=37).  
Figure 2.3: Forest plot for OCI meta-analysis 
68 
 
Funnel plots for A) OGI and B) OCI. In each plot, the reported study mean is plotted against its 
standard error. The population average is the dashed black line, its 95% percent CI is in dark 
gray, and its 95% prediction interval is in light gray. The lack of any asymmetry is evidence 
against substantial publication bias. The wide scatter around the population average, however, 
suggests that there is substantial heterogeneity between studies. 





Table 2.1: PRISMA checklist 
Section/topic # Checklist item Reported on page # 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: background; 
objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; limitations; 
conclusions and implications of key findings; systematic review 
registration number.  
51 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already 
known.  
51 
Objectives  4 Provide an explicit statement of questions being addressed with reference 
to participants, interventions, comparisons, outcomes, and study design 
(PICOS).  
51 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., 
Web address), and, if available, provide registration information 




6 Specify study characteristics (e.g., PICOS, length of follow-up) and 
report characteristics (e.g., years considered, language, publication status) 




7 Describe all information sources (e.g., databases with dates of coverage, 
contact with study authors to identify additional studies) in the search and 
date last searched.  
53 
Search  8 Present full electronic search strategy for at least one database, including 
any limits used, such that it could be repeated.  53, 69 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included 
in systematic review, and, if applicable, included in the meta-analysis).  53 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and 
confirming data from investigators.  
53 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, 
funding sources) and any assumptions and simplifications made.  53 
Risk of bias in 
individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies 
(including specification of whether this was done at the study or outcome 











14 Describe the methods of handling data and combining results of studies, 
if done, including measures of consistency (e.g., I2) for each meta-
analysis.  
53 
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the cumulative 
evidence (e.g., publication bias, selective reporting within studies).  53 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or subgroup 
analyses, meta-regression), if done, indicating which were pre-specified.  NA 
RESULTS  
 
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in 





18 For each study, present characteristics for which data were extracted 
(e.g., study size, PICOS, follow-up period) and provide the citations.  71 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, any outcome 




20 For all outcomes considered (benefits or harms), present, for each study: 
(a) simple summary data for each intervention group (b) effect estimates 
and confidence intervals, ideally with a forest plot.  
57, 66, 67 
Synthesis of 
results  
21 Present results of each meta-analysis done, including confidence intervals 
and measures of consistency.  57, 66, 67 
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies (see Item 
15).  57, 68 
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or subgroup 





24 Summarize the main findings including the strength of evidence for each 
main outcome; consider their relevance to key groups (e.g., healthcare 
providers, users, and policy makers).  
60 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at 
review-level (e.g., incomplete retrieval of identified research, reporting 
bias).  
60 
Conclusions  26 Provide a general interpretation of the results in the context of other 
evidence, and implications for future research.  60 
FUNDING  
 
Funding  27 Describe sources of funding for the systematic review and other support 
(e.g., supply of data); role of funders for the systematic review.  NA 
71 
 
Table 2.2: Summary characteristics of included studies 
Studies that were found only through searching the first authors records are indicated by a *. (NA = Not Applicable). 
 






















































1949 18 Table NA NA 25.1 4.04 SD Supine 

























1962 21 Table 10 Table 40.3 6.2 SD Control 











1963 15 Table NA NA 20.8 0.4 SE NA 






NA 1963 32 Table 18 Table 
21-
69 















1965 21 Table 20 Table 32.3 6.9 SD NA 









1967 9 Table NA NA 
21-
25 
NA NA NA 








1967 12 Table 12 Table 
30-
60 
NA NA NA 
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1972 6 Table NA NA 43 3 SE NA 











1990 7 Table NA NA NA NA NA NA 








1994 12 Table NA NA 25 2 SE NA 












1995 8 Table NA NA 25 NA NA Study 2 
























1996 8 Table NA NA 24 4 SD NA 








1999 12 Table 12 Table 23 1 SE NA 








2000 6 Table 6 Table 25 2 SD NA 









2002 10 Table 10 Table 25 4 SE Study 1 









2002 10 Table 10 Table 25 1 SE Study 2 












2002 8 Author 8 Author 25 NA NA NA 








2003 NA NA 10 Text 24 NA NA NA 











2003 31 Table 31 Author 33.3 8.3 SD Control 
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2003 NA NA 8 Figure 27 2 SE NA 









2003 8 Table NA NA NA NA NA NA 









2004 9 Text 9 Text 25 1 SE NA 











2004 NA NA 8 Text 22 1 SE NA 









2004 NA NA 7 Text 22 1 SE Cycling 









2004 NA NA 8 Text 26 1 SE 
Arm 
cranking 















Healthy men 2006 8 Author 8 Author 
22-
29 
NA NA NA 
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Healthy males 2008 8 Figure 8 Text 27 6 SD NA 







Healthy males 2008 6 Table 6 Table 32 4 SE NA 









Healthy men 2009 11 Author 10 Author 27 4 SD 
Normoxi
a 











2009 NA NA 8 Text 33 6 SD NA 











2009 7 Figure 7 Figure 32 6 SD 
Control 
After 











2009 7 Figure 7 Figure 32 6 SD 
Training 
Before 

























2009 10 Text 10 Text 24 3 SD 
Adrenali
ne 





















2010 16 Table 16 Table 
20-
34 








Young males 2010 7 Figure 7 Figure 
18-
34 
NA NA NA 








2010 9 Table 9 Table 23 4 SD NA 
















2012 9 Table 9 Table 26 6 SD NA 







Young adults 2013 11 Figure 11 Figure 22 1 SE NA 

















Healthy adults 2014 10 Table 10 Table 28 4.5 SD 
Hyperoxi
a trial 









2014 8 Table 8 Table 30 6 SD NA 









2015 6 Author 6 Author 28.2 8.2 SD Control 









2015 10 Text 10 Figure 29 5 SD NA 











2015 9 Table 9 Table 30.4 7 SD NA 









2016 14 Author 14 Table 29.5 7.3 SD NA 











2017 11 Author 11 Table 31 8 SD NA 
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Table 2.3: PubMed search terms 
Number Terms 
1 Oxygen AND Arterio AND Venous AND Brain 
2 Oxygen AND Arterio AND Venous AND Cerebral 
3 Lactate AND Arterio AND Venous AND Brain 
4 Lactate AND Arterio AND Venous AND Cerebral 
5 Glucose AND Arterio AND Venous AND Brain 
6 Glucose AND Arterio AND Venous AND Cerebral 
7 Oxygen AND Arterial AND Venous AND Brain 
8 Oxygen AND Arterial AND Venous AND Cerebral 
9 Lactate AND Arterial AND Venous AND Brain 
10 Lactate AND Arterial AND Venous AND Cerebral 
11 Glucose AND Arterial AND Venous AND Brain 
12 Glucose AND Arterial AND Venous AND Cerebral 
13 OGI AND Brain 
14 OGI AND Cerebral 
15 OCI AND Brain 
16 OCI AND Cerebral 
17 Oxygen AND Glucose AND Index AND Brain 
18 Oxygen AND Glucose AND Index AND Cerebral 
19 Oxygen AND Carbohydrate AND Index AND Brain 
20 Oxygen AND Carbohydrate AND Index AND Cerebral 
21 Oxygen AND Glucose AND Ratio AND Brain 
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22 Oxygen AND Glucose AND Ratio AND Cerebral 
23 Oxygen AND Carbohydrate AND Ratio AND Brain 




Table 2.4: Papers excluded after a full-text review 
Reference PMID Journal Reason for Exclusion 
Wortis et al. 1940103 NA The American journal of psychiatry Data not sufficient 
Gibbs et al. 1945104 NA The American journal of psychiatry No control data 
Kety et al. 1948a105 16695569 The Journal of clinical investigation Data not sufficient 
Kety et al. 1948b106 16695568 The Journal of clinical investigation Data not sufficient 
Kety et al. 1951107 14833874 Pharmacological reviews Data not sufficient 
Fazekas et al. 1952108 14902811 
The American journal of the medical 
sciences 
Data not sufficient 
Novack et al. 1953109 13042927 Circulation No control data 
Scheinberg et al. 1953110 13057407 
A.M.A. archives of neurology and 
psychiatry 
Data not sufficient 
Sokoloff et al. 1953111 13044828 The Journal of clinical investigation Data not sufficient 
Schieve et al. 1953112 13065315 The American journal of medicine Data not sufficient 
Shenkin et al. 1953113 13052708 The Journal of clinical investigation Data not sufficient 
Sokoloff et al. 1955114 14392225 The Journal of clinical investigation Data not sufficient 
Mangold et al. 1955115 14392224 The Journal of clinical investigation Data not sufficient 
Kety et al. 1956116 13306754 Journal of chronic diseases Data not sufficient 
Kennedy et al. 1957117 13449166 The Journal of clinical investigation Data not sufficient 
Rowe et al. 1959118 14439685 The Journal of clinical investigation Data not sufficient 
Kety et al. 1960119 NA Methods in Medical Research Data not sufficient 
Porta et al. 1964120 14127087 Metabolism: clinical and experimental No control data 
Alexander et al. 1968121 5635772 Journal of applied physiology No control data 
Lewis et al. 1974122 4154353 Journal of neurochemistry Data not sufficient 
Raichle et al. 1975123 1155625 The American journal of physiology Data not sufficient 
Gottstein et al. 1976124 1271691 Klinische Wochenschrift No control data 
Van Aken et al. 1976125 1015217 Acta anaesthesiologica Belgica Data not sufficient 
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Juhlin-Dannfelt et al. 
1977126 
929098 
Scandinavian journal of clinical and 
laboratory investigation 
Data not sufficient 
Hertz et al. 1981127 7009645 The Journal of clinical investigation No control data 
Eriksson et al. 1983128 6619869 Journal of neurochemistry Data not sufficient 
Dastur et al. 1985129 3972914 
Journal of cerebral blood flow and 
metabolism 
Data not sufficient 
Fox et al. 198812 3260686 Science PET study 
Hatazawa et al. 1988130 3259242 
Journal of cerebral blood flow and 
metabolism 
PET study 
Warrell et al. 1988131 2900921 Lancet No control data 
Blomqvist et al. 1998132 9789584 Acta physiologica Scandinavica Data not sufficient 
Grill et al. 1990133 2110424 The American journal of physiology 
Error of OGI/OCI not 
reported 
Leenders et al. 1990134 2302536 Brain Data not sufficient 
Gutniak et al. 1990135 2185663 The American journal of physiology Data not sufficient 
Burgess et al. 1991136 2020274 
Medicine and science in sports and 
exercise 
Data not sufficient 
Blomqvist et al. 1991137 1743207 European journal of nuclear medicine Data not sufficient 
Pollard et al. 1997138 9377885 Critical care medicine Data not sufficient 
Mielck et al. 1998139 9813515 British journal of anaesthesia OGI/OCI not reported 
Schaffranietz et al. 1998140 9584928 Neurological research No control data 
Wahren et al. 1999141 10440122 Diabetologia OGI/OCI not reported 
Madsen et al. 1999142 10197509 
Journal of cerebral blood flow and 
metabolism 
Data not sufficient 
Takahashi et al. 1999143 10369366 American journal of neuroradiology Data not sufficient 
Møller et al. 2002144 12027852 Acta anaesthesiologica Scandinavica Repeated data77 
Nybo et al. 2002145 12070186 Journal of applied physiology Repeated data80 
Lancaster et al. 2004146 15544165 Cell stress & chaperones Data not sufficient 
Dalsgaard et al. 2004147 15123562 Experimental physiology Repeated data82 
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Cremer et al. 2004148 15114206 Anesthesiology Data not sufficient 
Blomstrand et al. 2005149 16218925 Acta physiologica Scandinavica Data not sufficient 
Chieregato et al. 2007150 17893572 
Journal of neurosurgical 
anesthesiology 
No control data 
Seifert et al. 2008151 19053964 Acta physiologica Data not sufficient 
Quistorff et al. 20089 18653766 FASEB journal Data not sufficient 
Holbein et al. 2009152 19196488 Critical care No control data 
van Hall et al. 2009153 19337275 
Journal of cerebral blood flow and 
metabolism 
Data not sufficient 
Espenell et al. 2010154 20661680 Canadian journal of anesthesia No control data 
Powers et al. 2010155 20959851 
Journal of cerebral blood flow and 
metabolism 
PET study 
Rasmussen et al. 2010156 20102344 Acta physiologica No control data 
Smith et al. 2012157 23019310 Journal of applied physiology Data not sufficient 
Mikkelsen et al. 2014158 25415176 
The Journal of clinical endocrinology 
and metabolism 
No control data 
Glenn et al. 2015159 25279664 Journal of neurotrauma No control data 
Fabricius-Bjerre et al. 
2014160 
24903076 
Clinical physiology and functional 
imaging 
No control data 
Lewis et al. 2014161 25217373 The Journal of physiology Data not sufficient 
Trangmar et al. 2014162 24835170 The Journal of physiology Repeated data100 
Tholance et al. 2015163 25668478 Neurological research No control data 
Slusher et al. 2015164 25771935 Journal of neuroendocrinology Data not sufficient 
Grüne et al. 2017165 28207907 PloS one No control data 
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Table 2.5: Assessment of bias within studies. 
Abbreviations: NA = Not Applicable; NS = Not stated 





Gibbs et al., 19421 All males.  ~30 min. Supine None NS 
Scheinberg et al., 194965 
3 illness free 
hospital 
patients.  
40 to 50 min. Supine and Erect None Yes 
Sokoloff et al., 195725 
1 participant 





Some participants had been 
given LSD a week earlier. 
NS 
Eisenberg et al., 196226 None NS NS None Yes 
Dastur et al., 196366 None NS NS None NS 
Gottstein et al., 196367 Patients aged 
up to 61 years 
NS NS None NS 






20 min. Supine None Yes (12 hours) 
Cohen et al., 196768 All male NS Supine None Yes 
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NS NS None NS 






NS NS Given atropine NS 
Blomqvist et al., 199071 None NS NS None NS 
Boyle et al., 199472 None 2 hours NS 
Sleep reduction; Subjects 
were infused with 6,6-D2-
glucose; 
No 
Madsen et al., 199555 None ~1 hour Supine None Yes (14 hours) 
Hasselbalch et al., 199673 None 1 hour Supine Saline infusion No 
Ide et al., 199974 None NS Semi-supine None No 
Ide et al., 200075 None NS Semi-supine None NS 
Dalsgaard et al., 200276 None NS Semi-supine None NS 
Møller et al., 200277 None 1 hour Supine Subjects were infused with 
isotonic glucose 
Yes (Overnight) 
Dalsgaard et al., 200378 None NS Semi-supine None No 
Glenn et al., 200379 None NS NS None NS 
Nybo et al., 200380 All trained 
males 
30 min. NS None No 
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Strauss et al., 200381 None NS Supine Subjects were infused with 
5% glucose. 
Yes (Overnight) 
Dalsgaard et al., 2004a82 None NS Semi-supine None Yes (8 hours) 
Dalsgaard et al., 2004b83 All male 1 hour Semi-supine None Yes (Overnight) 
Dalsgaard et al., 2004c84 All male NS Semi-supine None Yes (Overnight) 
Ogoh et al., 200585 All male NS Semi-supine None Yes (Overnight) 
Rasmussen et al., 200644 All male 1.5 hours Semi-supine None Yes (Overnight) 
Larsen et al., 200886 All male 1 hour Semi-supine None Yes (Overnight) 
Voliantis et al., 200887 All trained 
male rowers 
NS Semi-supine None Yes (8 hours) 
Bailey et al., 200988 All male 30 min. Supine Subjects breathed 21% O2 Yes (12 hours) 
Gam et al., 200989 All male 1 hour Semi-supine None NS 
Seifert et al., 2009a90 All overweight 
males 
1 hour Semi-supine None No 
Seifert et al., 2009b91 None 1 hour Supine Some subjects received a 
saline control infusion 
No 
Rasmussen et al, 2010a92 All male NS Semi-supine None NS 
Rasmussen et al, 2010b93 All male NS Semi-supine 
Saline injected control; 
Some had received an EPO 
trial 3 months earlier 
NS 
Seifert et al., 201094 All male 30 min. Semi-supine None NS 
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Volianitis et al., 201195 




Saline infusion control; 
Some subjects performed 
bicarbonate trial ~1-2 weeks 
earlier 
Yes (Overnight) 
Overgaard et al., 201296 None 2 hours Supine 
Some subjects performed a 
hypoxia exercise trial at 
least two weeks prior; 
Infused with [1-13C] lactate 
and labeled bicarbonate 
No 
Fisher et al., 201397 None 1 hour Semi-supine None Yes (2h) 
Ainslie et al., 20145 None 30 min. Supine 
Some measurements were 
performed after hypoxia 
trials. 
Yes (2h) 
Smith et al., 201498 All male 25 min. Supine None Yes (4h) 
Glenn et al., 201599 None NS Semi-supine Infusion of [3-
13C] lactate 
and D2 glucose 
NS 
Trangmar et al., 2015100 All trained 
males 
~1 hour Semi-supine None NS 
Willie et al., 20156 All male ~30 min. NS Subjects underwent an 
arterial blood gas clamp 
NS 





30 min NS None NS 
Bain et al., 2017102 All subjects 
were elite 
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Chapter 3: Quantitative positron emission tomography reveals 
regional differences in non-oxidative glucose consumption 




Glucose and oxygen metabolism are tightly coupled in the human brain, with the 
preponderance of the brain’s glucose supply used to generate ATP via oxidative 
phosphorylation. A fraction of glucose is consumed outside of oxidative phosphorylation despite 
the presence of sufficient oxygen to do so. We refer to this process as non-oxidative glucose 
consumption (NOglc). A recent positron emission tomography study reported that NOglc is 
uniform within gray matter. Here, we analyze the same data and demonstrate robust regional 
differences in NOglc within gray matter, a finding consistent with previously published data.  
3.2 Introduction 
 
The energetic needs of the healthy human brain are almost entirely met by oxidative 
consumption of blood-borne glucose1,2. However, a fraction of the brain's glucose uptake does 
not undergo oxidative phosphorylation. This effect conventionally is quantitated using the 
oxygen-glucose index (OGI), which is the molar ratio of oxygen to glucose consumption. If no 
alternative fuels are used and all glucose undergoes complete oxidative phosphorylation, the OGI 
is exactly 6. However, multiple studies have shown that the OGI of the young adult human brain 
is less than 6, typically on the order of 5.53-7. Thus, around 10% of the whole brain’s glucose 
 
i This chapter is slightly modified version of a previously published article: Blazey TM, Snyder AZ, Su Y, Goyal 
MS, Lee JJ, Vlassenko AG et al. Quantitative positron emission tomography reveals regional differences in aerobic 
glycolysis within the human brain. J Cereb Blood Flow Metab 2018; 144: 271678X18767005. 
104 
 
consumption is metabolized through non-oxidative pathways. We define non-oxidative glucose 
consumption (NOglc) as the fraction of glucose metabolized outside of oxidative 
phosphorylation. NOglc is defined inversely proportional to OGI; thus areas of the brain that 
have high NOglc have low OGI ratios and vice versa. Note that NOglc is often referred to as 
aerobic glycolysis8, which dates back to Warburg’s discovery that cancer cells have high rates of 
glycolysis despite sufficient oxygen9.  
 Prior work from our laboratory has shown that, in resting, healthy young adults, NOglc is 
regionally greater in prefrontal cortex, lateral parietal lobe, and the precuneus/posterior cingulate 
cortex, relative to the rest of the brain8. These regions correspond to the default mode and fronto-
parietal control networks, which are areas of the cerebral cortex associated with higher-order 
cognition10. Conversely, NOglc in the cerebellum has been shown by us8, and others11, to be 
lower than in the rest of the brain. Hyder and colleagues7 recently published a study disputing the 
existence of regional variability in NOglc. Using quantitative positron emission tomography 
(PET) techniques, Hyder et al. measured OGI in 13 normal volunteers and reported that OGI is 
uniform within gray matter, which implies that NOglc is uniform as well. In the following, we 
refer to this study as "Hyder et al.”. To resolve the discrepancy between Hyder et al. and our 
previous findings, we reanalyzed the PET data from Hyder et al., which was generously shared 




We obtained processed, quantitative PET images of cerebral blood flow (CBF), oxygen 
utilization (CMRO2), and glucose consumption (CMRglc) for 13 normal adult males from Hyder 
et al.7 CBF and CMRO2 were measured using [15O]-H2O and [15O]-O2 respectively. A two-
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compartment (tissue and vascular distribution) kinetic model was used for both tracers12,13. No 
correction for recirculating [15O]-H2O was performed during [15O]-O2 modeling. CMRglc was 
obtained by fitting an irreversible two-compartment (free [18F]-FDG and trapped [18F]-FDG-6-
phosophate) model to the [18F]-FDG data14. No correction for vascular radioactivity was 
performed, and a lumped constant of 0.8 was used. All PET imaging data were acquired with 
arterial sampling, allowing for absolute quantitation of all metabolic parameters. For further 
methodological details please see the original publication7. As stated in the original report by 
Hyder et al.7, all subjects gave written informed consent in accordance with the Helsinki Protocol 
and all experimental procedures were approved by the ethical review committees of the Central 
Denmark Region and the Aarhus University Hospital, Aarhus Denmark.  
OGI Regional Computations 
 To assess regional differences in NOglc, we first calculated voxelwise OGI 
(CMRO2/CMRglc) in each subject. We then computed regional average OGI values in several 
regions of interest (ROIs). Prior to computing regional means, we excluded voxels that were 
outside five median absolute deviations (1.11) from the gray matter median (4.83)15. Excluded 
voxels were predominantly in areas of vascular artifact or on the edges of the PET images 
(4.09% of all voxels were excluded). We also excluded any voxels that were not classified as 
gray matter in the atlas used by Hyder et al.7 
 Our primary ROI set comprised seven resting state networks (Figure 3.1A), defined in a 
previous resting-state functional magnetic resonance imaging study16. Each ROI included only 
voxels in which the likelihood of network identity exceeded 90%. Resting state ROIs were 
transformed, using FSL17,18, into the atlas space used by Hyder et al. without alterations of the 
metabolic imaging data. We also created an ROI of the cerebellar gray matter within the atlas 
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used by Hyder et al.7 To accommodate incomplete cerebellar coverage of the PET data, the 
present results are limited to portions of the cerebellum in which the OGI was measured in every 
subject (Figure 3.2). 
Statistical Methods 
All statistical analyses were conducted in R19. A one-way ANOVA with region as a 
factor and subject as a repeated measure was used to determine if brain region explained any 
variance in OGI. Statistical significance was determined using a F-test on the region factor. One 
sample t-tests were used to determine if regional OGI values were different from 6. An OGI 
significantly (p<0.05, two-tailed) less than 6 means that the probability of finding such, or more 
extreme, data by chance is below 5%. We took this as indication that a portion of the glucose 
consumption in a given region undergoes only NOglc. In the same sense, paired t-tests were used 
to assess differences in OGI between regions. We used a significant difference (p<0.05, two-
tailed) as indication that NOglc is different between two regions. Correction for the 21 pairwise 
comparisons between networks was performed using False Discovery Rate (FDR) theory20. 
Reported values are means and 95% confidence intervals unless otherwise stated. 
The statistical thresholds that we defined above are dependent on the power of the Hyder 
et al. dataset. To determine the power of the Hyder et al. data we performed a power analysis 
using two previously published PET datasets. All power calculations were performed using the R 
package pwr21. Sasaki et al. reported the mean difference between the cortical and cerebellar 
gray matter OGI to be -1.48 (SD=0.42; n=7)11. The 13 subjects in the Hyder et al. dataset gives 
us 100% power to detect an effect of this magnitude. The mean OGI difference between the 
cortical gray matter and the basal ganglia was found by Hatazwa et al. to be 0.38 (SD=0.93; 
n=7)22. The Hyder et al. dataset would provide only 17.2% power to detect this effect. Taken 
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together, these analyses reveal that we are more than sufficiently powered to detect large 
regional differences, but are unlikely to capture smaller effects. 
3.4 Results 
 
Aerobic Glycolysis Varies by Resting State Network 
 To assess regional differences in NOglc, we computed OGI in seven resting state 
networks (Figure 3.1A). The means for other metabolic parameters (e.g., CBF) are reported in 
Table 3.1. With the exception of the visual network (VIS), all resting state networks had an OGI 
significantly less than 6 (p<0.05), indicating the presence of NOglc. A repeated measures, one-
way ANOVA revealed a highly significant difference in OGI across the brain (F6,72 = 74.16, p < 
0.001). Differences in OGI between specific network pairs are shown in Figure 1B; the RSNs are 
ordered by OGI and significant differences (p < 0.05, corrected) are highlighted by color. In 
agreement with previous work8, the OGI was low in default mode network (DMN) and high in 
the visual network (VIS). Unexpectedly, the ventral attention (VAN) network had the lowest 
OGI. We note that regional differences were highly consistent across individuals. For example, 
OGI in the DMN was less than OGI in the visual network (VIS) in every subject (Figure 3.1C).  
Aerobic Glycolysis in the Cerebellum 
 Previous studies have shown that NOglc in the cerebellum is lower than NOglc in the rest 
of the brain8,11. In the Hyder et al. data, the OGI in the superior cerebellum (see Methods) was 
6.50 (± 0.67), which was not significantly different from 6.0 (t=1.63, p=0.13). The difference 
between the cerebellum and the rest of gray matter (5.18 ± 0.51) was significant (t=-8.70, 
p<0.001). As the lumped constant in the cerebellum has been reported to be approximately 1.14 
times greater than in the whole brain23, we repeated our analysis after adjusting the cerebellum 
OGI for this difference. After the adjustment, the cerebellar OGI was 5.70 (± 0.58), again not 
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significantly different from 6.0 (t=-1.12, p=0.28), but still significantly different from the rest of 
gray matter (t=-4.00, p=0.0018). Thus, the cerebellum is characterized by a distinct lack of 
NOglc. 
Topography of OGI 
 The present results indicate that regional differences in NOglc exist between resting state 
networks as well as between the cerebellar and non-cerebellar gray matter. Figure 3.3A shows 
group averaged OGI (image obtained from the original authors) at a finer spatial scale. This 
figure is essentially identical to Figure 3A in Hyder et al. (reproduced here as Figure 3.3B) 
except for choice of color scale. Thus, presenting the identical results using a more 
physiologically meaningful scale (4-7 in Figure 3.3A as opposed to 1-10 in Figure 3.3B) 
demonstrates regional differences in OGI on inspection.  
3.5 Discussion 
 
Our reexamination of the data from Hyder et al. reveals two primary findings. First, many 
regions of the brain exhibit NOglc at rest. This result is consistent with both the regional PET 
literature11,22 as well as with whole-brain measurements of OGI3-6. Second, we observed 
significant regional differences in NOglc between gray matter regions that were highly preserved 
across subjects (Figure 3.1C).  
These findings are consistent with Vaishnavi et al., 2010, a previous study from our 
group that employed regional standardized uptake ratios8. The principal result of that study was 
that NOglc is significantly non-uniform across the brain. In particular, regions constituting the 
default mode network (DMN) had higher NOglc than other parts of the brain. In contrast, the 
cerebellum had lower NOglc. These findings are replicated here using the Hyder et al. dataset. 
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There are, however, a few differences between the two datasets. The fronto-parietal control 
network (FPC) had higher NOglc in the Vaishnavi et al. study compared to Hyder et al., and the 
NOglc in the ventral attention network (VAN) was much higher in the Hyder et al. data 
compared to Vaishnavi et al. (Figure 3.1B and C). It is not clear whether these differences are 
attributable to analytical approach (relative vs. quantitative PET), study population (the Hyder et 
al. study contained only male subjects), or other unknown factors. Therefore, although both 
datasets clearly support regional differences, more work is needed to resolve the discrepancies 
between the two studies.  
 On the basis of the same dataset, Hyder et al. argued that no regional differences in 
NOglc exist, and that findings reported by Vaishnavi et al. are artifacts attributable to the use of 
relative metabolic measures. The present results, obtained using the quantitative data identical to 
that from the Hyder et al. study, do not support this perspective. It follows that the discrepant 
perspectives are attributable to differences in analysis methodology. Specifically, Hyder et al. did 
not account for subject level variability common to all regions (e.g. use of ANOVA without a 
repeated measures factor). Figure 3.1C illustrates how OGI measures in two regions would 
appear to not be significantly different if variability attributable to subject is not taken into 
account.  
 Could the observed regional difference arise from non-biological artifacts? PET involves 
many technical decisions including choosing a kinetic model, accounting for vascular 
radioactivity, adjusting for recirculating metabolites, and correcting for the delay and dispersion 
of the arterial input function. Any of these factors could, in theory, produce an artefactual 
regional difference in NOglc. However, we think this unlikely for several reasons. First, despite 
the fact that there are regional differences in cerebral blood volume24 and arterial delay25, there is 
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no direct evidence that any of these technical factors produce a spatial artifact that induces 
regional differences in OGI. Second, using different procedures to analyze PET data, we8 and 
others11 have found regional differences in OGI similar to the present findings. Finally, 
additional evidence from different techniques suggests that NOglc varies throughout the brain. 
Using microdialysis in a transgenic mouse model of Alzheimer’s disease, Bero et al. reported 
regional differences in lactate levels in interstitial fluid, a result consistent with regional 
differences in NOglc26. Taken together, the available evidence supports the conclusion that 
regional differences in OGI are of biological origin.  
In the Hyder et al. dataset, NOglc accounts for 5.57 (± 2.65) µMol/hg/min, or 
approximately 19%, of the glucose consumption in the default mode network. From an energetic 
perspective, it may be surprising that NOglc accounts for so much glucose consumption in any 
part of the brain, as the quantity of ATP generated by NOglc is quite small compared to that 
generated by oxidative phosphorylation7. Therefore, a number of alternative explanations have 
been proposed, including rapid synthesis of ATP for the Na+/K+-ATPase27, generation of 
biosynthetic intermediates necessary for myelination as well as synaptic and neuritic formation 
and turnover8, alteration of cellular redox potentials28, regulation of glycogen levels through a 
hypothesized glycogen shunt29, and the uptake and recycling of glutamate by astrocytes30,31. The 
exact apportionment of NOglc among these alternatives remains uncertain. 
One way to elucidate the role of NOglc in the brain is through spatial topography. Past 
work in our laboratory has shown that the spatial distribution of NOglc correlates with the 
expression of genes related to synaptic development and growth32. The relationship between 
NOglc and synaptic plasticity is particularly intriguing given previous findings relating NOglc to 
task performance. Madsen et al. found that whole brain NOglc was elevated both during and 
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after performance of the Wisconsin Card Sorting Test33. Our group recently expanded on this 
finding. We measured relative OGI in subjects before and after the performance of a covert 
motor learning task34. We found that hours after the performance of the learning task, subjects 
had elevated NOglc in the left Brodmann area 44, an area recruited by task performance. 
Furthermore, we observed a correlation between task performance and subsequent increases in 
NOglc. These results link focal changes in NOglc to learning and suggests that regional 
differences in NOglc might reflect regional differences in synaptic plasticity.  
Other experiments have focused on the role of NOglc in aging and Alzheimer’s disease 
(AD). For example, it has been shown that higher levels of neural activity lead to increased 
amyloid-beta production in a mouse model of AD26. Moreover, this effect is associated with 
increased lactate levels in the interstitial fluid26. Cross-sectional studies in humans have found 
that brain NOglc decreases in AD35,36 as well as in normal aging 37 (two smaller aging studies 
have reported non-significant trends38,39). One interpretation of these findings is that the same 
processes that lead to high NOglc and synaptic plasticity in early life may ultimately lead to 
disease later in life40,41. 
Synaptic plasticity is but one of several, non-exclusive explanations for the brain’s use of 
NOglc. Much more work is needed before NOglc in the brain is fully understood. Any 
explanation of NOglc will need to consider regional differences, which have now been 
reproduced in an independent dataset. It is our hope that this report will serve as an impetus for 




A) Regions of interest for each of the seven resting state networks projected on the right 
hemisphere cortical gray matter surface of the Conte 69 atlas42 using Connectome Workbench43. 
Images show the right lateral and medial surfaces. B) Pairwise differences between each resting 
state network. Within each cell is the difference in OGI (∆OGI) between resting state networks 
along with the 95% CI of the difference. Positive numbers indicate greater OGI (less NOglc) in 
the network listed on the vertical axis. Only significant differences are shown in color. The 
numbers along the bottom row are the mean and the 95% CI for each network. Network 
abbreviations: fronto-parietal control (FPC), default mode (DMN), dorsal attention (DAN), 
ventral attention (VAN), language (LAN), somatomotor (SMN) and visual (VIS). (C) Within-
Figure 3.1: Differences in OGI between resting state networks 
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subject comparison of OGI evaluated within the default mode network versus visual network. 
The solid blue lines connect regional measurements within a single participant. Note consistency 
of regional differences in OGI from subject to subject. The DMN exhibited lower OGI than the 
visual network (VIS) in every subject.   
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Region was derived from the atlas used by Hyder et al. 7. Only voxels for which OGI was non-
zero in every subject were included. The MNI152 T1 template was resampled to the space of the 
PET data for anatomical reference.  
Figure 3.2: Cerebellar gray matter region of interest 
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A) A group-averaged OGI map obtained from the authors of the Hyder et al. study. Regional 
differences are found throughout the brain. B) Replication of Figure 3A from Hyder et al., 2016 
which shows little regional variation in OGI. Regional differences are masked by the use of a 
color scale that lacks a dynamic range which is not matched over the relevant physiologic range 
of the data. 





Table 3.1: Means and 95% CIs for selected regions and resting state networks 
Whole brain, gray matter, and white matter regions were taken from the atlas used by Hyder et al. 7. Resting state regions were from 
Hacker et al. 16. The cerebellum was excluded from all regions. Summary statistics were calculated after excluding voxels that exceed 
five median absolute deviations from the gray matter median15. The reported means for whole brain, as well as gray and white matter, 









Whole Brain 36.32 (2.89) 26.34 (1.59) 134.53 (13.76) 5.10 (0.50) 0.42 (0.04) 
Gray Matter 38.31 (3.14) 27.57 (1.74) 142.51 (14.89) 5.18 (0.51) 0.42 (0.04) 
White Matter 28.95 (2.11) 21.74 (1.15) 104.93 (9.79) 4.78 (0.47) 0.41 (0.04) 
Dorsal Attention 37.97 (3.90) 29.00 (1.98) 150.32 (17.26) 5.24 (0.58) 0.44 (0.05) 
Ventral Attention 45.40 (4.02) 32.13 (2.10) 147.13 (16.83) 4.65 (0.54) 0.37 (0.04) 
Somatomotor 39.51 (3.42) 28.99 (1.81) 141.74 (16.59) 4.95 (0.53) 0.41 (0.05) 




Control 40.63 (3.81) 30.17 (2.08) 152.25 (16.21) 5.10 (0.52) 0.42 (0.05) 
Language 41.58 (3.73) 29.88 (1.81) 152.86 (16.73) 5.20 (0.59) 0.41 (0.05) 
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Chapter 4: Regional changes in cerebral blood flow and glucose 




 In healthy individuals at rest, the cerebral metabolic rate of glucose consumption 
(CMRglc) is tightly coupled with cerebral blood flow (CBF). However, early studies showed that 
global CMRglc decreases more than global CBF in patients experiencing profound 
hypoglycemia. Whether this relationship holds in all brain regions is unclear, as there are few 
regional measurements of CMRglc during hypoglycemia in humans. However, several 
investigators have shown that changes in CBF in humans during hypoglycemia are confined to 
just a few brain regions. To determine whether regional changes in glucose metabolism match 
changes in CBF, we used 1-[11C]-D-glucose and [15O]-H2O PET to measure regional glucose 
metabolism and blood flow in healthy young adults undergoing hypoglycemic-hyperinsulinemic 
glucose clamps. We found that moderate hypoglycemia significant decreased CMRglc by 
approximately 20-30% in every brain region examined. Other aspects of glucose metabolism, 
such as glucose influx and tissue concentration, were also decreased in every region. Changes in 
CBF (~10%) were generally smaller than changes in CMRglc (~20%) and were only 
significantly different from euglycemia in a few regions. Our results indicate that hypoglycemia 
does not alter CBF to the same degree as CMRglc during hypoglycemia. Furthermore, they 
suggest that the purpose of focal increases in CBF during hypoglycemia is not to maintain 





Blood-borne glucose is the brain’s primary energy source1, with other fuel sources such 
as glycogen2, ketone bodies3, or lactate4 contributing only small amounts under normal 
conditions. Therefore, the regulation of blood-glucose level is critical for proper brain function5. 
Acute hypoglycemia has several known neurological effects, including confusion, drowsiness, 
speech difficulties, and lack of coordination6. If blood glucose drops too low from its normal 
value of ~90 mg·dL-1, seizures, coma, and even death, can occur5,7.  
Due to the counterregulatory responses of insulin, glucagon, epinephrine, and other 
hormones8, the incidence of hypoglycemia is rare in non-diabetic healthy individuals9. 
Hypoglycemic episodes are relatively common10, however, in individuals with type-1 diabetes 
(T1DM), who experience mild treatment-related hypoglycemia nearly twice a week11. 
Hypoglycemia can be particularly problematic for the approximately 25% of individuals with 
T1DM that experience hypoglycemic unawareness12, or the failure to develop hypoglycemia-
related symptoms. Without the warning provided by symptoms, individuals fail to take action to 
counter hypoglycemia (e.g., food consumption)10, which increases the risk of a more serious 
hypoglycemic episode13. 
Due to its potentially serious consequences, the impact of hypoglycemia on human brain 
metabolism is the subject of a large body of literature (e.g., see 14,15). The relationship between 
cerebral blood flow (CBF) and hypoglycemia has been particularly well-studied. Several early 
studies reported that compared to the cerebral metabolic rate of glucose (CMRglc), global CBF 
(i.e. whole-brain) is relatively stable during profound hypoglycemia (~30 mg·dL-1)16,17. Studies 
during mild hypoglycemia have reported mixed results, with some studies reporting no change in 
global CBF in healthy controls,18-22, while others have reported increases23-25 or decreases26. 
Studies examining regional changes in CBF have generally been more consistent (for divergent 
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findings see23,25,27 ). In both healthy controls26,28 and individuals with T1DM22,29-31, relative 
increases in CBF have been reported in a common set of brain regions including the thalamus, 
globus pallidus, and medial prefrontal cortex. 
The majority of studies examining CMRglc during hypoglycemia in humans have 
examined only global effects. These studies have found that CMRglc begins to decrease at blood 
glucose levels around 50 mg·dL-118-20,32,33, with large decreases seen during profound 
hypoglycemia16,17,34. The primary method used to measure regional CMRglc in humans is [18F]-
fluorodeoxyglucose (FDG) positron emission tomography (PET). Because glucose is not directly 
used as a tracer, a correction factor, called the lumped constant (LC), must be used to accurately 
measure CMRglc with FDG35. Unfortunately, the LC changes dramatically during 
hypoglycemia36, which limits the usefulness of FDG in subjects with low blood glucose 
concentrations. An alternative technique that avoids this complication is to use radiolabeled 
glucose. Very few studies, however, have used radiolabeled glucose to examine regional human 
brain metabolism during hypoglycemia. Perhaps the only exception is the combined work of 
Gutniak et al. and Blomqvist et al 18,37. The original report by Gutniak et al. measured CMRglc in 
several large regions using [U-11C]-glucose PET and found that CMRglc declined by 30-40% in 
every region37. Later Blomqvist et al. performed a voxelwise analysis of the same data to 
confirm the uniform decline in CMRglc on a much finer spatial scale18. 
The uniform decline in CMRglc during hypoglycemia reported by Gutniak et al. and 
Blomqvist et al. is in contrast to the focal CBF changes that predominate the literature14,15. A 
uncoupling between CBF and CMRglc changes might be surprising given the tight spatial 
correlation between the two parameters under normal euglycemic conditions38,39. It would, 
however, be consistent with the fact that during profound hypoglycemia, changes in global 
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CMRglc are much more pronounced than changes in either CBF or oxygen consumption16,17,34,40. 
Moreover, it has been proposed that the purpose of CBF changes during hypoglycemia in not to 
provide the brain with more glucose. Rather, CBF changes as a part of the brain’s 
counterregulatory hormonal response to hypoglycemia41,42. To determine whether brain glucose 
metabolism changes during hypoglycemia are regionally-specific or uniform, we used measured 
regional glucose metabolism with 1-[11C]-D-glucose and regional CBF with [15O]-H2O PET 
during stepped hypoglycemia in healthy participants. As a true glucose tracer, 1-[11C]-D-glucose 
enables quantitative estimates of CMRglc, glucose influx, free glucose concentration, and 
glucose extraction regardless of blood glucose level. 
4.3 Methods 
 
The original source for the data analyzed in this report is a previous study examining the 
relationship between hypoglycemia, whole-brain glucose metabolism, and counterregulatory 
hormones33. For further methodical detail, please see the cited reference. 
Participants  
A total of eighteen participants were included in this study. All participants were healthy 
young adults without a history of diabetes. Participants were randomly assigned to one of two 
groups. Subjects in the first group received hyperinsulinemic glucose clamps first at 90 mg·dL-1 
and then at 60 mg·dL-1. This group consisted of 10 individuals (6 female, 4 male) with an 
average age of 28.9 (SD 6.9) years and a BMI of 24.4 (SD 3.6) kg·m-2. The second group 
consisted of 8 subjects (2 female, 6 male) who received glucose clamps at 75 mg·dL-1and 45 
mg·dL-1. The average age was 27.6 (SD 8.2) years and a BMI of 24.0 (SD 2.8) kg·m-2. All 




Subjects reported in the morning after fasting overnight for 10 hours. Intravenous 
catheters were placed into the antecubital veins of both arms. The first catheter was used for the 
infusion of insulin, glucose, and potassium chloride, and the second for the injection of 
radioactive tracers. An arterial line was placed into the radial artery of one forearm for the 
collection of arterial input data. Subjects were then taken to the PET scanner, where the 
hyperinsulinemic glucose clamps were started after 30 minutes of supine rest. Human insulin 
was infused at 2.0 mU·kg-1·min-1 and 20% glucose was infused at a rate necessary to achieve the 
target glucose level. The first glucose clamp (90 or 75 mg·dL-1) was immediately followed by 
the second clamp (60 or 45 mg·dL-1). Each clamp lasted for 2 hours. During the clamping 
procedure, symptom scores and the arterial concentrations of epinephrine, norepinephrine, 
insulin, C-peptide, glucagon, cortisol, fatty acids, B-hydroxybutyrate, and lactate were measured 
every 30 minutes. All experimental procedures were approved by the Washington University 
School of Medicine Human Research Protection Office for compliance with the Helsinki 
Declaration of 1975.  
Image acquisition 
PET scanning began 20 minutes after blood glucose was maintained at the target level for 
twenty minutes. First, attenuation was measured with [68Ge]-[68Ga]-rotating rod sources. Next, 
subjects inhaled 22 ± 4 mCi of [15O]-CO for the measurement of cerebral blood volume (CBV) 
43. A single 5-minute long emission frame was acquired starting 2 minutes after inhalation. 
Cerebral blood flow (CBF) was then measured with the injection of 19 ± mCi of [15O]-H2O 44. 
The dynamic acquisition consisted of 60 2-second frames acquired immediately following 
injection. Finally, cerebral glucose metabolism was measured via the injection of 10 ± 3 mCi of 
1-[11C]-D-glucose45. The emission data was split into 45 frames spanning 60 minutes (16 x 30 s, 
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8 x 60 s, 16 x 120 s, 4 x 180s). All PET data was acquired with a ECAT EXACT HR+ PET 
scanner (Siemens/CTI, Knoxville, TN) in 3D mode with retraction of interslice septa and 
reconstructed using a filtered back-projection46. During [15O]-CO and [15O]-H2O acquisition, 
arterial input data was automatically sampled from the radial artery at a rate of 5 mL·min-1. 
During the 1-[11C]-D-glucose scan, manual arterial samples were acquired every 10-15 seconds 
during the first 3 minutes and every 10-15 minutes thereafter. The same PET scanning protocol 
was performed during both glucose clamps. Following the completion of the glucose clamping 
experiment, a high resolution T1-weighted MPRAGE was acquired using a Siemens 3T Trio 
(2400 ms TR, 3.16 ms TE, 256 x 256 x 176 FOV, 1 mm3 voxels). 
Image analysis 
All PET data was smoothed with a 5 mm isotropic Gaussian kernel to create images with 
an approximate resolution of 8 mm isotropic voxels47. After smoothing, the dynamic 1-[11C]-D-
glucose data was motion-corrected using previously described in-house software48,49. A mean 
image across time was then created for each PET series, resulting in two images for each tracer. 
Within each tracer, the average images were registered to each other by minimizing the error 
between the forward (image 1 -> image 2) and backward (image 2 -> to image 1) registrations48. 
Once aligned, an average within-tracer image was computed and registered to the high-resolution 
T1-weighted image using a vector gradient algorithm50.  
 The T1-weighted image was segmented using Freesurfer 5.151 to create 48 non-
overlapping cortical and subcortical regions of interest (ROIs; Figure 4.1).The Desikan atlas52 
was used to define 34 gyral-based cortical gray matter ROIs. Separate ROIs were created for 
subcortical gray regions (thalamus, caudate, putamen, pallidum, hippocampus, amygdala, and 
nucleus accumbens) and white matter (deep, superficial, corpus callosum)53. ROIs were also 
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created for cerebellar gray and white matter. Finally, the brainstem and ventral dienecephalon 
were separated into two ROIs. All ROIs were averaged across the cerebral hemispheres. The 
tissue class (white matter, gray matter, and CSF) of each voxel was determined separately using 
FSL’s54 FAST55. 
 A previously published and validated four-compartment model45 was used to describe the 
1-[11C]-D-glucose data: 
!"($) = !'( ∙ !*($) + ∫ !*(-) ∙ .($ −
0
1 -)	3- (4.1) 










where !"($) is the average tracer concentration within the ROI at time $, !*($) is the arterial 
tracer concentration, and .($) is the tissue impulse response function. The 4 and E terms are 






D, E = :F + :;. To simplify the model fitting, :H was assumed to equal CBF/CBV. 
The remaining rate constants were estimated for all 48 FreeSurfer ROIs using nonlinear least 
squares. Following Graham et al., we chose to optimize KL
(BMNBJ)
 instead of :F56. Prior to regional 
fitting, the delay between the input function, !*($), and the PET data was corrected for by fitting 
equation 4.1 to the average whole-brain tissue activity curve with the addition of a delay term. In 
accordance with previous procedures, all 1-[11C]-D-glucose modeling was done with whole-
blood arterial tracer concentration without correction for radiometabolities33,45,57. 
CBF was computed for each ROI using a one-compartment, two parameter model44: 
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!"($) = O ∫ !*(-) ∙ 5
6PQ(06R)	3-01   (4.3) 
where O is CBF and l is the blood brain partition coefficient. Before performing a nonlinear least 
squares fit on equation 4.3, the arterial input function, !*, was corrected for delay and dispersion. 
Correction for the dispersion between the automatic blood sampler and the radial artery was 
performed by assuming that the measured input function, !S, is the convolution of the actual 
input function, !*, with a measured kernel ℎ58:  
!S($) = ∫ !*(-) ∙ ℎ($ −
0
1 -)	3- (4.4) 
Therefore, the reconstruction of !* is a deconvolution problem. This problem was solved by 
assuming that !* follows the form described by Golish et al.59, and then minimizing the 
difference between !S and the right hand side of equation 4.4 with nonlinear least squares. 
Delay between !* and the [15O]-H2O PET data was corrected for using the same procedure as the 
1-[11C]-D-glucose data. 











where \ is the ratio of cerebral small to large vessel hematocrit and 3" and 3] are the densities 
of tissue and blood respectively. The values for these constants were set according to Martin et 
al.43: \ = 0.85, 3" = 3] = 1.05
b
Sc
. As CBV was not a parameter of interest and only needed to 
solve equation 4.1, we utilized a simple strategy to minimize the impact that noise in the CBV 
quantification had on our results. All voxels with a CBV less than 6 were replaced with the mean 
CBV value of their respective tissue class (white, gray, or CSF). All voxels with a CBV greater 
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or equal to 6 were replaced with the mean of all such voxels. The resultant image was then 
smoothed with 5 mm isotropic Gaussian kernel prior to computing the mean CBV within each 
FreeSurfer ROI. Without this correction fitting the C11-glucose model (Eq. 1 and 2) was often 
unstable, as low values of CBV from noisy voxels produced unrealistically high values of :H. 
 All optimization was performed using the optimize package in SciPy 60. Uniform weights 
were used for all nonlinear least square fits. 
Metabolic parameters 
The rate constants estimated from the regional 1-[11C]-D-glucose data were used to 
estimate five distinct parameters: 1) cerebral metabolic rate of glucose (CMRglc), 2) glucose 
influx, 3) free glucose concentration, 4) glucose first-pass extraction (Efp), and 5) net glucose 
extraction (Enet). These quantities were computed as follows45,61: 
!d\efg = 	 KLBJ
(BMNBJ)
∙ !h (4.6) 
ijOfkl = 	89!h (4.7) 
!mjg5j$.n$omj = 	 KL
(BMNBJ)









!h, the arterial whole blood glucose concentration, was estimated using !r, the measured arterial 
plasma glucose concentration45,62: !h = !r(1 − 0.3 ∙ ℎ5xn$mg.o$). We also computed whole-
brain normalized estimates of each parameter by dividing each regional value by the volume-





For each region, the relationship between !r and CMRglc, glucose influx, glucose 
concentration, CBF, Efp, and Enet was assessed using a multivariate linear mixed model63: 
yz{ = |z{E + }z + 5z{  (4.11) 
where yz{ is a 6 x 1 vector containing the metabolic parameter estimates for subject i during 
glucose clamp j. |z{ is a 1 x p row vector containing the fixed effect regressors. Here, p = 3 as 
|z{ is made up of three regressors: 1) Intercept (β0), 2) !r (β1), and 3) A restricted cubic spline 
term with boundary knots at the 0.1 and 0.9 quantiles and an interior knot at the 0.5 quantile 
(β2)64. The spline regressor was added to allow for a nonlinear relationship between !r and any 
of the metabolic parameters. Prior to fitting, the data in y and | were standardized so that each 
metabolic parameter and fixed effects regressor had a mean of zero and a SD of 1. The fixed 
effect regression coefficients are in the p x 6 matrix E. The 1 x 6 row vector }z contains a subject 
specific random intercept for each metabolic parameter. Finally 5z{ is a 1 x 6 row vector of 
independent and identically distributed errors. The random intercept terms were assumed to 
come from a multivariate normal distribution: }z~m.xnf(0, Ä), where Ä is a 6 x 6 
unstructured covariance matrix. Note that even though our model assumes the residual errors for 
each parameter are identical and independent, covariance between the parameters can be 
accounted for through their random intercepts63. 
Equation 4.11 was fit separately to the data from each FreeSurfer ROI using a Bayesian 
Hamilton Markov chain Monte Carlo (MCMC) with Stan65. The fixed effect coefficients where 
given a broad normal prior with a mean of 0 and a SD of 5. A half-Cauchy distribution with a 
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location of 0 and a scale of five was used as the prior for the residual error term. For modeling 
purposes, the random effects covariance matrix was decomposed into a 6x6 correlation matrix 
and a vector of SDs 66. The correlation matrix was given a LKJ Cholesky67 prior with a shape of 
1.0, which implies a uniform prior density for the correlation between the random effect 
parameters68. A half-Cauchy distribution with a location of 0 and a scale of five was used for the 
standard deviation parameters. Fitting was performed with four independent MCMC chains 
consisting of 5,000 iterations. The first 2,500 iterations of each chain were removed as warm-up, 
leaving a total of 10,000 iterations available for inference. The Gelman-Rubin \Å statistic was 
used to check that all four MCMC chains had converged 69,70. \Å is the ratio of within to between 
chain variance and should equal 1 after convergence. The \Å for all reported parameters was close 
to 1.0 for every regional fit (range=0.9996 to 1.036). 
 Regional CBF data was missing for three clamp studies. A univariate mixed model was 
used to interpolate the missing CBF values for each FreeSurfer region. The model consisted of a 
single random intercept and the same fixed effect regressors as equation 4.11. All fitting was 
performed using the R71 package lme472. The interpolated CBF values were used to optimize 
equation 4.1 and to compute Efp and Enet. They were not used to assess the relationship between 
CBF and !r with equation 4.11. Therefore, all inference for changes in CBF was based on 33 
data points and not 36 like the other metabolic parameters. To account for the missing CBF data, 
the Bayesian formulation of equation 4.11 included the missing data points as free parameters.  
 For each region, the overall association between !r and each of the six metabolic 
parameters (CMRglc, glucose influx, glucose concentration, CBF, Efp, and Enet) was tested by 
computing the 95% highest density region of the joint distribution between β1 and β2 (Figure 
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4.2). A significant relationship was reported if the coordinate β1 = 0.0, β2 = 0.0 was outside of the 
95% region. For example, a significant relationship between Cp and CMRglc would indicate that 
CMRglc changes as a function of blood glucose level. The R package ks was used estimate the 
95% highest density regions73. If a significant relationship with !r was found, than the marginal 
highest density interval (HDI) for the cubic spline term β2 was computed74. There was significant 
evidence for a nonlinear relationship with !r if the 95% HDI of β2 did not overlap 0.0. A 
nonlinear relationship with Cp indicates that that change in the metabolic parameter (e.g. 
CMRglc) cannot be described by a simple linear function. To visualize the effect of 
hypoglycemia, an image of the difference between euglycemia and hypoglycemia was made by 
computing the difference between the model prediction at !r= 90 mg·dL-1 and at !r = 45 mg·dL-
1 for each ROI. Spearman rank order correlations were used to assess the spatial correspondence 
between maps of metabolic change (e.g., CMRglc vs. CBF). Due to the autocorrelation present 
between brain regions75, as well as differences in ROI sizes, p-values for the correlation 




Regional changes in metabolism 
Figure 4.3 shows the individual CMRglc, glucose influx, glucose concentration, CBF, 
Efp, and Enet data in both the precuneus and deep white matter along with the population average 
fits from the multivariate linear mixed model. We chose the precuneus as an example gray matter 
region as it has one of the highest CMRglc at euglycemia. CMRglc, influx, and concentration 
dropped along with !r in both the precuneus and deep white matter (Figure 4.3A-C). 
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Conversely, Enet increased with decreasing !r (Figure 4.3F). CBF and Efp showed less 
pronounced changes during hypoglycemia (Figure 4.3D-E). 
To quantify this impression, we tested for the presence of a significant relationship 
between !r and each metabolic parameter in 48 separate FreeSurfer ROIs (see Methods). A 
significant relationship was found between !r and CMRglc (Figure 4.4B), glucose influx (Figure 
4.5B), glucose concentration (Figure 4.6B), and Enet (Figure 4.7B) in every region tested. A 
significant nonlinear relationship between !r and CMRglc was found for most (35/48), but not 
all, regions (Figure 4.4C). The regions showing only a linear relationship include both gray 
(amygdala, entorhinal cortex, and globus pallidus) and white (cerebellar white matter, corpus 
callosum, and deep white matter) matter. No region showed a nonlinear relationship between !r 
and glucose influx (Figure 4.5C) or concentration (Figure 4.6C), and only the globus pallidus 
had a significant nonlinear association between !r and Enet (Figure 4.7C).  
Quantitative changes in Efp and CBF were not nearly so widespread. Significant increases 
in Efp with decreasing !r were found in 17 out of 48 regions (Figure 4.8B). Both cortical and 
cerebellar gray and white matter regions displayed increases in Efp, though the only subcortical 
gray matter region which increased its first-pass extraction was the caudate. No evidence was 
found for a nonlinear relationship between !r and Efp (Figure 4.8C). A significant relationship 
between CBF and !r was found in only nine regions (Figure 4.9B). Significant decreases in CBF 
with hypoglycemia were found in the banks of the superior temporal sulcus, caudal anterior 
cingulate, interior temporal cortex, posterior cingulate, superior temporal cortex, frontal pole, 
transverse temporal cortex, and nucleus accumbens. A significant increase was found only in the 
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globus pallidus, which was also the only region with a significant nonlinear relationship between 
!r and CBF (Figure 4.9C).  
As many previous studies have reported relative changes in blood flow during 
hypoglycemia22,26,28, we repeated our previous analysis of CBF changes after first normalizing 
each CBF image by its global mean. A relative decrease in CBF was observed in the posterior 
cingulate, while relative increases were found in the thalamus, globus pallidus, brainstem, and 
ventral diencephalon (Figure 4.10B).  
Discrepancies between CMRglc and CBF changes 
To further investigate the discrepancy between the widespread changes in CMRglc 
(Figure 4) and the focal changes of CBF (Figures 7,10), we first correlated euglycemic metabolic 
values with the difference between euglycemia and hypoglycemia over all ROIs (see Methods). 
CMRglc, influx, and concentration all showed strong negative correlations. Regions with the 
greatest baseline values displayed the greatest changes during hypoglycemia (Figure 4.11A-C). 
Conversely, CBF, Efp, and Enet, the parameters which are directly dependent on blood flow, 
showed only modest correlations (Figure 4.11D-F), with the association between baseline and 
change in Efp being particularly weak (Figure 4.11E). 
Next, we correlated regional changes in CMRglc with regional changes in CBF. Changes 
in CBF and CMRglc showed only modest regional correlations, both quantitatively (Figure 
4.12A), and expressed as percent change (Figure 4.12B). This is in contrast with euglycemia, 
where regional CBF and CMRglc were tightly correlated (Ç = 0.86). Nearly every region 
exhibited CMRglc decreases in the 20-25% range, with the exception of deep white matter and 
the corpus collosum, the two regions with the lowest CMRglc at euglycemia (Figure 4.12B). 
Consistent with previous relative analysis (Figure 4.10B), CBF in most regions decreased 
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slightly, with the exception of the thalamus, globus pallidus, brainstem, and ventral diencephalon 




 A previous analysis of the same data analyzed here found whole-brain decreases in 
CMRglc, glucose influx, and free glucose concentration, an increase in Enet, and no change in 
CBF during moderate hypoglycemia (45 mg·dL-1)33. Importantly, changes in counterregulatory 
hormones (epinephrine and glucagon) were observed before changes in CMRglc. However, that 
study did not report any regional changes in metabolism during hypoglycemia. Here we found 
that hypoglycemia decreases CMRglc, glucose influx, and glucose concentration, and increases 
Enet, in every brain region we examined. Hypoglycemia induced changes in Efp, and especially 
CBF, were more regionally specific. Decreases in CMRglc, glucose influx, and glucose 
concentration correlated strongly with baseline values, whereas changes in CBF, Efp, and Enet 
showed only modest correlations. Regional changes in CMRglc did not correlate with regional 
changes in CBF, suggesting a difference between glucose metabolism and blood flow in the 
response to hypoglycemia. Finally, we found that glucose concentration in the cerebellum was 
much greater than any other brain region.  
Glucose Metabolism 
 Our finding that hypoglycemia decreases CMRglc in all brain regions is consistent with 
two previous paired studies in humans18,37. These studies reported that CMRglc declines by 
approximately 40% in all regions during an insulin-induced hypoglycemia of 50 mg·dL-1. 
Uniform declines in CMRglc are also found during short-term starvation, a condition that results 
in mild hypoglycemia76,77. Multiple studies in rats have also reported nearly uniform decreases in 
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CMRglc during hypoglycemia78-80. A few exceptions were observed in each study. Abdul-
Rahman and Siesjö reported that CMRglc in the hypothalamus and the cerebellum did not 
decline even after 30 minutes in an insulin-induced hypoglycemic coma78. Pelligrino et al. also 
reported that cerebellar CMRglc was maintained during modest hypoglycemia (approximately 40 
mg·dL-1) 80. Conversely, Bryan et al. reported CMRglc did not decrease in the pyramidal tracts79, 
even when blood glucose was lowered to nearly 25 mg·dL-1. An outlier to the studies discussed 
above is the work of Suda et al., who found much more variable changes CMRglc during 
moderate hypoglycemia (approximately 43 mg·dL-1)81. After Bonferroni correction for multiple 
comparisons, significant declines in CMRglc were found only in the dentate gyrus of the 
hippocampus and in several brainstem regions. Absolute CMRglc, however, declined in every 
region but the superior colliculus and the dentate nucleus of the cerebellum. It is possible that 
some of the variability in these results is due to differences in the degree of hypoglycemia. 
Indeed, Bryan et. al found that CMRglc declined only in a few regions when the blood glucose 
level was at 35 mg·dL-1, whereas all regions exhibited declines with more pronounced 
hypoglycemia.  
 Compared to CMRglc, the literature on regional changes in quantitative glucose influx, 
concentration, or extraction is relatively sparse. Indeed, this report is, to the best of our 
knowledge, the first to examine this question in humans. There are, however, relevant studies in 
animal models. In agreement with our results, hypoglycemia has been shown to reduce the free 
glucose concentration throughout the brain in mice82,83 and rats84,85. Interestingly, Paschen et al. 
found that the brain stem, hypothalamus, and thalamus still have some free glucose concentration 
even during deep hypoglycemia. As far as we are aware, this finding has not been replicated. 
LaManna and Harik found that glucose influx and Efp decreased in the frontal and parietal 
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cortices, cerebellum, and hippocampus86. This is only partially consistent with our results, as we 
did not find a significantly increase in hippocampal Efp. We are not aware of any data on regional 
changes in Enet during hypoglycemia, but our results are agreement with previous studies 
showing global increases33,45,87. 
We also found that the relationship between plasma glucose and CMRglc was nonlinear 
in most brain regions, with CMRglc changing little until plasma glucose was lowered to around 
45 mg·dL-1. This is consistent with the finding that glucose metabolism is largely maintained 
during modest hypoglycemia in humans19,32,33 and in animal models45,78,79. A nonlinear 
relationship between CMRglc and plasma glucose is expected under normal conditions, as 
cerebral glucose influx far outstrips glucose consumption, and therefore, glucose consumption 
only declines once CMRglc and influx are nearly equal88. Conversely, we found little evidence 
for nonlinearity in any of the other parameters that we examined. No regions had a significant 
nonlinear relationship with glucose influx, glucose concentration, or Efp, and only the globus 
pallidus had a nonlinear relationship with Enet.  
Our finding of linear changes in glucose influx and concentration generally agrees with 
the literature. Several studies using a variety of techniques have found that brain glucose 
concentration is linear with respect to plasma glucose over a wide range85,89-93. Two studies in 
rats reported that changes in brain glucose influx are largely linear in the blood glucose range we 
studied here, before saturating at higher concentrations86,94. Using a similar experimental design 
to ours, Powers et al. also showed a roughly linear decline in glucose influx in macaques45. Our 
results are somewhat in conflict with previous studies of glucose first-pass extraction in animal 
models86,95,96. These studies found a nonlinear relationship between Efp and blood glucose levels, 
with large increases in Efp during more profound hypoglycemia. Here, although Efp did increase 
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in many regions, the increase was fairly small and did not deviate significantly from linearity. It 
is likely that, if we had studied more profound levels of hypoglycemia, larger changes in Efp 
would have been observed.  
Cerebral Blood Flow 
Unlike glucose metabolism, alterations in CBF were restricted to a select set of regions. 
Quantitative decreases in CBF were found in a handful of cortical regions, including the caudal 
anterior cingulate, inferior temporal cortex, and posterior cingulate, as well as in the nucleus 
accumbens. Nwokolo et al. also reported that hypoglycemia decreases CBF in the temporal 
lobe97, prefrontal cortex42,97, and globus pallidus42. We also found that relative to the rest of the 
brain, the CBF response to hypoglycemia was significantly lower in the posterior cingulate and 
significantly higher in the thalamus, globus pallidus, brainstem, and ventral diencephalon. In 
both healthy and in individuals with T1DM, hypoglycemia has been shown to increase relative 
blood flow in the thalamus26,28-31,98-100, medial prefrontal cortex26,28,31,99, globus pallidus26,28,31, 
and anterior cingulate cortex28,31. Although we did find a relative decrease in the posterior 
cingulate29, we did not find any relative increases in CBF in the cerebral cortex. One possible 
explanation is that hypoglycemia was not maintained long enough to alter blood flow in these 
regions. In support of this hypothesis, two recent studies found that regional increases in CBF 
become more pronounced the longer hypoglycemia is maintained28,31. However, relative 
decreases in MPFC CBF have been found using a protocol similar to the one we used here42.  
Research in animal models have also found regional variability in the CBF response to 
hypoglycemia79,88,101. There are, however, a few important discrepancies from the human 
literature. First, animal model studies have generally found that hypoglycemia increases global 
CBF79,92,101-104. The human literature is much more mixed15, with a large number of studies 
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reporting no change in global CBF during mild to moderate hypoglycemia 18-22,105. It is tempting 
to argue that the reason for this discrepancy is that human studies do not measure CBF at low 
enough levels of hypoglycemia. Multiple studies in rats have shown that, although CBF 
increases rapidly once the blood glucose level drops below 40 mg·dL-1, it is relatively stable 
above this point79,92,104. A few human studies have found that whole-brain CBF increases once 
blood glucose is lowered below 40 mg·dL-123-25,34. However, other studies have reported small 
and/or non-significant changes in subjects whose blood glucose is low enough to induce a 
hypoglycemic coma16,17. Whether increased CBF during hypoglycemia is a species specific 
phenomenon, or a by-product of different measurement techniques, remains to be determined. 
Second, studies in animal models have consistently reported that hypoglycemia increases CBF in 
nearly every region of the brain79,101,103,104. There is, however, regional variability in the 
magnitude of the increase. For example, particularly large increases in CBF have been found in 
the cerebellum101,103 and the thalamus79,101. This is in contrast with the human literature, which 
has consistently shown that hypoglycemia selectively increases CBF in a network of regions 
including the thalamus and medial prefrontal cortex 15. Part of this difference may be that unlike 
animal studies, studies in humans have tended to report regional changes relative to the whole-
brain22,26,28-31. Normalization is unlikely to fully account for the discrepancy, however, as we, in 
agreement two other studies42,97, did not observe CBF changes in every region even with 
quantitative CBF. It is also possible that a species difference may explain the discrepancy 
between animal and human studies. Metabolic rates are higher in rodents106, so it is conceivable 
that they are more effected by hypoglycemia than humans.  
Metabolic coupling during hypoglycemia 
Our results show clearly that during hypoglycemia there is an uncoupling between 
regional changes in glucose metabolism and CBF. Glucose metabolism was altered in every 
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region we examined, while CBF was changed in smaller set of regions. Furthermore, there was 
only a modest regional correlation between changes in CMRglc and changes in CBF. This 
suggests that the purpose of increased CBF during hypoglycemia is not, at least completely, to 
increase the supply of glucose to the brain. A similar proposal was made by Powers et al., who 
found that the increase in CBF in the somatosensory cortex during tactile stimulation was the 
same in euglycemic and mildly hypoglycemic (~60 mg·dL-1) subjects107. If CBF increased 
during hypoglycemia in order to prevent a fall in glucose consumption, one would expect 
CMRglc to be relatively maintained in regions with increased CBF (e.g. the globus pallidus). 
Instead, we found that declines in CMRglc were largely determined by baseline metabolic rates, 
and that most regions declined by a little over 20% once the blood glucose level was lowered to 
45 mg·dL-1. In contrast, CBF fell in most regions by around 10% and baseline CBF was much 
less predictive of CBF changes. It is possible that CBF increases in order to supply the brain with 
alternative fuels such as lactate or ketone bodies. We are not able to rule out this possibility with 
our present data. However, studies measuring whole-brain changes in metabolism have reported 
that lactate and β-hydroxybutyrate can account for only a modest proportion of the brain’s 
metabolic rate during insulin induced hypoglycemia20,87. Furthermore, the plasma concentrations 
of both lactate and β-hydroxybutyrate were not significantly altered by hypoglycemia in our 
study33. This makes it unlikely that either substance was being used as an alternative, as the 
consumption of both lactate108 and β-hydroxybutyrate3is limited strongly by plasma 
concentration.  
An alternative hypothesis is that focal increases in CBF are part the sympathetic 
counterregulatory hormonal response to hypoglycemia109. In healthy individuals, hypoglycemia 
is counteracted by the release of several key hormones, the foremost of which is insulin8. 
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However, hypoglycemia is also accompanied by the release of glucagon, epinephrine, growth 
hormone, and cortisol. If the release of these hormones fails to restore the blood glucose to 
normal levels, then cognitive decline begins to occur110. It has been proposed109 that these 
counterregulatory responses are regulated by a network of brain regions consisting largely of the 
thalamus and medial prefrontal cortex. Consistent with this idea, acute hypoglycemia has been 
show to increase CBF in the thalamus and medial prefrontal cortex22,26,28,30,42,99, and there is a 
positive correlation between thalamic CBF and autonomic symptom scores during 
hypoglyemia97 . Both the thalamus and medial prefrontal cortex are part of a network of regions 
that, along with the hypothalamus, regulate the brain’s autonomic response to sensory stimuli111. 
Furthermore, Arbelaez et al. reported that while recurrent hypoglycemia attenuates hormonal 
responses in healthy individuals, it actually augments the increase in thalamic CBF that is 
normally seen during acute hypoglycemia98. Based on this finding, and the assumption that 
increased CBF is a marker of increased neural activity, Arbelaez et al. proposed that hormonal 
responses are blunted by repeated hypoglycemia because of increased inhibition of the 
hypothalamus by the thalamus98. More work is needed to confirm this hypothesis, however, as 
more recent studies have reported that the increase in thalamic CBF during hypoglycemia is 
blunted, not increased, in type-1 diabetics with hypoglycemic unawareness22,30.  
 The fact that hypoglycemia effects oxygen metabolism much less than glucose 
metabolism is well established16,17,34,40. This disconnect is particularly prevalent during extreme 
hypoglycemia, where the molar ratio of oxygen-to-glucose metabolism (OGI) rises well above 
its theoretical value of 6.0102,112,113. In the normal resting brain, OGI is approximately 5.5, which 
indicates that nearly 10% of the brain’s glucose metabolism is consumed via non-oxidative 
pathways114. OGI values greater than 6.0 indicate that the brain is oxidizing energy sources other 
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than glucose106. Studies have shown that that the rat brain quickly uses its supply of free glucose, 
glycogen, lactate, and pyruvate during profound acute hypoglycemia82-84,115,116. After this point, 
endogenous amino acids, such as glutamine102, and phospholipids113 are used to maintain ATP 
concentration until the onset of hypoglycemic coma. Although glucose consumption is reduced 
more than oxygen consumption even in moderate hypoglycemia20, how oxidative metabolism is 
maintained in this condition is not fully understood. Lubow et al. estimated that lactate uptake 
could account for up to 25% of the brain’s glucose deficit during moderate hypoglycemia20. 
Glycogen has also been suggested as a potential fuel source117-119, though it is unclear how long 
it can used as fuel source as glycogen is largely restricted to astrocytes120 and is present in fairly 
small amounts2. It is likely that oxidative metabolism is maintained by some combination of 
these and other fuels121. Part of the glucose debt that occurs during moderate hypoglycemia 
could be paid by reducing the approximately 10% of glucose metabolism that is non-oxidative114. 
Although this idea has not been tested, it would help to support whether non-oxidative glucose 
consumption is involved in learning, synaptic plasticity, and development122,123 (but see124).  
Cerebellar Metabolism 
 We did not expect to find such a striking difference in free glucose concentration between 
the cerebellum and other brain regions (Figure 4.6A, Figure 4.11C). At euglycemia, the average 
free glucose concentration in the cerebellar cortex was 0.68 μMol·g-1, compared to 0.42 μMol·g-
1for the cerebral cortex. Regional differences in free glucose concentration have not been well-
studied in humans. There are, however, some exceptions. Heikkilä et al. found that compared to 
the cerebral cortex, the ratio of free brain glucose to water was twice as high in the 
cerebellum125. Herzog et al. reported that the concentration of both free glucose and glycogen 
was higher in the cerebellar cortex126. Similar results have been obtained in animal models as 
well82-84,127, although it should be noted that the differences are smaller than what has been 
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ported in humans, and that other studies have failed to find any difference80,85. Higher glucose 
concentration in the cerebellum is relevant for two reasons. First, the cerebellum seems to 
respond differently to hypoglycemia than other brain regions. There is evidence that CMRglc in 
the rat cerebellum is maintained during both moderate80 and profound hypoglycemia78. Although 
we did not replicate this finding in our study, it is possible that our subjects were hypoglycemic 
too long for the cerebellum’s higher free glucose concentration to serve as an effective buffer. 
The cerebellum is also more resistant to hypoglycemia induced decreases in ATP84,128 and 
protein synthesis129. Finally, the cerebellum appears to be more resistant to hypoglycemia-
induced cell death than other brain regions. Prolonged severe hypoglycemia causes neuronal 
death throughout the cortex and subcortex130-132, with neuronal loss in the dentate gyrus being a 
defining feature. In contrast, cerebellar neurons, particularly Purkinje cells and granule cells, are 
largely intact even after extended periods of profound hypoglycemia128,131. Given these results, 
one hypothesis is that higher levels of free glucose provide the cerebellum with some resistance 
to hypoglycemia. The role of free glucose in preserving energy metabolism is likely minor 
though, as the cerebellum’s glucose concentration of 0.68 μMol·g-1 is small compared to its 
baseline metabolic rate of 20.5 μMol·hg-1·min-1.  
Second, the higher glucose concentration in the cerebellum is relevant to studies using 
FDG PET to measure brain glucose metabolism. The LC for FDG has traditionally been assumed 
to be the same for all brain regions35. Multiple studies have shown that the LC decreases as brain 
free glucose concentration increases133,134. This suggests that the higher free glucose in the 
cerebellum would result in a lower LC than the rest of the brain, which is exactly what was 
found by Graham et al56. Our results support the findings of Graham et al. and suggest that 
studies using FDG to study cerebellar metabolism need to account for regional differences in the 
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LC. In particular, if the same LC is used to measure CMRglc in all brain regions, then cerebellar 
CMRglc will be underestimated relative to other regions. 
Limitations 
 A few caveats should be considered when interpreting our results. First, our ability to 
detect regional effects was limited by our small sample size. This fact, combined with the 
difficulty in fitting a model with four compartments and four free parameters, limited our 
examination of regional changes to larger ROIs. Therefore, it is possible that we missed changes 
in smaller regions that were not uniquely defined in our region set (e.g., hypothalamus). Second, 
our experimental design was set up so that each subject was studied during only two glucose 
clamps. As a result, we did not observe in a single subject the transition from euglycemia (90 
mg·dL-1) to moderate hypoglycemia (45 mg·dL-1). All inferences are therefore based on 
population level statistics. Third, the first glucose clamp for each subject was always at a higher 
blood glucose level than the second clamp. This is concerning as order effects have been 
reported with FDG PET135,136, although the direction is not always consistent. A systematic order 
effect would result in biased estimates of metabolic change during hypoglycemia. Finally, our 
study was limited to observing changes in total glucose metabolism during hypoglycemia. We 
did not collect any data on oxygen metabolism to see if hypoglycemia decreased glycolytic 
glucose metabolism to a greater extent than oxidative glucose consumption. We also did not 
acquire any data that would enable us to determine the metabolic fates of glucose during 
hypoglycemia. Such analyzes would be possible using other techniques, such as labeled 13C-





 We found that moderate hypoglycemia produces uniform declines in brain glucose 
metabolism while only altering CBF in a select set of regions. Therefore, it appears that 
maintaining CMRglc is not the primary driving force behind focal increases in CBF during 
hypoglycemia. Instead, our results are consistent with the hypothesis that focal increases in CBF 
are part of the sympathetic counterregulatory response to hypoglycemia. Elucidating exactly how 




The ROI set consisted 48 non-overlapping regions that were averaged across the cerebral 
hemispheres. The cortical gray matter was parcellated in to 34 regions52, the subcortical gray 
matter into 7 ROIs (thalamus, caudate, putamen, pallidum, hippocampus, pallidum, 
hippocampus, amygdala, and nucleus accumbens), and the white matter into 3 (deep white 
matter, cortical white matter, and corpus callosum). The cerebellum was also divided into white 
and gray ROIs. The remaining two regions were the brain stem and the ventral diencephalon.  





















Each dot represents a single posterior sample from the Bayesian Markov-chain Monte Carlo 
(MCMC) used to model the change in brain free glucose concentration during hypoglycemia (see 
Methods). The x-axis is the coefficient for a linear relationship between plasma glucose (Cp) and 
glucose concentration in the precuneus, while the y-axis is the coefficient for a nonlinear 
association (a restricted cubic spline). The color indicates density, with yellow indicating the 
area of highest density. To assess whether there was any relationship between Cp and glucose 
Figure 4.2: Joint parameter distribution 
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concentration, the 95% confidence region (black line) was computed (see Methods). A 
relationship between Cp and glucose concentration was significant if the point (0.0, 0.0) was 
outside of the 95% confidence region. In this example, (0.0, 0.0) is well outside the 95% 
confidence region, so we can infer that the glucose concentration in the precuneus decreases 
significantly as blood glucose level decreases
150 
 
A) CMRglc, B) glucose influx, C) glucose concentration, D) CBF, E) Efp, and F) Enet as a function of hypoglycemia. Dots are 
individual data points, and light lines connect the data from individual subjects. Solid lines are the population median (see Methods). 
Figure 4.3: Hypoglycemia induced metabolic changes 
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Data from the precuneus is shown in blue and deep white matter in red. Hypoglycemia induced pronounced changes in A) CMRglc, 
B) Influx, C) Concentration, and F) Enet. Changes in D) CBF and E) Efp were less marked. 
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A) Map of regional CMRglc during euglycemia (Cp = 90 mg/dL). Values were computed using 
the linear mixed model described in the Methods section of the text. Regions were averaged 
across hemispheres so the map is symmetric by definition. B) Estimated difference between 
Figure 4.4: Regional CMRglc 
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CMRglc at hypoglycemia (Cp = 45 mg/dL) and euglycemia. Only regions where there was a 
significant association between Cp and plasma glucose are shown. Note that CMRglc fell during 
hypoglycemia in every single region (48/48). C) Coefficient for the natural cubic spline term of 
the linear mixed model. Regions were the highest density interval (HDI) for the spline 
coefficient overlapped zero are not shown (13/48).  
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Figure convention as in Figure 4.4. Similar to CMRglc (Figure 4.4), glucose influx decreased in 
every brain region with hypoglycemia. 
Figure 4.5: Regional glucose influx 
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Figure convention as in Figure 4.4. B) Similar to CMRglc (Figure 4.4), glucose concentration 
decreased in every brain region with hypoglycemia. 
Figure 4.6: Regional glucose concentration 
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Figure convention as in Figure 4.4. B) Unlike CMRglc (Figure 4.4), Enet increased in every brain 
region with hypoglycemia. 
Figure 4.7: Regional Enet 
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Figure convention as in Figure 4.4. B) Unlike Enet (Figure 4.7), Efp did not significantly increase 
in all regions during hypoglycemia. Particularly notable absences are subcortical gray matter 
regions (e.g,. thalamus) and the brain stem.  
Figure 4.8: Regional Efp 
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Figure convention as in Figure 4.4. B) Unlike CMRglc (Figure 4.4), changes in CBF during 
hypoglycemia were confined to only a few regions.  
Figure 4.9: Regional CBF 
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CBF values are normalized relative to the whole-brain mean (see Methods). Figure convention as 
in Figure 4.4 . B) Compared to absolute CBF (Figure 4.9B), normalization revealed additional 
regions where hypoglycemia increased CBF. Particularly prominent are the brain stem and the 
thalamus. 
Figure 4.10: Regional normalized CBF 
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Spatial correlation between maps of euglycemia (Cp = 90 mg/dL) and change (90 mg/dL – 45 mg/dL) for A) CMRglc, B) glucose 
influx, C) glucose concentration, D) CBF, E) Efp, and F) Enet. Each point is the linear mixed model estimate for a single FreeSurfer 
Figure 4.11: Variable spatial correspondence between maps of baseline metabolism and hypoglycemia induced change 
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region. Blue dots are gray matter, red dots are white matter, and green dots are the brain stem/ventral dienecephalon. Light lines are 
95% highest density intervals. Strong correlations between baseline and change were found for A) CMRglc, B) influx, and C) 
concentration but not for D) CBF, E) Efp, or F) Enet. 
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Each dot represents the linear mixed model estimate for the difference between euglycemia (Cp = 90 mg/dL) and hypoglycemia (Cp = 
45 mg/dL) for a single FreeSurfer region. Blue dots are gray matter, red dots are white matter, and green dots are the brain 
stem/ventral diencephalon. Light lines are 95% highest density intervals. A) Only a modest correlation was found the between map of 
CBF change and the map of CMRglc change. B) Expressed as a percent change, the spatial correspondence between the two maps is 
even weaker. The cluster of four regions on the right of B) are the thalamus, globus pallidus, brainstem, and ventral diencephalon. The 
two regions at the bottom of B) are the deep white matter and corpus callosum.
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Chapter 5: Hyperglycemia selectively alters cerebral glucose 




At normal blood glucose levels, glucose influx into the brain greatly exceeds it basal 
metabolic rate. Despite this fact, hyperglycemia alters cerebral glucose metabolism. To 
investigate this surprising finding, we performed PET and MRI imaging in participants 
undergoing euglycemic (90-100 mg·dL-1 and hyperglycemic (250-300 mg·dL-1) glucose clamps 
with basal insulin replacement. Hyperglycemia significantly altered the topography of brain 
glucose metabolism measured with [18F]-FDG PET. Relative to the rest of the brain, glucose 
consumption increased in white matter and in cerebellar and medial temporal lobe gray matter. 
Conversely, relative glucose consumption decreased throughout the rest of gray matter. The 
change in the topography of glucose metabolism was caused by a quantitative increase in the 
cerebral metabolic rate of glucose (CMRglc) in white matter and the brain stem. Hyperglycemia 
did not change the topographies of blood flow, blood volume, oxygen consumption, or oxygen 
extraction measured with PET. Quantitative cerebral blood flow (CBF), measured with pseudo-
continuous arterial spin labeling (pCASL) MRI, also was not affected by hyperglycemia. As 
hyperglycemia did not alter the topography of oxygen consumption, the ratio of relative oxygen-
to-glucose consumption decreased in the white matter and brain stem, which suggests that the 






The fact that glucose is the brain’s primary fuel source1 makes transport of glucose 
between the blood and brain critically important. Glucose is transported across the blood-brain 
barrier by facilitated diffusion through the GLUT1 transporter2. Therefore, the flux of glucose 
into the brain is dependent on the concentration of glucose in the blood. Fortunately, at normal 
blood glucose concentrations, the transport of glucose into the brain far exceeds the brain’s 
baseline metabolic requirements3. As a result, the brain is relatively insensitive to small 
decreases in plasma glucose concentration, with glucose consumption only dropping after 
moderate hypoglycemia has occurred4,5. 
Given that the brain normally receives more than enough glucose to meet its needs, one 
would predict that increasing the blood glucose concentration would not have an effect on brain 
glucose consumption. Several studies, however, suggest that this may not be the case. Mild 
hyperglycemia has been shown to alter the relative uptake pattern of [18F]-FDG, a PET tracer 
used for the measurement of regional glucose metabolism6. Kawasaki et al. found that, relative to 
the brain as a whole, acute mild hyperglycemia decreases [18F]-FDG uptake throughout cortical 
gray matter7. This finding has since been replicated multiple times, both by the same research 
group8-11, and by independent investigators12. 
Although intriguing, these studies are limited by the lack of quantitative estimates of the 
cerebral metabolic rate of glucose (CMRglc). Instead, CMRglc was approximated by computing 
the ratio of [18F]-FDG uptake within a brain region to [18F]-FDG uptake within a reference 
region. With this approach, all metabolic measurements are not absolute, but are relative to the 
reference region. As a result, it is unclear if glucose consumption is decreasing in cortical gray 
matter during acute hyperglycemia, or if it is simply changing less than the reference region. The 
extant literature favors the later possibility. With one possible exception13, all the studies 
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measuring absolute CMRglc during acute hyperglycemia in humans have reported whole-brain 
increases10,14-16, although only in the report by Blomqvist et al. was the increase significant15. 
Furthermore, studies in both rats 17,18 and humans10,15,16 have failed to report significant regional 
decreases in CMRglc. In fact, Blomqvist et al. found that CMRglc actually increased in every 
region examined15. Interestingly, Blomqvist et al. also reported an inverse relationship between 
baseline CMRglc and the change induced by acute hyperglycemia, with the largest increases in 
CMRglc occurring in regions with the lowest baseline rates15. For example, CMRglc in white 
matter increased by approximately 50%, which is much greater than the whole-brain average 
increase of around 20%. A similarly large increase in white matter CMRglc was also reported by 
Hasselbalch et al., where the centrum semiovale was the only region where CMRglc was 
significantly altered by acute hyperglycemia16. 
Taken together, the results of the studies discussed above suggest that, in humans, acute 
hyperglycemia modestly increases global cerebral glucose consumption, with larger increases 
occurring in regions with lower baseline metabolic rates. This conclusion is consistent with a 
previous analysis of regional CMRglc data in hyperglycemic rats19. It also explains why many 
studies have found that acute hyperglycemia decreases glucose metabolism in cortical gray 
matter relative to the rest of the brain. Cortical gray matter regions have high basal CMRglc, and 
therefore CMRglc changes much less during hyperglycemia than in regions, such as white 
matter, where basal CMRglc is low. This is essentially what was recently found by Ishibashi et 
al.10. The authors first reported that there we no significant decreases in CMRglc in several gray 
matter regions10 during mild hyperglycemia. After normalizing the CMRglc images by the 
whole-brain mean, however, decreases were found in several regions, including in the precuneus 
and posterior cingulate10. The most straightforward explanation of these finding is not that 
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CMRglc is decreasing in these regions; rather, it is simply increasing less than the rest of the 
brain. 
If hyperglycemia is increasing CMRglc in regions with low basal metabolic rates, it is 
unclear what effect it is having on other aspects of cerebral metabolism. Although studies in 
animal models have reported that hyperglycemia decreases cerebral blood flow (CBF) 
throughout the entire brain20,21, the findings in humans have not been so consistent. Multiple 
studies have reported that the whole-brain average CBF does not change with 
hyperglycemia13,14,16,22. Moreover, although significant regional changes in blood flow have been 
reported8,23, the set of affected brain regions differed between studies. Even less clarity exists on 
changes in the cerebral rate of oxygen consumption (CMRO2). Two initial reports found that 
global CMRO2 was unaltered by hyperglycemia13,14, whereas a recent study found that it was 
significantly decreased22. We know of no data examining regional changes in oxygen 
consumption during hyperglycemia. 
Several studies from our laboratory have highlighted the importance of measuring 
changes in glucose consumption, blood flow, and oxygen consumption under the same 
conditions24-26. Although these quantities are normally tightly coupled at rest27, they do not 
always remain so during brief episodes of increased brain activity24 or during more sustained 
changes in brain structure and function across the life-span25,26. To explore the possibility that 
acute hyperglycemia selectively affects key components of brain metabolism, we acquired 
regional measurements of glucose metabolism, oxygen metabolism, blood flow, and blood 






Data from twenty-six participants are included in this report. Participants were healthy 
young adults with a mean BMI of 25.3 (SD 3.3) and no history of diabetes. The participants 
(females=15, males=11) had an average age of 35.1 years (SD 10.2). Complete data during both 
the euglycemic and hyperglycemic clamp conditions were obtained for most, but not all, 
participants. The total number of subjects for each metabolic parameter of interest is listed in 
Table 5.1. All participants gave written informed consent. Experimental procedures were 
approved by the Washington University School of Medicine Human Research Protection Office 
and were compliant with the Helsinki Declaration of 1975. 
Experimental design 
The target plasma glucose level was 90-100 mg·dL-1 for the euglycemic clamp and 250-
300 mg·dL-1 for the hyperglycemic clamp. The majority of participants (18/26) were scanned 
during both clamp conditions. The condition order was counterbalanced across participants. 
Three participants had data from two separate euglycemic clamp visits. The second euglycemic 
visit was acquired as part of a separate study exploring the effect of hyperinsulinemia on brain 
metabolism. Any data points from repeated euglycemic visits were averaged together prior to 
subsequent analysis. The median time between visits was 34.0 days with a range of 7.0 – 966.0 
days. 
All participants were admitted to the Washington University in St. Louis Clinical 
Research Unit after fasting overnight for at least 10 hours. An arterial line was placed into the 
radial artery to allow for the sampling of arterial tracer concentration. Plasma insulin, c-peptide, 
β-hydroxybutyrate, lactate, and pyruvate levels were measured via the arterial line every 30 
minutes. An intravenous catheter was then placed into each arm. The first catheter was placed in 
a vein in the dorsal forearm and used for radiotracer injection. The second catheter was 
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positioned in an forearm vein and was used for infusion of octreotide, insulin, dextrose (20%), 
glucagon, and potassium. Dextrose was infused at a variable rate determined by the clamp 
condition and plasma glucose measurements taken every 5 minutes. Octreotide, a somatostatin 
analogue, was infused at a rate of 30 ng·kg-1·min-1 to suppress endogenous secretion of insulin, 
glucagon, and growth hormone28. Plasma insulin and glucagon were maintained with continuous 
infusions of 0.1 mU·kg-1·min-1 and 1.0 ng·kg-1·min-1 respectively. Finally, potassium chloride 
was given at a rate of 5 mmol·h-1 to prevent insulin-induced hypokalemia29. 
Image Acquisition 
PET and MRI data were acquired simultaneously using a Siemens Biograph PET/MRI. 
PET data acquisition began after the desired plasma glucose level was reached. First, 
approximately 25 mCi of [15O]-H2O was injected for the measurement of blood flow. Cerebral 
oxygen metabolism and blood volume were assessed with the inhalation of 25 mCi of [15O]-O2 
or [15O]-CO respectively. Repeat scans were obtained for all three tracers if possible. All the 
[15O] tracers imaging data was acquired using a dynamic acquisition that started prior to tracer 
administration. [15O]-H2O and [15O]-O2 scans lasted for five minutes, whereas the [15O]-CO scan 
went for seven minutes. Following the [15O] scans, 5 mCi of [18F]-FDG was injected, and 
cerebral glucose metabolism was measured using a 60 minute dynamic PET scan. For 
attenuation correction, a Siemens Biograph 40 PET/CT was used to acquire a CT image of the 
head (120 keV, 25 effective mAs, voxel size = 0.59 x 0.59 x 3.0 mm, acquisition matrix = 512 x 
512 x 74 mm voxels). From the CT image, µ-maps were created by converting the CT 
Hounsfield values into attenuation coefficients30,31. 
Concurrent with the [15O]-H2O PET scans, quantitative cerebral blood flow (CBF) was 
measured using pseudo-continuous arterial spin labeling (pCASL). 2D pCASL acquisition 
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included 80 images, each with 20 slices, voxel size 3.4 x 3.4 x 5.0 mm, and a 64 x 64 mm in 
plane acquisition matrix. The TR was 4.0 seconds, the TE 12.0 milliseconds, and an acceleration 
factor of 2.0 was applied. Two separate pCASL runs were acquired during each study visit. A 
gradient echo field map was also acquired in a subset of subjects (16/24) to allow for the 
correction for EPI distortions (TR = 646.0 ms. TE 1 = 5.19 ms, TE 2 = 7.65 ms, slices = 45, 
voxel size = 1.7 x 1.7 x 3.0, acquisition matrix = 212 x 212 mm. A sagittal high resolution T1-
weighted MPRAGE was also obtained (TR = 2400 ms, TE = 2.13 ms, FOV = 256 x 256 x 176 




FreeSurfer 5.332 was used to segment the T1-weighted structural image from each 
subject’s first study visit into 48 non-overlapping and bilaterally symmetric cortical regions 
(Figure 2.1). Cortical gray matter was parcellated into 34 gray-based regions of interest (ROIs), 
according to the Desikan atlas33. The remaining gray matter ROIs comprised seven subcortical 
gray matter regions (amygdala, caudate, hippocampus, nucleus accumbens, pallidum, putamen, 
and thalamus), and the cerebellum34. White matter was divided into cerebellar white, cortical 
white matter, the corpus callosum, and deep white matter. The cortical white matter region was 
created by combining all of the superficial white matter regions that are part of FreeSurfer’s 
standard output. Finally, separate ROIs were created for the brain stem and ventral diencephalon. 
Each subject’s T1-weighted image was also nonlinearly aligned to MNI152 atlas space using a 
combination of FLIRT35 and FNIRT in FSL36. To increase SNR, atlas registration was performed 





Preprocessing of the pCASL data began with correction for odd-even slice intensity 
artifacts37. For each ASL run, non-labeled frames were used to compute separate scaling factors 
for odd and even slices. These scaling factors where then applied to both the control and labeled 
frames to remove any systematic odd-even slice intensity artifacts. Images were then motion 
corrected using FSL’s mclirt tool with the temporal mean image as the target38. Following the 
recommendation of Wang et al., motion correction was performed separately for label and 
control frames39. After motion correction, FSL’s flirt was used to compute a rigid body 
transformation between the average label and average control images. A rigid body 
transformation was then computed between the realigned pCASL timeseries and each’s subject’s 
average T1-weighted image using FSL’s flirt. For subjects where field maps were acquired, the 
field map magnitude image was used as an intermediary between the pCASL and T1 images. All 
transformations were then combined, and the pCASL time series was resampled to MNI152 
2mm atlas space in a single step. 
Once in atlas space, a high pass (0.08 Hz) temporal filter was applied to the pCASL data. 
Sinc subtraction was then used to create perfusion weighted images40. The perfusion weighted 








 [mL/hg/min]   (5.1) 
Where	F is the labeling efficiency (0.85), G is the blood/brain partition coefficient for water 
(0.9), HIJKLMNKO and HIOPQ7O are the control and label image intensities,	HIRS is the intensity from a 
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proton-density image, TUV is the post labeling delay (1.5 sec), W is the labeling duration (1.517 
sec), and XB,QOKKY is the longitudinal relaxation rate of blood (1.65 sec). The values for F, G, and 
XB,QOKKY were set according to the recommendations of Alsop et al.42. HIRS was approximated by 
taking the average of the control images43. When computing the mean CBF for a single pCASL 
run, a weighting scheme was applied to down weight frames where subject motion produced 
large global shifts in image intensity43. The mean difference in global noise between control and 
label images (-43.77 ± 107.80) between hyperglycemic (290.19 ± 88.80) and euglycemic (333.96 
± 80.97) runs was not significantly different from zero (p = 0.434). The median CBF was 
calculated over the whole-brain as well within each of the 48 FreeSurfer ROIs. 
PET Preprocessing 
All PET reconstruction was performed using the ordered-subset expectation 
maximization (OSEM) algorithm44 implemented in Siemens e7tools. Our PET reconstruction 
strategy consisted of two stages. In the first stage, the listmode data was scatter corrected and 
reconstructed without attenuation correction. All of the [15O] PET data was reconstructed into 30 
second frames. The [18F]-FDG reconstruction consisted of ten 30 second frames followed by 55 
60 second frames. Attenuation correction was not done at this stage because motion between 
frames precluded the use of a single µ-map for all frames. 
To correct for between-frame motion, we used a modified version of a previously 
published strategy45. Briefly, within each tracer each frame was registered to every other frame. 
From this set of pairwise registrations, a linear system was created from which it was possible to 
compute the least squares transformation between any two frames. These transformations were 
used to align the previously computed µ-map with the time-resolved PET sinograms. The 
aligned µ-maps were used in the second stage of reconstruction to create time-sliced PET images 
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with attenuation, decay, and scatter correction. The use of motion and attenuated correction in 
the second stage allowed us to use shorter time bins for PET reconstruction. The final [15O]-H2O 
and [15O]-O2 images were reconstructed into 40 three second frames followed by 18 ten second 
frames. The [15O]-CO data was reconstructed into 40 three second frames and then 30 ten second 
frames. Finally, the [18F]-FDG scan was separated into 12 ten second frames, six 30 second 
frames, and 55 60 second frames.  
After reconstruction, the motion corrected time series for each tracer was summed across 
time to create a single 3D PET image. Within individual participants, the sum images for each 
tracer were aligned to each other using rigid body registration46. After alignment, the sum images 
were averaged to create a mean image for each tracer. The mean [18F]-FDG image was then 
brought into alignment with the T1-weighted image using rigid body registration and a vector 
gradient algorithm47. The final linear transformation within computed by minimizing the error 
between the forward ([18F]-FDG -> T1) and backward (T1 -> [18F]-FDG) transformations45. The 
same procedure was used to align the [15O] sum images to the [18F]-FDG sum image. The 
computed transformations were combined and used to resample each PET time series into 
MNI152 2mm atlas space. 
Relative PET 
Standardized uptake values ratios (SUVRs) were computed for each tracer. SUVR is a 
semi-quantitative measure where the tracer uptake at each brain region is reported relative to a 
reference region. SUVR is useful in examining changes in the topography of brain metabolism, 
but not absolute changes. When computing an SUVR one must select both a reference region and 
the time window over which to sum the tracer counts. The whole-brain (excluding the lateral 
ventricles) was used a reference region for all SUVR analyses. Specific time windows were 
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selected for each tracer. For [18F]-FDG, a time window from 40 to 60 minutes post injection was 
chosen. A sixty second window, starting approximately after the bolus reached the brain, was 
used for the [15O]-H2O and [15O]-O2 data. A one minute window starting 180 seconds after the 
bolus reached the brain was used for the [15O]-CO scans. All SUVR images were computed in 
native space and then resampled to MNI152 2mm space. To minimize the impact of vascular 
artifact on our SUVR measurements of oxygen metabolism, a voxelwise spatial regression was 
run using the resampled [15O]-O2 SUVR as a dependent variable and [15O]-H2O and [15O]-CO 
SUVR as independent variables48. The [15O]-O2 SUVR was adjusted by subtracting from it the 
product of the [15O]-CO SUVR and its regression coefficient. An SUVR approximation of OEF 
(rOEF) was calculated by dividing the adjusted [15O]-O2 SUVR by the product of the [15O]-H2O 
SUVR and its regression coefficient. Finally, a SUVR estimate of the relative oxygen-to-glucose 
index (rOGI) was computed by dividing the [15O]-O2 SUVR by the [18F]-FDG SUVR. Prior to 
any statistical comparisons, all atlas space SUVR images are were normalized to a whole-brain 
mean of 1.0 and smoothed with a 5 mm FWHM gaussian kernel. 
Quantitative PET 
We were able to obtain quantitative estimates of CMRglc in a subset of participants in 
whom hand drawn arterial samples were acquired during the [18F]-FDG scan. Given the greater 
noise at the voxel level, we chose to limit our quantitative analysis to ROIs. All ROIs were 
resampled to the space of the [18F]-FDG data. A reversible two-compartment model was fit to the 
dynamic [18F]-FDG from each ROI6. The first compartment is thought to represent free [18F]-
FDG in the brain, while the second is [18F]-FDG that has been metabolized to [18F]-FDG-6-
phosophate. The model includes four rates constants (K1, k2, k3, and k4) and an additional term, 
Vb, that accounts for arterial blood volume. K1 and k3 describe influx from the blood and first 
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compartment, respectively. Loss of tracer from the first compartment is described by k2, and 
efflux from the second compartment to the first is designated by k4. Prior to model fitting, the 
time delay between the arterial samples and the [18F]-FDG data was accounted for by fitting a 
one-compartment model to the first sixty seconds (post bolus arrival) of the [18F]-FDG data49. 
This one-compartment model included a shift term that accounted for the temporal delay. The 
whole-brain time activity curve was used to determine the shift, which was then applied to all 
regional fits. Model fitting was performed using non-weighted nonlinear least squares using the 
limited-memory BFGS algorithm50 implemented in Numerical Python51. Following the 
recommendation of Wu et al52, a lumped constant of 0.81 was used to calculate CMRglc. 
Statistics 
All statistical analyses were done using the R53 programming language. A linear mixed 
model with a fixed effect for clamp condition and a random intercept for subject was used to 
determine if differences in brain metabolism between conditions were statistically significant. No 
other covariates were added to the model. The voxelwise mixed models were fit using the nlme 
package54, whereas the ROI models used lme455. For the lme4 models, p-values were calculated 
using the lmerTest package56, which implements Satterthwaite’s method for determining the 
degrees of freedom in a mixed model. The difference between conditions was considered 
significant when the p-value was less than 0.05. Multiple comparison across space were 
accounted for by controlling the False Discovery Rate (FDR) at 0.0557. No multiple comparisons 
adjustment was made for the multiple modalities that were considered. 
The lme4 package was used to perform a piecewise linear regression on the plasma 
glucose and insulin data that was obtained during the glucose clamps. The fixed effects included 
time, clamp condition, and the interaction between time and condition. There were two 
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regressors, one for each condition, that allowed for the slope of the regression line to vary after a 
breakpoint. The breakpoint was fixed at 90 minutes. We also included a random intercept for 
study visit nested within subject. Slopes that were different from 0.0 at the p < 0.05 level (no 
correction for multiple comparisons) were considered significant. Spearman correlation was used 
to quantify the degree of spatial correspondence between baseline metabolism and the change 
induced by hyperglycemia. All reported values are means and 95% confidence intervals (Cis) 
unless otherwise stated. 
5.4 Results 
 
Blood glucose and insulin levels 
The time-courses for plasma glucose and insulin during the glucose clamps are shown in 
Figure 5.1. All measurements excluding the initial baseline measurements were taken after the 
target plasma glucose level had been reached. There was no significant difference found between 
conditions (euglycemia, hyperglycemia) in baseline plasma glucose (97.7 ± 3.5 mg·dL-1; p=0.61) 
or insulin (42.6 ± 11.0 pmol·L-1; p=0.95). The target plasma glucose levels were achieved in 
both conditions, with the blood glucose level reaching 300 mg·dL-1 in the hyperglycemic clamp 
and remaining near 100 mg·dL-1 in the euglycemic clamp (Figure 5.1A). 
However, in both conditions plasma glucose rose slightly above the target concentration 
during the beginning of the glucose clamp and then slow decreased throughout the study period 
(Figure 5.1A). The time-course for plasma insulin during the euglycemic clamp exhibited a 
similar behavior (Figure 5.1B). To quantify this impression, we performed a piecewise linear 
regression where the slope of the regression line was allowed to differ after 90 minutes into the 
glucose clamp (see Methods). Table 5.2 reports the slope for each segment. For the first 90 
minutes, plasma glucose and insulin increased significantly with time in both conditions (p < 
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0.05). However after 90 minutes, plasma glucose decreased with time during both clamps (p < 
0.01) and plasma insulin decreased in the euglycemic condition (p < 0.0001). Plasma insulin 
continued to increase with time after 90 minutes during the hyperglycemic clamp (p < 0.0001). 
Importantly, insulin levels never approached values typically seen after a carbohydrate meal 
(Figure 5.1B). 
Changes in the topography of brain metabolism 
To assess regional changes in brain metabolism, whole brain normalized SUVR images 
were computed from the [18F]-FDG, [15O]-H2O, [15O]-O2, and [15O]-CO data (see Methods). The 
group average image of glucose consumption during hyperglycemia (Figure 5.2A) had much less 
contrast than the average image during euglycemia (Figure 5.2B). After correcting for multiple 
comparisons (FDR 0.05), significant differences between the two conditions were found 
throughout the brain (Figure 5.2C). Glucose consumption generally decreased relative to the rest 
of the brain in gray matter and increased in white matter. There were, however, exceptions. 
Relative glucose consumption increased in the gray matter of the medial temporal lobe and the 
cerebellum (Figure 5.2C). Despite the changes in the topography of glucose consumption, 
hyperglycemia did not alter the topography of blood flow (Figure 5.3), oxygen consumption 
(Figure 5.4), oxygen extraction (Figure 5.5), or blood volume (Figure 5.6). As the topography of 
oxygen consumption was unaffected by hyperglycemia (Figure 5.4), changes in the ratio of 
relative oxygen-to-glucose metabolism (rOGI) were essentially opposite to those found for 
glucose metabolism (Figure 5.7). rOGI significantly increased in gray matter, with the exception 




To eliminate the possibility that the limited SNR at the voxelwise level prevented us from 
detecting changes in the topography of brain metabolism, we performed a ROI analysis on the 
regional PET data (Figure 5.8). Two ROIs were created. The first ROI contained voxels where 
relative glucose consumption increased, and the second voxels were the relative glucose 
consumption decreased (Figure 5.8A). The values within these two ROIs for each metabolic 
parameter are shown in Figure 5.8B-G. A significant (p < 0.0001) change with hyperglycemia 
was found in both ROIs for glucose consumption (Figure 5.8B) and rOGI (Figure 5.8G). No 
significant differences were found in either ROI for blood flow (Figure 5.8C), oxygen 
consumption (Figure 5.8D), rOEF (Figure 5.8E), or blood volume (Figure 5.8F). 
Quantitative changes in brain metabolism 
The analyses in Figures 1-7 show that the topographies of glucose consumption and rOGI 
are altered by hyperglycemia, whereas the topographies of cerebral blood flow, oxygen 
consumption, oxygen consumption, and blood volume are unchanged. To explore the 
quantitative basis of these changes, we obtained quantitative estimates of cerebral glucose 
consumption and blood flow (see Methods). We first examined quantitative changes for the brain 
as a whole as well as within the same two ROIs as Figure 5.8 (Figure 5.9). Although the whole-
brain CMRglc at hyperglycemia (27.3 ± 2.0 μMol·hg-1·min-1) was slightly higher than at 
euglycemia (25.1 ± 2.1 μMol·hg-1·min-1), the difference (2.18 ± 2.84 μMol·hg-1·min-1) was not 
significant (p = 0.151; Figure 5.9A). We did, however, find significant decreases in the two 
forward rate constants K1 and k3, and a significant increase in the backward rate constant k4 (p < 
0.01; Table 5.3). CMRglc within the ROI where relative glucose consumption decreased did not 
change (p = 0.207; Figure 5.9B). However, CMRglc was significantly higher at hyperglycemia 
(23.7 ± 2.3 μMol·hg-1·min-1) than at euglycemia (18.2 ± 2.5 μMol·hg-1·min-1) within the ROI 
where relative glucose consumption increased (p = 0.006; Figure 5.9B). Hyperglycemia did not 
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significantly (p > 0.5) alter CBF in either the whole-brain (Figure 5.9C) or in either ROI (Figure 
5.9D). 
To examine quantitative metabolic change at a finer spatial scale, we calculated CMRglc 
and CBF (see Methods) within 48 ROIs defined using FreeSurfer (Figure 2.1). Figure 5.10A 
shows the estimated change in CMRglc induced by hyperglycemia for each ROI. The only 
regions that were significant at the FDR 0.05 level were the brain stem, cortical white matter, 
corpus callosum, and deep white matter. The largest change was found in the deep white matter 
(9.65 ± 2.09 μMol·hg-1·min-1; Figure 5.10B), where hyperglycemia increased CMRglc from 15.1 
± 1.7 to 24.8 ± 1.6 μMol·hg-1·min-1 (p < 0.0001). The large increase in deep white matter was 
part of the strong negative spatial correlation (Z = -0.91) between baseline CMRglc and change 
in CMRglc during hyperglycemia (Figure 5.10C). Compared to CMRglc, the regional changes in 
CBF were smaller and less consistent (Figure 5.11). The difference in CBF between 
hyperglycemia and euglycemia was not significant for any region (Figure 5.11A). This was true 
even for regions, like the deep white matter (p = 0.667; Figure 5.11B), where CMRglc increased. 
Furthermore, the spatial correlation between baseline CBF and change in CBF (Z = -0.53) was 




Several previous studies have examined the effect of acute hyperglycemia on regional 
cerebral glucose metabolism in humans8-11,15,16. Our study is the first, however, to examine 
changes in glucose metabolism along with both regional changes in both blood flow and oxygen 
metabolism. Measuring all three aspects of metabolism allowed us to obtain several new 
findings. First, we found that although acute hyperglycemia changes the topography of glucose 
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metabolism, it does not significantly alter the topography of blood flow or oxygen consumption. 
Second, because the topography of oxygen consumption was unchanged, the topography of 
relative oxygen-to-glucose consumption (rOGI) was altered inversely to glucose consumption. 
rOGI was therefore significantly increased in gray matter and decreased in white matter. 
Exceptions to this pattern were gray matter in the cerebellum and the medial temporal lobe, 
where rOGI decreased, although not as robustly as glucose consumption decreased. Third, we 
were able to show that although quantitative CMRglc was significantly increased in the brain 
stem, corpus callosum, cortical white matter, and deep white matter, no quantitative changes in 
CBF were found in these, or any other, regions. 
Glucose consumption 
As previously mentioned, multiple studies have shown that acute hyperglycemia 
decreases glucose consumption in most of gray matter relative to the rest of the brain7-11,58. We 
have largely replicate these findings, with two exceptions. First, contrary to the original report by 
Kawasaki et al.7, glucose metabolism in the gray matter of the cerebellum and medial temporal 
increased relative to the rest of the brain. Second, we found additional relative increases 
throughout white matter. Although Kawasaki et al. did report some increases, they were either 
very focal or found only when gray matter was used as a reference region. Methodological 
differences are perhaps the most likely reason for the differences between our results and those 
reported elsewhere in the literature. The original study by Kawasaki et al7, as well as its 
subsequent replications8-11, made subjects mildly hyperglycemic using oral glucose consumption. 
This paradigm was much different from ours in several ways. First, our participants were much 
more hyperglycemic (~300 mg·dL-1 ) than the participants in the Kawasaki et al. study (~135 
mg·dL-1 ). Second, the hyperglycemic clamp technique we used produces a relatively constant 
hyperglycemia. The glucose load applied by Kawasaki et al. most likely resulted in a decline in 
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blood glucose level during the experiment. Finally, we prevented a large rise in blood insulin 
levels during hyperglycemia by suppressing endogenous insulin secretion with octreotide. 
Insulin was then infused to keep blood concentrations within a normal range. Insulin was not 
controlled in the Kawasaki et al. study. Although the effect of insulin of cerebral metabolism is 
still a matter of active research59, it has been reported that hyperinsulinemia can alter the regional 
pattern of cerebral glucose consumption60. 
We were able to use quantitative PET to verify the changes in relative glucose 
metabolism. Consistent with studies in humans10,14,16 and rats17, we found that hyperglycemia 
induced a small, but not significant, increase in whole-brain CMRglc. This is also generally in 
agreement with Blomqvist et al., who reported a significant 20% increase in global CMRglc 
during acute hyperglycemia15. In contrast, Rowe et al. found that although whole-brain CMRglc 
was insignificantly elevated from fasting levels 15 minutes after the consumption of a meal, it 
actually was significantly less than fasting values 30 minutes later13. Whether postprandial 
increases in blood glucose cause fluctuations in global CMRglc requirements confirmation. 
Taken as a whole, however, the literature suggests that global CMRglc increases slightly during 
hyperglycemia. 
Regionally, we found that CMRglc was significantly elevated in the brain stem, corpus 
callosum, cortical white matter, and the deep white matter. This is consistent with two prior 
studies that have reported that CMRglc increases by approximately 40-50% in white matter 
during acute hyperglycemia15,16. CMRglc did not significantly decrease in any region, even in a 
large region encompassing all voxels were relative glucose consumption was found to decrease. 
Finally, we replicated work in humans15 and rats19 showing that the change in CMRglc induced 
by hyperglycemia is inversely correlated with baseline metabolic rates. Taken together, our 
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quantitative results suggest that decreases in gray matter FDG uptake (relative to the rest of the 
brain) during hyperglycemia do not truly reflect a decrease in metabolic rate. Rather, the 
metabolic rate in these regions simply changes less than other regions, which then could be 
interpreted as a decrease after whole-brain normalization. This is what was found by Ishibashi et 
al., who reported significant declines in whole-brain normalized CMRglc during hyperglycemia 
even though the absolute rate in these regions was increased by a small, nonsignificant amount10. 
It is possible that the metabolic rate is really declining in gray matter during hyperglycemia, but 
by such a small amount that we, and others10,16, have failed to detect it. This possibility seem less 
likely considering another study reported significant increases in CMRglc throughout all of gray 
matter15. 
Blood flow and oxygen consumption 
Regional increases in CMRglc during acute hyperglycemia are somewhat surprising. At 
euglycemia the influx of glucose into the brain exceeds its basal CMRglc3, so one would not 
necessarily predict that raising the blood glucose concentration would increase glucose 
consumption. Combining our regional glucose consumption data with our PET measurements 
blood flow and oxygen consumption is helpful in understanding this surprising finding. In 
contrast to the changes in the topography of glucose metabolism, no changes were found in the 
topography of either blood flow or oxygen consumption. To confirm that this was not due to 
limited SNR at the voxel level, we made ROIs representing the brain regions where relative 
glucose metabolism was altered. Relative oxygen consumption and blood flow were unchanged 
within these ROIs as well. Consistent with the lack of changes in oxygen consumption and blood 
flow, relative blood volume and oxygen extraction were also unaffected by hyperglycemia. 
Finally, we measured quantitative CBF using pCASL MRI. In agreement with the relative blood 
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flow data, we found that, despite increases in CMRglc, hyperglycemia did not significantly alter 
blood flow in any region. 
Although we are not aware of any studies measuring regional oxygen consumption 
during hyperglycemia, multiple studies have investigated regional blood flow. Studies in animal 
models have consistently found that hyperglycemia decreases CBF throughout the entire 
brain18,20. Reports in humans, however, are somewhat mixed. Ishibashi et al found that, relative 
to the rest of the brain, blood flow was reduced by approximately 2% in the frontal cortex, lateral 
parietal cortex, and precuneus/posterior cingulate8 during mild hyperglycemia. A different set of 
regions was reported by Page et al., who found that mild hyperglycemia decreases CBF in the 
anterior cingulate, hypothalamus, insula, striatum, and thalamus23. It is not clear why our results 
are not in agreement with those of Ishibashi et al. or Page et al. Like Kawasaki et al., both studies 
used an oral glucose load to induce mild hyperglycemia, so the previously mentioned caveats 
with this approach apply. Ishibashi et al. also only measured relative blood flow in four small, a 
priori ROIs. It is possible that any changes in blood flow were either too small for our limited 
SNR voxelwise analysis or too focal for our large ROIs. However, these possibilities are not 
consistent with the fact that that we failed to observe any changes in quantitative CBF using both 
smaller ROIs and a larger sample size. Finally, although our results are not consistent with those 
of Page et al. and Ishibashi et al., they are in agreement with studies reporting no global change 
in CBF during hyperglycemia13,14,16,22. 
Non-oxidative glucose consumption 
Because the spatial pattern of oxygen consumption was unaltered by hyperglycemia, 
rOGI changed inversely to glucose consumption. Relative to the whole-brain average, rOGI 
increased in gray matter and decreased in white matter. Exceptions to this pattern were gray 
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matter in the medial temporal lobe and cerebellum, where rOGI decreased. Overall the changes 
in rOGI indicate that hyperglycemia produces relative decreases in non-oxidiative glucose 
consumption (NOglc) in gray matter regions and relative increases in white matter regions. It 
should also be mentioned that hyperglycemia essentially eliminated the regional difference in 
rOGI between gray and white matter (Figure 5.7A-B, Figure 5.8G). 
As we did not measure quantitative oxygen consumption, we could not verify the changes 
we observed in rOGI with quantitative data. To the best of our knowledge, there have been no 
other studies examining regional changes in non-oxidative glucose during acute hyperglycemia. 
Blomquist et al. argued that the increases in CMRglc during acute hyperglycemia were due to 
increased oxidative glucose metabolism, although this was not based on measurements of 
oxygen metabolism15. Instead, it relied on a prior validation study performed in euglycemic 
participants61. This validation study showed that, compared to arterio-venous measurements, 
whole-brain CMRglc measured with their [1-11C]-glucose PET method was closer to 1/6th of 
CMRO2 than it was to CMRglc61. If true, this would imply their method measures oxidative 
glucose metabolism, not total glucose consumption. Only a small number of subjects were used 
in that verification study, however, and no statistical comparison between the two methods were 
performed. Furthermore, the method used by Blomqvist et al. relied on correction factors 
obtained at euglycemia15,61. Therefore, there is reason to question whether Blomqvist et al. were 
able to distinguish between oxidative vs. non-oxidative glucose metabolism during 
hyperglycemia. 
Studies measuring global changes in CMRO2 during hyperglycemia have reported that it 
is either unaltered during acute hyperglycemia13,14, or decreased22. If, as we found, there are no 
regional effects of hyperglycemia on oxygen metabolism, then these studies would suggest that 
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oxygen consumption is either unaffected or modestly decreased by hyperglycemia in all brain 
regions. This, in turn, would imply that the increased CMRglc, as well as the decrease in rOGI, 
within the white matter and brain stem reflect quantitative increases in non-oxidative, not 
oxidative, glucose consumption. It is less clear how to interpret the increases in rOGI we found 
within gray matter. It is likely that such increases simply reflect the relative decreases in glucose 
consumption we found in these same regions. As discussed previously, it is unlikely that 
CMRglc actually declines in gray matter, and therefore unlikely that NOglc decreases. 
Consistent with this idea, Gottstein et al. found that the whole-brain NOglc was slightly elevated, 
albeit not significantly, by acute hyperglycemia14. 
If NOglc is increased in white matter and brain stem during hyperglycemia, it is unclear 
how the additional glucose is being consumed. At normal blood glucose levels, the majority of 
glucose in white matter is consumed oxidatively to provide energy for non-signaling tasks (e.g., 
maintaining the resting membrane potential)62. There are, however, non-oxidative pathways for 
glucose consumption in the brain63,64. Among these pathways are glycogen synthesis, the 
glycolytic pathway, the pentose phosphate shunt, and the polyol pathway. The TCA cycle also 
produces intermediates that are used for the synthesis of amino acid and neurotransmitters, 
including acetylcholine, aspartate, GABA, and glutamate64. Interestingly, alterations in some of 
these pathways have been linked to hyperglycemia. 
Both acute and chronic hyperglycemia have been shown to upregulate pentose phosphate 
activity in cultured astrocytes65, although to our knowledge this has not been replicated in vivo. 
A recent study found that acute hyperglycemia increased the production of lactate, an end-point 
of the glycolytic pathway, in the hippocampus of a mouse model of Alzheimer’s disease66. If 
lactate production is increased during hyperglycemia, it is unclear how it is removed from the 
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brain. Two studies in humans reported that lactate efflux from the brain to the blood was not 
significantly increased by hyperglycemia13,14. The glymphatic system has been proposed as an 
alternative route for lactate efflux67,68, but there is no evidence suggesting that hyperglycemia 
increases lactate efflux through the glymphatic system. It is possible that hyperglycemia 
produces excess lactate which is then subsequently used as a fuel source. Recent work has 
indicated that lactate can play a prominent role in white matter metabolism69. In developing 
mice, lactate is taken up by oligodendrocytes and can be used to support myelination when 
glucose levels are low70. Conversely, in adult mice lactate is exported from oligodendrocytes into 
axons, where it is presumably used to produce ATP via oxidative phosphorylation71,72. A transfer 
of excess lactate between cell types does not, however, explain our results, which suggest that 
hyperglycemia causes an increase in white matter glucose consumption without a detectable 
increase in oxygen consumption. 
Another possible explanation for increased NOglc in white matter and brain stem during 
hyperglycemia is an increase in the production of sorbitol and fructose through the polyol 
pathway. Although it plays a very minor role in the brain at normal blood glucose levels73, polyol 
pathway activity has been shown to increase in animal models during both acute74 and chronic 
hyperglycemia75. It is also interesting to note that activation of the polyol pathway is a well-
known features of diabetes mellitus76, a disease defined by chronic hyperglycemia. Increased 
polyol activity in diabetes results in oxidative stress77, and contributes to the development of 
several complications including cardiovascular disease, retinopathy, neuropathy, and 
cataracts76,78. There is however, no direct evidence linking hyperglycemia with increased polyol 
activity in white matter or the brain stem. Perhaps the best evidence is the work of Hwang et al., 
who used magnetic resonance (MR) spectroscopy to show that acute hyperglycemia increases the 
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fructose concentration of the human brain by about 0.5 mMol·L-179. However, their 
measurements, which were performed in a large voxel (30 x 20 x 30 mm3) in the occipital lobe, 
likely contained a combination of gray matter, white matter, and CSF. Clearly, although the 
literature suggests several possibilities, there is not yet sufficient evidence to explain how white 
matter consumes additional glucose during hyperglycemia. To resolve this issue, future studies 
will have to employ techniques, such as MR spectroscopy, that can track glucose consumption 
down metabolic pathways within specific brain regions. 
Our results have implications for human health and disease. Previous studies from our 
research group have established that non-oxidative glucose use plays a role in aging and 
Alzheimer’s disease (AD)80. Studies in humans have shown that NOglc varies between gray 
matter regions48,81, and that the regions that have the most NOglc in youth are the same regions 
that develop the greatest amyloid plaque loads in AD82. Studies in mouse models of AD have 
also shown that regional lactate production correlates with levels of amyloid plaques83. We also 
reported recently that non-oxidative glucose use decreases substantially with aging, with the 
largest decreases occurring in regions which, in young adults, have the most rates of NOglc26. 
Finally, regional deposition of phosphorylated tau has been shown to be inversely correlated with 
NOglc in individuals with high levels of amyloid plaques84. Considered as a whole, these 
findings suggest that, although NOglc may play an important role in development, plasticity, and 
learning25,85, over the course of a lifetime high levels of NOglc may increase the risk of 
neurodegeneration and disease. It is therefore tempting to hypothesize that elevated non-
oxidative glucose use in white matter may play a role in the development of the white matter 
disease that is often found in individuals with Type-2 diabetes mellitus (T2DM)86, or even that 
NOglc is part of the connection between T2DM and AD59,87. In support of the latter idea, it has 
198 
 
been shown that acute hyperglycemia increases both lactate and amyloid production in a mouse 
model of AD66. Determining whether NOglc is elevated in the brains of individuals with chronic 
hyperglycemia is an important question for future studies. 
Limitations 
A few limitations should be considered when interpreting our results. First, although we 
did show that CMRglc quantitatively increases in both the brain stem and white matter during 
hyperglycemia, we did not have any quantitative measurement of oxygen consumption. 
Quantification of CMRO2 traditionally requires invasive automatic arterial sampling, which our 
facility only recently acquired the ability to do in a PET/MR environment. Instead we reported 
that, relative to the whole-brain average, there were no changes in [15O]-O2 SUVR in any brain 
region. Although SUVRs are not quantitative measurements, they are a commonly used 
technique because they do not require arterial sampling and because normalization by a reference 
region is useful in removing global intensity artifacts88. Despite the absence of quantitative 
CMRO2 data, we believe that our data is most consist with an increase in NOglc within white 
matter and brain stem. As discussed previously, the increase in CMRglc, the absence of a relative 
decrease in oxygen consumption, the decrease in rOGI, and the fact that previous studies have 
failed to report an increase in global CMRO213,14,22, all point to an increase in non-oxidative 
glucose use within white matter and brain stem during hyperglycemia. We do acknowledge, 
however, that relative PET techniques can be misleading89. Indeed, we have argued here that 
decreases in gray matter [18F]-FDG uptake during hyperglycemia7 likely do not reflect decreases 
in CMRglc. Our laboratory is therefore currently performing experiments necessary to quantify 
CMRO2 and NOglc during hyperglycemia. 
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All of our measurements of CMRglc relied on [18F]-FDG, which requires a correction 
factor to account for the differences in transport and phosphorylation kinetics between FDG and 
glucose90. We chose to use the same value for this correction factor, referred to as the lumped 
constant (LC), in both the euglycemic and hyperglycemic conditions. Direct measures of the LC 
in rats have shown that it decreases very slightly during hyperglycemia91. As lower values for the 
lumped constant result in larger CMRglc, this would imply that our estimates of CMRglc, and 
therefore AG, are underestimated during hyperglycemia. To address this possibility, we followed 
the strategy of van Golen et al., and adjusted the LC using data expressing the LC as a function 
of blood glucose level in rats92. This amounted to decreasing the LC by approximately 6% in 
hyperglycemic individuals. Adjusting the LC had essentially no impact on our regional data. We 
did not identify any new regions with significantly altered CMRglc, and CMRglc remained 
significant in all the regions where it was so without LC adjustment. The only difference that 
adjusting the LC introduced in our results was that the increase in global mean CMRglc, which 
was not significant before the adjustment (p = 0.151), became significant afterwards (p = 0.018). 
The difference was quantitatively minor, however, as the increase in whole-brain CMRglc with 
hyperglycemia changed from to 2.18 ± 2.84 to 3.98 ± 2.97 μMol·hg-1·min-1. Given the small 
change in the LC during hyperglycemia, and the minimal impact it had our results, we chose to 
use a fixed LC for all of our analyses. 
Studies in humans have reported that the LC decreases to a greater extent than what we 
assumed above10,16. As lowering the LC increases the apparent CMRglc, it is possible that, if we 
had assumed a smaller value for the LC during hyperglycemia, we would have found increased 
CMRglc in a greater number of regions. In support of this possibility, a study using [1-11C]-
glucose PET15, which does not require a LC, reported increased CMRglc in all brain regions 
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during hyperglycemia. There is, however, reason to be skeptical of a larger decrease in the LC 
during hyperglycemia. The two studies reporting changes in the LC in hyperglycemic humans 
did not measure the LC directly10,16. Measuring the LC typically requires estimates of the 
metabolic rate of glucose and FDG in the same individuals93,94. Instead these studies used only 
[18F]-FDG data along with a mathematical model95 that assumes: 1) the ratio of the K1 for 
glucose to the K1 for FDG is known and unchanged by hyperglycemia, 2) the ratio of K3 between 
glucose and FDG is similarly known and unaffected by hyperglycemia, and 3) all the glucose-6-
phosophate that is created is metabolized. Although the K1 ratio is unaffected by 
hyperglycemia96, we are not aware of any study verifying the stability of the k3 ratio. We are also 
not aware of any study comparing directly LC values estimated with this model with direct 
measurements in humans. Hasselbalch et al. did attempt to validate the model based approach93. 
However, their verification was circular as the measured LC was used to compute the k3 ratio 
that was subsequently entered into the model. It should be noted, too, that even the studies that 
used the model-based method to correct for changes in the LC produced CMRglc results that 
were in agreement with ours. They found that during acute hyperglycemia: 1) whole-brain 
CMRglc increased by a non-significant amount10,16, 2) gray matter CMRglc was unchanged in 
every region examined10,16, and 3) CMRglc within white matter significantly increased by over 
40%16. 
Finally, it should be acknowledged that all of our metabolic measurements were made in 
an experimental setting. Endogenous insulin and glucagon secretion were blocked using 
infusions of the somatostatin analog octreotide. Although somatostatin has several roles in the 
CNS97, blood-brain barrier permeability for somatostatin analogs are low98, and we know of no 
studies reporting changes in CBF, CMRO2, or CMRglc after octreotide administration. Infusions 
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of glucagon and insulin were also used to were used to keep both hormones at normal values. 
This was done to isolate the effect of hyperglycemia on brain metabolism. However, 
hyperglycemia typically sharply increases the concentration of insulin in the blood. Although 
plasma insulin did rise slightly during our hyperglycemic clamp, it always remained lower than 
what is seen during an oral glucose tolerance test99 or after the consumption of a meal100. As a 
result, our results do not mirror naturally occurring hyperglycemia. It is therefore encouraging 
that our results are broadly consistent with studies that do not perform basal insulin 
replacement7,10,15. Determining what, if any, differences there are in brain metabolism between 
hyperglycemia with and without elevated insulin will require direct studies. 
Conclusion 
Our work is a novel addition to studies examining the effect of acute hyperglycemia on 
the brain. We reported that in humans, acute hyperglycemia increases CMRglc in white matter 
and brain stem, without altering regional blood flow, blood volume, or oxygen metabolism. This 
suggests that acute hyperglycemia alters normal brain metabolism by increasing NOglc in white 
matter and brain stem. Expanding upon this finding is an important topic for future research. 
Among the most pressing questions are quantifying the increase in NOglc during acute 
hyperglycemia, identifying the metabolic pathways responsible for elevated non-oxidative 
glucose use, and determining if NOglc remains high in individuals with chronic hyperglycemia. 
Addressing these questions will not only further our understanding of brain metabolism during 





A) After the hyperglycemic clamp (red) the plasma glucose level was approximately 300 mg·dL-
1
,
 whereas it remained near 100 mg·dL-1 during the euglycemic clamp (blue). A piecewise linear 
regression with a breakpoint at 90 minutes (black dot) was used to compute population estimates 
(thick lines) and their 95% CIs (gray ribbons). In both groups, blood glucose level increased 
prior to the breakpoint and then decreased afterwards (see Results). B) Plasma insulin also 
increased in both groups prior to the breakpoint. However, after the breakpoint insulin decreased 
during euglycemic clamp and increased in the hyperglycemic clamp. The dashed black line 
indicates a published value for the peak plasma insulin concentration after a 75 gram oral 
glucose tolerance test99. Note that even though plasma insulin increased throughout the 
hyperglycemic clamp, it was always below this value. The light lines and dots are data from 
individual sessions.  
Figure 5.1: Time course of plasma glucose and insulin levels during glucose clamping 
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A) Group average (n=18) image of [18F]-FDG SUVR during the euglycemic clamp. Values are 
normalized to the whole-brain mean. B) Group average (n=15) image of [18F]-FDG SUVR 
during the hyperglycemic clamp. C) Group average difference in [18F]FDG SUVR between the 
hyperglycemic and euglycemic clamp. Only voxels that are significantly different from zero after 
Figure 5.2: Hyperglycemia induced changes in relative glucose consumption 
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correction for multiple comparisons (FDR 0.05) are shown in color. [18F]-FDG uptake in blue 
voxels decreased relative to the whole brain mean during hyperglycemia, whereas orange/yellow 
voxels increased.   
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All conventions as in Figure 5.2. No significant differences (p > 0.05) were found between A) 
euglycemia (n=19) and B) hyperglycemia (n=15) after C) correction or multiple comparisons 
with FDR.  




All conventions as in Figure 5.2. No significant differences (p > 0.05) were found between A) 
euglycemia (n=18) and B) hyperglycemia (n=14) after C) correction or multiple comparisons 
with FDR.  




All conventions as in Figure 5.2. No significant differences (p > 0.05) were found between A) 
euglycemia (n=18) and B) hyperglycemia (n=14) after C) correction or multiple comparisons 
with FDR.  
Figure 5.5: Relative oxygen extraction fraction (rOEF) measured with whole-brain 
normalized [15O]-O2 and [15O]-H2O SUVR 
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All conventions as in Figure 5.2. No significant differences (p > 0.05) were found between A) 
euglycemia (n=18) and B) hyperglycemia (n=14) after C) correction or multiple comparisons 
with FDR.  




A) Group average images of rOGI during the euglycemic clamp (n=17) and B) hyperglycemic 
(n=14) clamp. rOGI was computed by taking the ratio of the [15O]-O2 SUVR and [18F]-FDG 
SUVR images and then normalizing the result so that the whole-brain mean was equal to 1. C) 
Figure 5.7: Hyperglycemia induced changes in relative oxygen-to-glucose (rOGI) 
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Group average difference in relative rOGI between the hyperglycemic and euglycemic clamp. 
Only voxels that are significantly different from zero after correction for multiple comparisons 
(FDR 0.05) are shown in color. rOGI in blue voxels decreased relative to the whole brain mean 
during hyperglycemia, whereas the rOGI orange/yellow voxels increased.  
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A) Regions-of-interest (ROIs) extracted from the voxelwise analysis of relative glucose 
consumption (Figure 5.2). The blue region is composed of voxels where relative [18F]FDG 
SUVR decreased during hyperglycemia, and the red region is voxels were relative uptake 
increased. Subsequent figures show values within these ROIS for B) [18F]-FDG SUVR (glucose 
consumption), C) [15O]-H2O SUVR (cerebral blood flow), D) [15O]-O2 SUVR (oxygen 
consumption), E) rOEF (ratio of [15O]-O2 and [15O]-H2O SUVR), F) [15O]-CO SUVR (blood 
Figure 5.8: Hyperglycemia changes relative glucose consumption but not blood flow, blood 
volume, or oxygen metabolism 
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volume), and G) rOGI (ratio of [15O]-O2 and [18F]-FDG SUVR). Relative to the whole-brain, 
metabolic changes are only observed in glucose consumption and in rOGI. Significant (p < 
0.0001) No changes were seen in blood flow, oxygen metabolism, or in blood volume.   
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A) Whole-brain average cerebral metabolic rate of glucose (CMRglc) during the euglycemic 
(25.1 ± 2.1 μMol·hg-1·min-1; n=9) and hyperglycemic (27.3 ± 2.0 μMol·hg-1·min-1; n=10) clamp 
conditions. The increase in CMRglc with hyperglycemia (2.18 ± 2.84 μMol·hg-1·min-1) did not 
reach significance (p = 0.151) . B) Regional CMRglc in the same regions as Figure 5.8A. A 
significant increase (p = 0.006; see Methods) was found with hyperglycemia in the ROI where 
relative glucose metabolism increased (red), but not (p = 0.207) in the ROI were relative glucose 
metabolism increased (blue). No significant difference in CBF (measured with ASL) were found 
Figure 5.9: Quantitative glucose consumption and blood flow during hyperglycemia 
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between euglycemia (n=22) and hyperglycemia (n=19) in either the C) whole-brain or D) the 
ROIs from Figure 5.8A (p > 0.5).  
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A) Difference between hyperglycemia and euglycemia within 48 FreeSurfer derived ROIs 
(Figure 2.1). After correction for multiple comparisons using FDR, significant (p < 0.05) 
increases were found in the brain stem, cortical white matter, corpus callosum, and deep white 
matter. No significant decreases were found. B) CMRglc data from the deep white matter ROI, 
showing a robust increase in glucose consumption with hyperglycemia (9.65 ± 2.09 μMol·hg-
1·min-1; p < 0.0001). C) Scatterplot of CMRglc during euglycemia vs. the difference between 
hyperglycemia and euglycemia. Each dot is the group estimate CMRglc within a single 
FreeSurfer region. Blue dots are gray matter, red dots are white matter, and green dots are the 
brain stem/ventral diencephalon. Lines are 95% confidence intervals. There is a strong 
Figure 5.10: Quantitative increases in CMRglc in regions with low basal metabolic rates 
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correlation between baseline CMRglc and hyperglycemia induced change, with the regions with 
the smallest baseline values showing the greatest change.  
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A) Difference in CBF between hyperglycemia and euglycemia within FreeSurfer ROIs. The 
change in CBF was not significant (p > 0.05) in any ROI after correction for multiple 
comparisons using FDR. B) Unlike CMRglc (Figure 5.10B), CBF does not increase in the deep 
white matter during hyperglycemia (0.32 ± 1.42 mL·hg-1·min-1; p > 0.05). C) Scatterplot of CBF 
during euglycemia vs. the difference between hyperglycemia and euglycemia. Only a moderate 
correlation exists between baseline CBF and the change in CBF induced by hyperglycemia. All 
other conventions as in Figure 5.10.




















ID Eugly. Hyper. Eugly. Hyper. Eugly. Hyper. Eugly. Hyper. Eugly. Hyper. Eugly. Hyper. Eugly. Hyper. Eugly. Hyper. 
1 ✓  ✓  ✓  ✓  ✓  ✓      
2 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓   ✓ ✓ 
3               ✓ ✓ 
4               ✓ ✓ 
5 ✓  ✓  ✓  ✓  ✓  ✓    ✓ ✓ 
6 ✓  ✓  ✓  ✓  ✓  ✓    ✓  
7 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓   ✓ ✓ 
8 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
9  ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  ✓  ✓ ✓ ✓ 
10 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
11 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  ✓ ✓ 
12 ✓  ✓  ✓  ✓  ✓  ✓    ✓  
13 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
14 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
15                 
16 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
17 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
18 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  ✓ ✓ 
19 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓  ✓ ✓ ✓ 
20  ✓  ✓  ✓  ✓  ✓  ✓  ✓  ✓ 
21 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
22               ✓  
23                ✓ 




Table 5.1: Breakdown of participants with each imaging data-type 
25               ✓  
26 ✓ ✓ ✓ ✓           ✓ ✓ 
Totals 18 15 19 15 18 14 18 14 18 14 17 14 9 10 21 19 
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Table 5.2: Slope estimates from piecewise regression of plasma glucose and insulin time-
courses 
Values are means and symmetric 95% confidence intervals. All slopes are significantly different 






Eugly. Hygly. Eugly. Hygly. 
Before breakpoint 0.099 ± 0.093 2.7 ± 0.094 0.47 ± 0.17 0.58 ± 0.18 





Table 5.3: Whole-brain parameter estimates from the irreversible 2-compartment FDG 
model 
For each parameter, a linear mixed model was used to estimate the population mean and 95% CI 
during both the euglycemic (n=9) and hyperglycemic (n=10) clamp. K1 and k3 were significantly 
decreased during hyperglycemia, whereas k4 was significantly increased. 
Parameter Eugly. Hygly. Hygly. – Eugly. p-value 
K1 
(mL·hg-1·min-1) 
11.17 ± 1.45 6.09 ± 1.37 -5.07 ± 1.82 3.0 · 10-4 
k2 (min-1) 0.28 ± 0.11 0.24 ± 0.10 -0.041 ± 0.15 5.9 · 10-1 
k3 (min-1) 0.14 ± 0.034 0.062 ± 0.032 -0.082 ± 0.047 3.3 · 10-3 
k4 (min-1) 0.0098 ± 0.0023 0.016 ± 0.0022 0.0070 ± 0.0031 7.6 · 10-3 
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 The goal of this thesis was to explore the relationship between cerebral blood flow 
(CBF), the cerebral metabolic rate of glucose consumption (CMRglc), and the cerebral metabolic 
rate of oxygen consumption (CMRO2). In particular, I wanted to investigate the role of non-
oxidative glucose consumption (NOglc) in the brain. To explore these issues, I performed the 
analyses that make up Chapters 2-5. Roughly speaking, these chapters can be divided into two 
parts. The focus of the first part, which consists of Chapters 2 and 3, is quantifying how much of 
the brain’s glucose consumption is metabolized via non-oxidative pathways. The aim of the 
second part of the thesis is to determine if CBF, CMRglc, and CMRO2 all are affected equally by 
hypoglycemia (Chapter 4) and hyperglycemia (Chapter 5). 
 There are three primary findings in Chapters 2 and 3. First, when considering the brain as 
a whole, NOglc accounts for approximately 9% of resting CMRglc. This shows that a substantial 
portion of the brain's glucose consumption does not undergo complete oxidative 
phosphorylation. Second, nearly 7% of resting whole-brain CMRglc is consumed via non-
oxidative pathways that do not end in lactate transport to the venous blood. It is therefore likely 
that a portion of the brain’s glucose consumption is directed to other pathways, including the 
synthesis of nucleic and amino acids. Third, the proportion of NOglc varies throughout the brain. 
In the precuneus and prefrontal cortex, regions that are part of the default mode network, NOglc 
accounts for nearly 20% of resting CMRglc. Conversely, there does not appear to be any NOglc 
in the cerebellum at rest.  
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 In Chapter 4, I found a dissociation between regional changes in CBF and CMRglc 
during moderate hypoglycemia. Specifically, I found that hypoglycemia increases CBF in the 
globus pallidus and decreases CBF in the nucleus accumbens and a handful of cortical regions. 
In the majority of regions, however, CBF was not affected by hypoglycemia. Conversely, I found 
that hypoglycemia significantly decreases CMRglc in every region of the brain. Moreover, 
regional changes in CMRglc were highly correlated with baseline CMRglc and not changes in 
CBF, generally increase during hypoglycemia in order to maintain delivery of glucose. The most 
likely explanation of increased CBF in the thalamus, globus pallidus, brainstem, and ventral 
diencephalon is to promote arousal and behavioral food-seeking behaviors.   
I reported in Chapter 5 that hyperglycemia produces a shift in the topography of cerebral 
glucose metabolism. Glucose consumption in regions with high baseline metabolic rates, such as 
the visual cortex, decreased relative to the rest of the brain, whereas regions with low baseline 
metabolic rates (e.g., white matter) increased. The major effect of hyperglycemia is a significant 
quantitative increase in CMRglc in cerebral white matter and brain stem. Interestingly, no 
changes in quantitative CBF or relative blood flow, blood volume, oxygen metabolism, or 
oxygen extraction were found in any brain region. Taken together, these findings suggest NOglc 
is elevated in the white matter and brain stem during hyperglycemia.  
6.2 Significance and Future Directions 
 
 In Chapter 1, I reviewed the fairly large literature examining the relationship between 
cerebral metabolism and functional activity, with a particular emphasis on examples of 
uncoupling between CBF, CMRglc, and CMRO2. This literature has conclusively shown that, 
although focal elevations in neural activity substantially increase CBF and CMRglc, CMRO2 
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changes only modestly. As a result, enhanced neural activity results in a temporary increase in 
NOglc. The uncoupling between CBF, CMRglc, and CMRO2 in responses to task paradigms is 
responsible for the blood oxygen dependent (BOLD) signals underlying fMRI.  
Although metabolic uncoupling now is well established, there are still several outstanding 
questions surrounding it. The rest of this chapter will focus on three of the more prominent areas 
of research. 
Non-oxidative glucose consumption during neural activity 
 One of the most important remaining questions is why task-evoked activity focally 
increases NOglc. In Chapter 1, I discussed several possibilities including a modified astrocyte-
neuron lactate shuttle, glycogen or glutamate synthesis, lactate production, or biosynthesis of 
amino acids and proteins. None of the analyses included in this thesis favor any of these 
possibilities, as all of the data were collected in resting conditions. As I argued in Chapter 1, a 
complete account of NOglc during responses to task paradigms likely will need to examine 
several different mechanisms that operate in both neurons and glia. Furthermore, recent studies 
implicating the role of lactate as a signaling molecule1,2, suggest that the role of NOglc extends 
beyond energy metabolism. Therefore, to further our understanding of task-related changes in 
NOglc, we need quantitative studies that track the creation and movement of glucose 
intermediates between cell types in vivo. Without direct evidence indicating which non-oxidative 
pathways are active, the reason why task performance elevates NOglc will remain unclear. 
 
Non-oxidative glucose consumption at rest 
 The role of NOglc at rest has been examined to a far lesser extent than it has been during 
periods of increased neural activity. In Chapter 2, I reported that NOglc accounts for nearly 10% 
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of the brain’s resting glucose consumption, replicating previous findings3. Although most 
investigators acknowledge that NOglc accounts for a portion of resting CMRglc, it is sometimes 
asserted that this a fairly small amount that can be safely ignored as it is due entirely to excess 
lactate production4,5. Much less common are reports that actively consider the possibility that 
NOglc plays a role in resting brain metabolism and function. The results presented in this thesis 
favor the possibility that NOglc plays an important role in the brain at rest. I found that a 
substantial portion of the brain’s resting NOglc cannot be accounted for by lactate efflux to the 
venous blood. Therefore, other mechanisms must be invoked to explain why the brain is 
consuming glucose without complete oxidative phosphorylation. 
One way to assess what role NOglc has in the resting brain is to correlate the spatial 
topography of NOglc with the topographies of other biological markers. A previous study from 
our group found a positive correlation between regional NOglc and the expression of genes 
related to synaptic plasticity and development6. This finding suggests that NOglc could be used 
to generate the biosynthetic intermediates necessary for synaptic plasticity. Consistent with this 
idea, other work from both our group7 and others8 has shown that NOglc is elevated hours after 
the performance of a learning task. 
In Chapter 3, I directly quantified NOglc in several regions of the brain at rest. In regions 
such as the precuneus, lateral parietal cortex, and medial prefrontal cortex, NOglc accounts for as 
much as 20% of resting CMRglc. Conversely, there does not appear to be any NOglc in the 
cerebellar gray matter. Therefore, if NOglc plays a role in synaptic plasticity, its importance may 
vary by region. The cerebellum is of particular interest in this regard, as it has little to no NOglc 
despite being a classical example of plasticity in certain types of motor learning9,10. 
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Given the limitations of human studies, none of the work I have presented here directly 
tests which cellular mechanisms underlie resting NOglc. It is likely, however, that the same 
mechanisms that are behind NOglc in responses to task paradigms also operate in the resting 
brain. Although the use of task paradigms in functional neuroimaging studies has encouraged the 
belief that task and rest are fundamentally different states, this is an oversimplification. Indeed, 
the brain is highly active even when it is not performing any overt task11, and only a small 
fraction of the brain’s energy is devoted to responding to external stimuli12. Therefore, it is 
parsimonious to hypothesize that the same mechanisms that are responsible for NOglc during 
task responses also operate at rest. 
Metabolic uncoupling and altered states 
 As was discussed in Chapter 1, metabolic derangements often result in uncoupling 
between CBF, CMRglc, and CMRO2. A classic example is profound hypoglycemia, which 
decreases global CMRglc to a much greater extent than CBF or CMRO2
13. In Chapter 4, I 
expanded upon this literature by examining regional CBF and CMRglc during moderate 
hypoglycemia. I found that, although hypoglycemia decreased CMRglc in every brain region, it 
decreased CBF in only a handful of regions. Interestingly, the only region where hyperglycemia 
increased CBF was the globus pallidus. This is in contrast to the animal literature, which has 
consistently reported that hypoglycemia increases global14 and regional15 CBF. An increase in 
CBF during hypoglycemia would suggest than blood flow is upregulated during hypoglycemia to 
increase the amount of glucose that is delivered to the brain. However, the data presented in 




An alternative possibility is that CBF changes during hypoglycemia are part of the 
brain’s counterregulatory response to changes in blood glucose concentration. The release of 
insulin during hypoglycemia is typically followed by the release of several counterregulatory 
hormones, including of glucagon, epinephrine, growth hormone, and cortisol16. Studies 
examining changes in blood flow in humans have typically reported focal increases in the globus 
pallidus, thalamus, and medial prefrontal cortex17-19. Interestingly, although the hormonal 
response to hypoglycemia is diminished after multiple hypoglycemic episodes, the increase in 
CBF in the thalamus is amplified20. These findings have led to the hypothesis that focally 
increased thalamic CBF during hypoglycemia is a marker of hypothalamic inhibition20,21. With 
repeated episodes of hypoglycemia, the amount of inhibition is increased, resulting in a 
diminished sympathetic response20. 
However, the results shown in Chapter 4 are not entirely consistent with this hypothesis. 
Although hypoglycemia did increase CBF in the thalamus, the increase was not statistically 
significant, possibly owing to the global noise inherent in absolute quantification of CBF. CBF in 
the thalamus was significantly elevated from euglycemia when expressed relative to whole-brain 
CBF. In any case, more work is needed to establish why CBF changes during hypoglycemia. It 
would also be particularly interesting to measure regional oxygen consumption during 
hypoglycemia. As mentioned earlier, profound hypoglycemia produces little change in global 
CMRO2
13. If this is true during moderate hypoglycemia, it would suggest than most of the 
decrease in CMRglc I reported in Chapter 4 was due to a decrease in NOglc. This could have 




 In Chapter 5, I found that metabolic uncoupling is increased during acute hyperglycemia, 
as in hypoglycemia. Specifically, hyperglycemia altered the topography of cerebral glucose 
consumption, whereas the topographies of blood flow and oxygen consumption were unchanged. 
The change in the regional distribution of glucose consumption was due to a selective 
quantitative increase in CMRglc within the white matter and brain stem. Taken together, these 
findings suggest that, during hyperglycemia, NOglc is selectively increased in the white matter 
and brainstem. It is worthwhile noting that Type-2 diabetes mellitus (T2DM), which leads to 
chronic hyperglycemia, is associated with white matter disease22. Speculatively, it is possible 
that chronically elevated NOglc in white matter is a risk factor for the development of white 
matter disease in individuals with T2DM. In support of this possibility, increased concentration 
of sorbitol, a sugar alcohol produced from glucose via non-oxidative pathways, has been 
implicated in the development of diabetic retinotopy and neuropathy23. Therefore, determining 
whether individuals with T2DM have increased NOglc in white matter would be an important 
next step.  
 Finally, it is interesting to consider that both NOglc24 and diabetes25 have been suggested 
to play a role in the development of dementia. Individuals with diabetes are more likely to 
develop dementia26 and chronic hyperglycemia, even in the absence of diabetes, is a risk factor 
for Alzheimer’s disease (AD)27. Although alterations in NOglc have not yet been shown to be a 
risk factor for dementia, there is evidence that NOglc is involved in the development of amyloid 
plaques, one of the pathological hallmarks of AD. A previous study from our laboratory found 
that regions that have high levels of NOglc in healthy young adults go on to develop amyloid 
plaques in individuals with AD28. Consistent with this finding, Bero et al. reported a positive 
correlation between amyloid plaque loads and lactate production in a mouse model of AD29. In 
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the same model, Shannon et al. also found that hyperglycemia increases both amyloid production 
and lactate release in the hippocampus30. Other studies have reported that global NOglc is lower 
in both early31 and late32 onset AD, although both these studies involved small sample sizes (20 
patients or less). A recent report from our group also found that aging decreases NOglc, 
particularly in regions with high rates of NOglc in young individuals33. Given these connections, 
it is tempting to argue that individuals with diabetes have an increased risk for the development 
of dementia, in part, because of the effect of hyperglycemia on NOglc. Detailed mechanistic 
studies will be required to verify whether this hypothesis has merit. A longitudinal study 
establishing that individuals with abnormal NOglc do go on to develop AD at higher rates would 
also be of great interest. 
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